<?xml version='1.0' encoding='UTF-8' ?>
<Trials_downloaded_from_ICTRP>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13632109
    </Internal_Number>
    <TrialID>NCT06214377
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Transcranial Direct Current Stimulation for Treating Parkinson´s Disease-related Pain in OFF State
    </Public_title>
    <Scientific_title>Effects of Transcranial Direct Current Stimulation (tDCS) on Pain Modulation in Individuals With Parkinson's Disease in the Off State
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Universidad Francisco de Vitoria
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20231129
    </Date_registration3>
    <Date_registration>29/11/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06214377
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 1, 2023
    </Date_enrollement>
    <Target_size>15
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Spain
    </Countries>
    <Contact_Firstname> ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Juan Pablo Romero, MD, PhD;Josué Fernández Carnero, PT, PhD;Marcos Moreno Verdú, PT, PhD;Juan Pablo Romero, MD, PhD;Juan Pablo Romero, MD. PhD
    </Contact_Lastname>
    <Contact_Email>;;;p.romero.prof@ufv.es;p.romero.prof@ufv.es
    </Contact_Email>
    <Contact_Tel>;;;+34917091400;+34917091400
    </Contact_Tel>
    <Contact_Affiliation>Universidad Francisco de Vitoria, Facultad de Ciencias Experimentales;Universidad Rey Juan Carlos;Universidad Francisco de Vitoria;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of Idiopathic Parkinson´s Disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of Parkinson´s Disease-related pain in the off-state.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neuroimaging study without previous pathologies.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Score &gt; 5 in transfers (bed to chair and back) item in Barthel Index.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Score = or &gt; 26 in Montreal Cognitive Assessment (MoCA).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Tolerability for the application of electrotherapy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to provide informed consent to participate in the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pain intensity &gt;= 3 in Visual Analogue Scale or equivalent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neurologic disease different from PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pain non-related to PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dermatologic problems, wounds, or ulcers in the electrode's application area.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of implants or metal pieces in the head.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of cardiac pacemaker, vagal, brain or transcutaneous stimulators, medication&#x0D;&lt;br&gt;             pumps, ventriculoperitoneal shunts or aneurysm clips.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Significative difficulties in language.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of alcohol or drugs abuse.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-controlled medical problems.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Epilepsy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Pain
    </Condition>
    <Intervention>Device: Active Transcranial Direct Current Stimulation;Device: Sham Transcranial Direct Current Stimulation;Drug: Dopaminergic medication
    </Intervention>
    <Primary_outcome>Change in Conditioned Pain Modulation;Change in Conditioned Pain Modulation;Changes in Pain Pressure Threshold;Changes in Pain Pressure Threshold;Changes in Visual Numeric Pain Rating Scale;Changes in Visual Numeric Pain Rating Scale;Changes in Global Rating of Change;Changes in Global Rating of Change
    </Primary_outcome>
    <Secondary_outcome>Changes in Brain Symmetry Index in electroencephalography;Changes in Brain Symmetry Index in electroencephalography;Changes in Unified Parkinson´s Disease Rating Scale;Changes in Finger tapping task
    </Secondary_outcome>
    <Secondary_ID>ParkOFF-tDCS
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Universidad Rey Juan Carlos;Hospital Beata María Ana
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13632108
    </Internal_Number>
    <TrialID>NCT06214364
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Transcranial Direct Current Stimulation and Gamified Rehabilitation for Upper Limb Function in Pediatric Brain Damage
    </Public_title>
    <Scientific_title>Transcranial Direct Current Stimulation as Adjuvant to Gamified Rehabilitation for Upper Limb Function in Pediatric Non-progressive Brain Damage: a Randomized Controlled Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Universidad Francisco de Vitoria
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20231127
    </Date_registration3>
    <Date_registration>27/11/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06214364
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>7 Years
    </Inclusion_agemin>
    <Inclusion_agemax>15 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 2024
    </Date_enrollement>
    <Target_size>36
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Spain
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Juan Pablo Romero Muñoz, PhD, MD;Marcos Ríos Lago, PhD;Beatriz Gavilán Agustí, PhD;Juan Pablo Romero Muñoz, PhD, MD
    </Contact_Lastname>
    <Contact_Email>;;;p.romero.prof@ufv.es
    </Contact_Email>
    <Contact_Tel>;;;+34 91 409 09 03
    </Contact_Tel>
    <Contact_Affiliation>Universidad Francisco de Vitoria;Universidad Nacional de Educación a Distancia;Hospital Beata María Ana;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ischemic or hemorrhagic stroke.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Traumatic brain injury.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cerebral palsy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acquired Brain Injury.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other causes of non-progressive brain damage susceptible to treatment with the&#x0D;&lt;br&gt;             established procedures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evolution of the injury of at least one year.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 7 and 15 years, with adequate language development and capacity to&#x0D;&lt;br&gt;             comprehend the proposed procedure.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neuroimaging study done.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Absence of previous brain injuries prior to the one prompting treatment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Score between II and IV on the MACS scale for manual ability assessment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Signed informed consent by the patient and their legal guardian in case the&#x0D;&lt;br&gt;             participant is 12 or older. If the participant is younger than 12 years, only the&#x0D;&lt;br&gt;             caregiver signed informed consent will be necessary.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Increased tone according to the modified Ashworth scale ranging from 1 to 1+.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Minimum score of 1 on each item assessed in the Melbourne Assessment 2 scale.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dermatological problems in the electrode application area (psoriasis, dermatitis on&#x0D;&lt;br&gt;             the scalp or face).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of implants or metal pieces in the head excluding fillings.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pacemakers, medication pumps, stimulators (vagal, cerebral, transcutaneous),&#x0D;&lt;br&gt;             ventriculoperitoneal shunts, or aneurysm clips.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neurological disease different from that described in the inclusion criteria.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Significant language difficulties that unable proper understanding of activities or&#x0D;&lt;br&gt;             severely limit expression.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Moderate or severe mood disorders diagnosed by the regular pediatrician.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Uncontrolled medical issues (acute phase pathologies without medical or&#x0D;&lt;br&gt;             pharmacological treatment with proven efficacy or life-threatening conditions).&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Paediatric Brain Damage;Cerebral Palsy;Paediatric Stroke;Paediatric Traumatic Brain Injury;Paediatric Acquired Brain Injury
    </Condition>
    <Intervention>Device: Active Transcranial Direct Current Stimulation;Device: Sham Transcranial Direct Current Stimulation
    </Intervention>
    <Primary_outcome>Changes in Melbourne Assessment 2 (MA-2);Changes in kinematic and kinetic upper limb analysis - Velocity of the movement;Changes in kinematic and kinetic upper limb analysis - Movement acceleration;Changes in kinematic and kinetic upper limb analysis - Duration of the movement;Changes in kinematic and kinetic upper limb analysis - range of motion;Changes in Box and Block Test (BBT)
    </Primary_outcome>
    <Secondary_outcome>Changes in and grip strength;Changes in finger flexor muscles spasticity;Changes in finger extensor muscles spasticity;Changes in Children's hand-use experience questionnaire (CHEQ);Changes in Wechsler Intelligence Scale for Children V (WISC-V);Changes in Beery-Buktenica Developmental Test of Visual-Motor Integration (Beery VMI);Changes in Neuropsychological battery for children NEPSY-II;Changes in Test of Everyday Attention for Children (TEA-Ch) Changes in Test for everyday attention for children (TEA-Ch);Changes in Verbal learning test for children Spain-Complutense (TAVECI);Changes in Behavior rating inventory for executive function 2 (BRIEF-2);Changes in Evaluation System for children and adolescents (SENA);Changes in Kidscreen-52 scale
    </Secondary_outcome>
    <Secondary_ID>CHILDBOOST
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Universidad Nacional de Educación a Distancia;Hospital Beata María Ana
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13579253
    </Internal_Number>
    <TrialID>NCT06145776
    </TrialID>
    <Last_Refreshed_on>11 December 2023
    </Last_Refreshed_on>
    <Public_title>The Role of EEG in Identifying Cognitive Changes in Parkinson's Disease
    </Public_title>
    <Scientific_title>Effects of Cognitive-motor Dual-Task Training and tDCS on Brain Electrical Activity Assessed by EEG and Cognitive Performance in Patients With Parkinson's Disease: a Randomized, Double-blind, Controlled Clinical Trial.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Federal University of Paraíba
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20231117
    </Date_registration3>
    <Date_registration>17/11/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT06145776
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 2, 2023
    </Date_enrollement>
    <Target_size>36
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Suellen Andrade, Doctor;Suellen M Andrade, Doctor
    </Contact_Lastname>
    <Contact_Email>;suellen.andrade@academico.ufpb.br
    </Contact_Email>
    <Contact_Tel>;83993812744
    </Contact_Tel>
    <Contact_Affiliation>Federal University of Paraiba;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  being diagnosed with idiopathic Parkinson's disease by a neurologist based on&#x0D;&lt;br&gt;             definitive evidence of responsiveness to levodopa at the start of the disease and the&#x0D;&lt;br&gt;             history of progressive hypokinesia with asymmetric onset. PD will be diagnosed based&#x0D;&lt;br&gt;             on Parkinson's Disease Society Brain Bank (PDSBB) criteria, as described in Hughes et&#x0D;&lt;br&gt;             al. (1992)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age between 40 and 70 years, with no distinction for sex, schooling level or other&#x0D;&lt;br&gt;             sociodemographic characteristics;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  disease staging between 1.5 and 3, according to the modified Hoehn and Yahr scale&#x0D;&lt;br&gt;             (Hoehn and Yahr, 1998);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  undergoing regular pharmacological treatment with levodopa (equivalent dose &gt; 300 mg)&#x0D;&lt;br&gt;             or taking antiparkinsonian medication, such as anticholinergics, selegiline, dopamine&#x0D;&lt;br&gt;             agonists, and COMT (catechol-O-methyl transferase) inhibitors for at least 4 weeks&#x0D;&lt;br&gt;             prior intervention;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  score of more than 24 points on the Mini-Mental State Examination (Folstein et al.,&#x0D;&lt;br&gt;             1975);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  not exhibiting other associated neurological diseases; and&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  no musculoskeletal and/or cardiorespiratory changes that could compromise gait.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of atypical Parkinson's disease;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  neuropsychiatric comorbidities;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  convulsions, metal clips and/or pacemaker;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  deep brain stimulation implant;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  history of epilepsy; neurosurgery;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  traumatic brain injury;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  alcohol abuse or drug dependency;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  associated diseases of the peripheral or central nervous system;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  undergoing physical therapy at another location;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  inability to walk 10 meters;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  presence of important dyskinesia that prevents the participant from sitting in a&#x0D;&lt;br&gt;             chair;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  abnormal and persistent increase in systemic blood pressure before or during training,&#x0D;&lt;br&gt;             after three measurements taken 5 min apart-Cut-off: systolic blood pressure = 140 mm&#x0D;&lt;br&gt;             Hg and/or diastolic = 90 mm Hg (Malachias et al., 2016);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  not understanding any of the training protocol stages; chemical scalp treatment within&#x0D;&lt;br&gt;             the previous 30 days, and experiencing severe pain and/or discomfort that precludes&#x0D;&lt;br&gt;             performing the proposed activities.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Cognition Disorder;EEG With Abnormally Slow Frequencies
    </Condition>
    <Intervention>Other: tDCS + tredmill training (Standart trehab training);Other: Cognitite-motor Dual Task Training (DT training)
    </Intervention>
    <Primary_outcome>EEG outcomes;clinic outcome
    </Primary_outcome>
    <Secondary_outcome>Total Montreal Cognitive Assessment (MoCA);domains of MoCA;Trail Making Test part B (TMT-B);Stroop Test;Movement Disorder Society - Unified Parkinson's Disease Rating Scale PART II Score Compare insights MDS-Unified Parkinson's Disease Rating Scale part II (UPDRS-II)
    </Secondary_outcome>
    <Secondary_ID>EEG_DPcog
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13393400
    </Internal_Number>
    <TrialID>ACTRN12623001065684
    </TrialID>
    <Last_Refreshed_on>9 October 2023
    </Last_Refreshed_on>
    <Public_title>Non-Invasive Brain Stimulation for Children and Young People with Cerebral Palsy
    </Public_title>
    <Scientific_title>Safety and Feasibility of Remotely Monitored Transcranial Direct Current Stimulation in Children with Cerebral Palsy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>Monash University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20231004
    </Date_registration3>
    <Date_registration>04/10/2023
    </Date_registration>
    <Source_Register>ANZCTR
    </Source_Register>
    <web_address>https://anzctr.org.au/ACTRN12623001065684.aspx
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>8 Years
    </Inclusion_agemin>
    <Inclusion_agemax>17 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both males and females
    </Inclusion_gender>
    <Date_enrollement>01/11/2023
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Purpose: Treatment; Allocation: Non-randomised trial; Type of endpoint: Safety;
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Australia
    </Countries>
    <Inclusion_Criteria>Inclusion criteria: 1. Aged between 8 years 0 days and 17 years 364 days&#x0D;&lt;br&gt;2. Children with a confirmed diagnosis of CP and a history of perinatal stroke or PVL&#x0D;&lt;br&gt;3. Receptive language function to follow two-step commands&#x0D;&lt;br&gt;4. Ability to report pain or discomfort through expressive language function or other&#x0D;&lt;br&gt;5. No or mild intellectual disability&#x0D;&lt;br&gt;6. Greater than or equal to 10 degrees of active motion at the metacarpophalangeal joint&#x0D;&lt;br&gt;7. Children who have had surgeries which may influence motor function (e.g., tendon transfer) will be included, and surgical history documented and included in any publication within a participant characteristics table.&#x0D;&lt;br&gt;8. Home set-up: Internet access and a working computer/laptop device, table suitable to perform Box and Blocks Test&#x0D;&lt;br&gt;9. Informed consent obtained by parent, and child/adolescent where appropriate. Assent sought from child/adolescent where consent cannot be obtained
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Inaccessibility to internet or unreliable internet coverage&#x0D;&lt;br&gt;2. Conductive Implants&#x0D;&lt;br&gt;3. Abnormal cell growth (e.g., neoplasm)&#x0D;&lt;br&gt;4. Metabolic Disorders&#x0D;&lt;br&gt;5. Seizure within two years preceding the study&#x0D;&lt;br&gt;6. Acquired Traumatic Brain Injury&#x0D;&lt;br&gt;7. Known current pregnancy&#x0D;&lt;br&gt;8. Indwelling metal or incompatible medical devices&#x0D;&lt;br&gt;9. Evidence of skin disease or skin abnormalities on the scalp&#x0D;&lt;br&gt;10. Disorder of Cellular Migration and Proliferation&#x0D;&lt;br&gt;11. Concomitant participation in another neuromodulation study&#x0D;&lt;br&gt;12. Centrally-acting agent or other agent that may lower seizure threshold or affect cortical plasticity&#x0D;&lt;br&gt;13. Limited ability to communicate insight into a preferred future (needs, wants, desires) in spoken English or through augmentative/alternative communication
    </Exclusion_Criteria>
    <Condition>Cerebral Palsy; &lt;br&gt;Cerebral Palsy;Neurological - Other neurological disorders
    </Condition>
    <Intervention>This is an exploratory pilot open label trial that will assess the safety and feasibility of active transcranial Direct Current Stimulation (tDCS) in the home setting under caregiver and remote investigator supervision, activation and monitoring. Sessions will be supervised by a paediatric neurologist with a minimum of 10 years' experience,&lt;br&gt;&lt;br&gt;tDCS stimulates the brain by using low levels of electricity to affect the activity and connections between brain cells. The electricity is applied using sponges placed at specific locations on the scalp. Participation will occur over five days for one hour each day. Active stimulation sessions will be 20 minutes in duration, at a current intensity of 1.5 mA. Individual participant tolerance will be assessed prior to stimulation sessions, and current intensity adjusted as necessary. The tDCS device used in the study is the Soterix Medical 1x1 Transcranial Direct Current Stimulator Mini - Clinical Trials (CT), model 1601. Accessories used will include head straps with disposable sponge pads; measuring tape, alcohol swabs, skin pencils and a Box and Blocks Test kit.&lt;br&gt;&lt;br&gt;Caregiver training will be provided in the first intervention session by the supervising remote investigator. Caregivers will be shown two instructional videos, one to perform head measurements to select the correct sized headgear, and another to demonstrate tDCS device set up. The caregiver will then be stepped through both processes in real time by the supervising remote investigator. This process is estimated to take approximately 30 minutes. The caregiver will be asked to take a photograph of the device set up using their phone and upload this to REDCap for review by the study team. The intervention session will not progress until the set up has been revi
    </Intervention>
    <Primary_outcome>Safety of remotely-delivered tDCS, assessed via frequency and nature of adverse events reported pre-, during and post-stimulation. Adverse events include, but are not limited to, redness, tingling and itching at the electrode site. All adverse events are measured on a 4-point likert scale.[ Stimulation sessions, days 1 - 5 ]
    </Primary_outcome>
    <Secondary_outcome>Ease of tDCS device set up via pre-stimulation set up survey. This survey steps caregivers through each stage of the set up process and asks them to rate the difficulty of each step using a Likert scale. This survey has been adapted from Christopher et al (2023) Safety, tolerability and feasibility of remotely-instructed home-based transcranial direct current stimulation in children with cerebral palsy. Brain Stimulation, 16:1325-1327.[ Stimulation sessions, days 1 - 5];Quality of device set up via electrode contact quality, recorded using feedback from the tDCS device throughout the session. The tDCS device has a coloured light that should remain green throughout the session, indicating good electrode contact quality. The number of times the coloured light is orange or red, indicating poor contact quality, will be recorded by the research team, along with the duration of time this occurs over the 20 minute stimulation period.[ Stimulation sessions, days 2 - 5];Speed of tDCS device set up, measured using a REDCap timer at the beginning of the 'Pre-stimulation set up survey'. The survey steps caregivers through each stage of the set up process and asks them to rate the difficulty of each step. The timer is stopped at the end of the survey.[ Stimulation sessions, days 1 - 5];Post-stimulation comfort and set up survey, measured via a series of questions assessing post-stimulation device positioning, participant comfort, and caregiver and participant feedback. This survey has been adapted from Christopher et al (2023) Safety, tolerability and feasibility of remotely-instructed home-based transcranial direct current stimulation in children with cerebral palsy. Brain Stimulation, 16:1325-1327.[ Stimulation sessions, days 1 - 5]
    </Secondary_outcome>
    <Secondary_ID>Nil known
    </Secondary_ID>
    <Source_Support>Cerebral Palsy Alliance Research Foundation ;Brain Australia;Thrasher Research Fund
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>07/06/2023
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13188849
    </Internal_Number>
    <TrialID>RBR-3ksnxkm
    </TrialID>
    <Last_Refreshed_on>26 July 2023
    </Last_Refreshed_on>
    <Public_title>Comparative Study between Transcranial Direct Current Stimulation and Binaural Vibro-Acoustic Brain Stimulation in Parkinson&amp;apos;s
    </Public_title>
    <Scientific_title>Comparative study between transcranial direct current stimulation and binaural vibro-acoustic brain stimulation in Parkinson&amp;apos;s patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
    </Scientific_title>
    <Primary_sponsor>Hospital Universitário Onofre Lopes
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230628
    </Date_registration3>
    <Date_registration>28/06/2023
    </Date_registration>
    <Source_Register>REBEC
    </Source_Register>
    <web_address>https://ensaiosclinicos.gov.br/rg/RBR-3ksnxkm
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>55Y
    </Inclusion_agemin>
    <Inclusion_agemax>70Y
    </Inclusion_agemax>
    <Inclusion_gender>-
    </Inclusion_gender>
    <Date_enrollement>01/04/2023
    </Date_enrollement>
    <Target_size/>
    <Study_type>Intervention
    </Study_type>
    <Study_design/>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname>Gleidson Franciel
    </Contact_Firstname>
    <Contact_Lastname>de Medeiros
    </Contact_Lastname>
    <Contact_Address>Av. Elisa Branco Pereira dos Santos, 95
    </Contact_Address>
    <Contact_Email>dr.gleidsonmedeiros@gmail.com
    </Contact_Email>
    <Contact_Tel>+55(84)988775494
    </Contact_Tel>
    <Contact_Affiliation>Hospital Universitário Onofre Lopes
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Have a diagnosis of Parkinson&amp;apos;s Disease; in stage 2 or 3 of the disease; both genders; being between 55 and 70 years old; with independent gait
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Make use of Deep Brain Stimulation; make use of cochlear implants; having uncontrolled labyrinthitis; having uncontrolled hypertension
    </Exclusion_Criteria>
    <Condition>Parkinson&amp;apos;s Disease;C10.228.140.079.862
    </Condition>
    <Intervention>The study will be a randomized, controlled, uni blinded, two-group clinical trial with a sample of 42 subjects, of both sexes, aged between 55 and 70 years, diagnosed with Parkinson&amp;apos;s, in grades 2 or 3. The subjects will be evaluated and randomized from the www.randomizer.com website, and allocated in two groups in a confidential way, by sealed and increasingly named envelopes, which will be filled with the coding referring to the dosi groups described below:&lt;br&gt;The Experimental Group, which will consist of 21 people treated with Binaural Vibroacoustic Brain Stimulation associated with treadmill gait training.  And the control group, formed by 21 subjects treated with Transcranial Direct Current Stimulation.  Both will receive treatment for four weeks, three times a week, totaling 12 appointments.  Later they will be reassessed, obeying the same initial evaluation criteria.  After 60 days, they will be called for a final evaluation, in the same way as the previous ones, for Follow up purposes.
    </Intervention>
    <Primary_outcome>It is expected to find a better response in the gait performance of subjects with Parkinson&amp;apos;s treated with Vibroacoustic Brain Stimulation, compared to those treated with Transcranial Direct Current Stimulation
    </Primary_outcome>
    <Secondary_outcome>It is expected to observe improvement in the posture of subjects with Parkinson&amp;apos;s treated with Vibroacoustic Brain Stimulation, compared to those treated with Transcranial Direct Current Stimulation;It is expected to observe improvement in the tremor of subjects with Parkinson&amp;apos;s treated with Vibroacoustic Brain Stimulation, compared to those treated with Transcranial Direct Current Stimulation;It is expected to observe improvement in the phenomenon of the arrest of subjects with Parkinson&amp;apos;s treated with Vibroacoustic Brain Stimulation, compared to those treated with Transcranial Direct Current Stimulation
    </Secondary_outcome>
    <Source_Support>Hospital Universitário Onofre Lopes
    </Source_Support>
    <Secondary_Sponsor>Hospital Universitário Onofre Lopes
    </Secondary_Sponsor>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>29/06/2022
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>cep.huol@ebserh.gov.br
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Comitê de Ética em Pesquisa do  Hospital Universitário Onofre Lopes da Universidade Federal do Rio Grande do Norte
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+55(84)3342-5003
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>cep.huol@ebserh.gov.br
    </Ethics_review_contact_email>
    <results_date_completed>30/01/2024
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13140733
    </Internal_Number>
    <TrialID>IRCT20090301001722N29
    </TrialID>
    <Last_Refreshed_on>26 June 2023
    </Last_Refreshed_on>
    <Public_title>Effects of Electrical stimulation and Whole Body vibration therapy with transcranial direct current stimulation on spactic cerebral palsy children
    </Public_title>
    <Scientific_title>Comparison of the conjunct effects of Electrical Stimulation and Whole-Body Vibration Therapy with Transcranial Direct Current Stimulation and Whole-body Vibration Therapy on Balance and Function in Spastic Cerebral Palsy Children.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Tehran University of Medical Sciences
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230615
    </Date_registration3>
    <Date_registration>2023-06-15
    </Date_registration>
    <Source_Register>IRCT
    </Source_Register>
    <web_address>http://en.irct.ir/trial/70443
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 years
    </Inclusion_agemin>
    <Inclusion_agemax>15 years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2023-06-05
    </Date_enrollement>
    <Target_size>42
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Before the process of randomization, we will screen all the participants and assign them a unique number from 1 to 42. Then the process of randomization will be carried out using Random Allocation software version 1.0 (developed by the Department of Anaesthesia, Isfahan University of Medical Sciences, Isfahan, Iran). It is a randomization software for parallel group trials. It requires the total sample size and the total number of groups. We will add a total sample size of 42 participants and 3 groups into the software with only one block. The software generates an output file that can be opened with internet explorer. The output file contains a list of number along with assigned groups. In our case, the groups will be A, B, C with 14 participants in each group. Then this sequence will be used for participant allocation in the study grou
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Pakistan
    </Countries>
    <Contact_Firstname>Dr.Mohammad-Reza Hadian Rasanani
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Rehabilitation Faculty, Pich e Shemiran, Enghelab Street Tehran Tehran Iran,
    </Contact_Address>
    <Contact_Email>hadianrasan@gmail.com
    </Contact_Email>
    <Contact_Tel>+98 21 8891 3469
    </Contact_Tel>
    <Contact_Affiliation>Tehran University of Medical Sciences
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Age of 5- 15 years.&lt;br&gt;Both Genders (Boys and Girls).&lt;br&gt;Children diagnosed with Spastic Hemiplegic cerebral palsy.&lt;br&gt;Degree of Spasticity Grade 1, 1+, and 2 according to Modified Ashworth Scale in the following muscles (hip flexors, hip adductors, hamstrings and ankle plantar flexors).&lt;br&gt;Level I(Can walk indoors and outdoors and climb stairs without using hands for support, and II (ability to walk indoors and outdoors and climb stairs with a railing ) of Gross Motor Function Classification System.&lt;br&gt;Manual Ability Classification System level I to IV.&lt;br&gt;No history of epilepsy.&lt;br&gt;No unhealed fractures.&lt;br&gt;No visual impairments and auditory impairments.&lt;br&gt;Not taking botulinum toxin injections.&lt;br&gt;Does not have any sensory and motor loss.&lt;br&gt;Does not have cardiopulmonary problems.&lt;br&gt;Does not have recent surgery (less than 1 year).&lt;br&gt;Children who would not experience joint contractures&lt;br&gt;Children with no Muscle or tendon inflammation&lt;br&gt;Children with no Leg length discrepancy
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: The child or the guardian is not interested to carry out the study.&lt;br&gt;Failing to complete the study.
    </Exclusion_Criteria>
    <Condition>Cerbral Palsy. &lt;br&gt;G80;Cerebral P
    </Condition>
    <Intervention>Intervention 1: Intervention group 1 WBV training for 20 min a day,4 days a week for 4 weeks. The children will be instructed to maintain a standing posture on the vibration platform. Children will stand barefooted with feet parallel and in slight flexion (30°). The feet will be placed at an equal distance from the center line of the device when standing. During the 20 min of therapy, every 3 minutes of vibration training and 2 minutes of rest will be repeated 4 times. The frequency of the WBV stimulation will be (12–18 Hz) and will achieve gradually increase by 1 Hz per 2 seconds, till the desired frequency is achieved. Intervention 2: Intervention group 2 WBV training for 20 min a day,4 days a week for 4 weeks. The children will be instructed to maintain a standing posture on the vibration platform. Children will stand barefooted with feet parallel and in slight flexion (30°). The feet will be placed at an equal distance from the center line of the device when standing. During the 20 min of therapy, every 3 minutes of vibration training and 2 minutes of rest will be repeated 4 times. The frequency of the WBV stimulation will be (12–18 Hz) and will achieve gradually increase by 1 Hz per 2 seconds, till the desired frequency is achieved. Functional Electrical stimulation with Rectangular biphasic pulses with a pulse width of 250 µs, the stimulus intensity 70 mA, and a frequency ranged from 40 Hz,4 days a week for 4 weeks will be administered on motor points of the spastic muscles mainly for the lower extremity ( quadriceps and gastrocnemius and soleus). Intervention 3: Intervention group 3 Transcranial Direct Current Stimulation (tDCS) will be given with 2mA intensity for 20 min a day,4 days sessions a week for 4 weeks. 5*7 cm square electrodes will be placed as Anodal 
    </Intervention>
    <Primary_outcome>Range of Motion. Timepoint: Before and After the intervention for Upper  and lower extremity joints. Method of measurement: Universal Goniometer.;Hand Grip Strength. Timepoint: Before and After the intervention for Upper Limb. Method of measurement: Hand Held Digital Dynamometer.;Isometric Muscle strength test. Timepoint: Before and After the intervention for  lower extremity muscles. Method of measurement: digital force gauge SF-500.;Centre of Gravity, and Balance test scores. Timepoint: Before and After the intervention for  lower extremity. Method of measurement: Nintendo Wii-Fit, Balance board.;Gait parameters (walking speed, cadence(stride length and step length) using cinematography. Timepoint: Before and after the intervention for the lower extremity. Method of measurement: Kinovea software version 0.9.5.;Timed up and go test. Timepoint: Before and After the intervention. Method of measurement: One Chair, Measurement Tape and Stop Watch.;Manual dexterity. Timepoint: before and after the intervention for the upper extremity. Method of measurement: 9 hole and peg board.;Modified Ashworth Scale. Timepoint: before and after intervention for upper and lower extremity. Method of measurement: Modified Ashworth Scale Questionnaire.;Berg balance scale. Timepoint: before and after the intervention for spastic Cerebral palsy children. Method of measurement: Berg Balance scale questioner.;Gross motor function. Timepoint: before and after the intervention for spastic crebral palsy children. Method of measurement: GMFM-88 scale ( Standing and sitting component).
    </Primary_outcome>
    <Source_Support>Tehran University of Medical Sciences
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>31/05/2023
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Tehran University of Medical Sciences (TUMS)
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13611184
    </Internal_Number>
    <TrialID>NCT05919485
    </TrialID>
    <Last_Refreshed_on>8 January 2024
    </Last_Refreshed_on>
    <Public_title>The Effects of Specific tDCS on Cognition in MCI
    </Public_title>
    <Scientific_title>The Effects of Specific Transcranial Direct Current Stimulation tDCS on Cognition in Mild Cognitive Impairment: A Novel Study Protocol
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Istanbul Medipol University Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20230608
    </Date_registration3>
    <Date_registration>08/06/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT05919485
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>45 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 1, 2023
    </Date_enrollement>
    <Target_size>120
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Turkey
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Burak Yulug, Prof. DR. MD;Cennet Sena Parlatan, pHD Cand
    </Contact_Lastname>
    <Contact_Email>burakyulug@gmail.com;cennet.parlatan@std.medipol.edu.tr
    </Contact_Email>
    <Contact_Tel>+90 242 510 6135;05077799164
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Providing an informed consent;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Literate and between 45-80 years of age;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. 60 females and 60 males;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Diagnosed with PD based on criteria suggested by UK Parkinson's Disease Society, Brain&#x0D;&lt;br&gt;             Bank and PD-MCI in accordance with the diagnostic criteria suggestions by Litvan;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Diagnosed with aMCI based on diagnosis criteria (CDR&amp;gt;0.5) suggested by Petersen;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. On a stable pharmacological treatment minimum for one month with no washout period.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Illiterate or education level less than primary school&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having an existing and/or prior neurological disease; psychiatric disease or head&#x0D;&lt;br&gt;             trauma; and/or irreversible hearing or sight problems or other medical illness (e.g.&#x0D;&lt;br&gt;             diabetes mellitus, hypertension);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Exhibiting signs of dementia for PD group ;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Having medical issues that prevent undergoing fMRI or for tDCS application.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Alzheimer Disease;Parkinson Disease
    </Condition>
    <Intervention>Procedure: tDCS
    </Intervention>
    <Primary_outcome>Neuropsychological Tests Scores
    </Primary_outcome>
    <Secondary_outcome>EEG Power Spectrum Analysis;EEG Coherence Analysis;EEG functional connectivity analysis;Volumetric Magnetic resonance Imaging (MRI) and functional magnetic resonance imaging (rest-fMRI)
    </Secondary_outcome>
    <Secondary_ID>2023IMU_ALKU
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Alanya Alaaddin Keykubat University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>12962731
    </Internal_Number>
    <TrialID>NCT05752240
    </TrialID>
    <Last_Refreshed_on>10 April 2023
    </Last_Refreshed_on>
    <Public_title>Transcranial Direct Current Stimulation of the Primary Motor Cortex to Treat Levodopa-induced Dyskinesias
    </Public_title>
    <Scientific_title>Transcranial Direct Current Stimulation of the Primary Motor Cortex to Treat Levodopa-induced Dyskinesias in Patients With Parkinson's Disease.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Fondazione Policlinico Universitario Agostino Gemelli IRCCS
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20230221
    </Date_registration3>
    <Date_registration>21/02/2023
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05752240
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>30 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 10, 2022
    </Date_enrollement>
    <Target_size>32
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Italy
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Francesco Bove, MD;Flavia Torlizzi
    </Contact_Lastname>
    <Contact_Email>francesco.bove@policlinicogemelli.it;flavia.torlizzi@policlinicogemelli.it
    </Contact_Email>
    <Contact_Tel>+390630156433;+390630156433
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients with diagnosis of idiopathic Parkinson's disease according to Movement&#x0D;&lt;br&gt;             Disorder Society (MDS) criteria and levodopa-induced dyskinesia;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age between 30 and 80 years;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  ongoing therapy with levodopa;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  fulfillment of requirements for the application of transcranial magnetic stimulation&#x0D;&lt;br&gt;             (TMS), assessed by completion of the TMS screening questionnaire.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  patients unable to give informed consent;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  cognitive impairment (MMSE = 24);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  history of epilepsy;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pregnant women.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Transcranial direct current stimulation
    </Intervention>
    <Primary_outcome>Reduction of dyskinesia
    </Primary_outcome>
    <Secondary_ID>3944
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>12776696
    </Internal_Number>
    <TrialID>NCT05678725
    </TrialID>
    <Last_Refreshed_on>23 January 2023
    </Last_Refreshed_on>
    <Public_title>Transcranial Direct/ Alternating Current Stimulation for Parkinson's Disease Treatment
    </Public_title>
    <Scientific_title>Comparison of Transcranial Direct Current Stimulation and Transcranial Alternating Current Stimulation Treatments in Improving the Motor and Cognitive Performance in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Anhui Medical University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20221214
    </Date_registration3>
    <Date_registration>14/12/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05678725
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 15, 2022
    </Date_enrollement>
    <Target_size>80
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Junjie Bu, Professor
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Anhui Medical University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of idiopathic PD according to the movement disorder society criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  right-handed&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  no clinically known hearing or vision impairment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  no history of epilepsy, dementia, other brain disorders apart from PD, severe internal&#x0D;&lt;br&gt;             organs disease, age-related frailty, etc.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  parkinsonism due to drugs, Cerebrovascular disease, encephalitis, poisoning, traumatic&#x0D;&lt;br&gt;             brain injury, etc.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Metal implants in the head (i.e., deep brain stimulator or aneurysm clips)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe somatic or psychiatric disorders that require medication or routinely&#x0D;&lt;br&gt;             monitoring&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  participated in other interventional studies within the past 3 months&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;tACS;tDCS
    </Condition>
    <Intervention>Device: tACS;Device: tDCS;Device: sham
    </Intervention>
    <Primary_outcome>the changes in UPDRS III;the changes in MoCA
    </Primary_outcome>
    <Secondary_outcome>simple reaction task;the changes in EEG power
    </Secondary_outcome>
    <Secondary_ID>tAtDComparePD
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>12776574
    </Internal_Number>
    <TrialID>NCT05670522
    </TrialID>
    <Last_Refreshed_on>23 January 2023
    </Last_Refreshed_on>
    <Public_title>Transcranial Direct Current Stimulation Versus Virtual Reality on Gait in Children With Spastic Diplegia
    </Public_title>
    <Scientific_title>Transcranial Direct Current Stimulation Versus Virtual Reality on Gait in Children With Spastic Diplegia
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Beni-Suef University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20221206
    </Date_registration3>
    <Date_registration>06/12/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05670522
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>7 Years
    </Inclusion_agemin>
    <Inclusion_agemax>12 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 11, 2020
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Egypt
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Hoda Eltalawy, PT, PhD;Asmaa Radwan, PT, MSc
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Cairo University, Egypt;Beni-Suef University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosed with diplegic CP&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  the ages 7-12 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  minimum spasticity grades of 1 and 1+ according to modified Ashworth Scale&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Gross motor function classification system (GMFCS) at level I or II.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Independent ambulation without any assistance or with minimal assistance&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A degree of cognition that allows understanding of the proposed procedures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  children who had visual impairments, hearing damage, fixed deformities at lower limbs,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of orthopedic surgeries or injection with botulinum toxin in the previous year&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Had metal implants in the skull&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of epilepsy or other neurological disorders&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  or inability to understand the task.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cerebral Palsy
    </Condition>
    <Intervention>Device: Transcranial direct current stimulation;Device: Virtual reality
    </Intervention>
    <Primary_outcome>Gait velocity (m/s) (Pre-treatment);Gait velocity (m/s) (post-treatment);Gait velocity (m/s) (Follow up)
    </Primary_outcome>
    <Secondary_outcome>Cadence (steps/min) (Pre-treatment);Cadence (steps/min) (post-treatment);Cadence (steps/min) (Follow up);Stance time (s) (Pre-treatment);Stance time (s) (post-treatment);Stance time (s) (Follow up);Swing time (s) (Pre-treatment);Swing time (s) (post-treatment);Swing time (s) (Follow up);Step length (cm) (Pre-treatment);Step length (cm) (post-treatment);Step length (cm) (Follow up);Stride length (cm) (Pre-treatment);Stride length (cm) (post-treatment);Stride length (cm) (Follow up);Maximum force (kg) (Pre-treatment);Maximum force (kg) (post-treatment);Maximum force (kg) (Follow up);Maximum peak pressure (N/cm²) (Pre-treatment);Maximum peak pressure (N/cm²) (post-treatment);Maximum peak pressure (N/cm²) (Follow up)
    </Secondary_outcome>
    <Secondary_ID>tDCS verus VR
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Shirley Ryan AbilityLab;Cairo University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>12510684
    </Internal_Number>
    <TrialID>IRCT20220725055552N1
    </TrialID>
    <Last_Refreshed_on>29 August 2022
    </Last_Refreshed_on>
    <Public_title>The effect of electrical stimulation in the treatment of upper limbs of cerebral palsy
    </Public_title>
    <Scientific_title>The effect of Transcranial Directed Current Stimulation on upper limb function in children with unilateral cerebral palsy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Shahid Beheshti University of Medical Sciences
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220727
    </Date_registration3>
    <Date_registration>2022-07-27
    </Date_registration>
    <Source_Register>IRCT
    </Source_Register>
    <web_address>http://en.irct.ir/trial/64932
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 years
    </Inclusion_agemin>
    <Inclusion_agemax>10 years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2022-07-26
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Randomization: Randomized, Blinding: Double bli
    </Study_design>
    <Phase>3
    </Phase>
    <Countries>Iran (Islamic Republic of);Iran (Islamic Republic of)
    </Countries>
    <Contact_Firstname>Behnam Ghaderian
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Seventh Floor, Haft Tir Crossroad, the beginning of Student Blvd., in front of the police station clinic, Ghasemi Alley, Arad Doctors Building, 7th floor
    </Contact_Address>
    <Contact_Email>behnamgh7491@gmail.com
    </Contact_Email>
    <Contact_Tel>+98 26 3271 5709
    </Contact_Tel>
    <Contact_Affiliation>Shahid Beheshti University of Medical Sciences
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: The person must be a hemiplegic cerebral palsy&lt;br&gt;The person must be 5-10 years old&lt;br&gt;The person without unstable medical conditions such as seizures
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Failure to attend more than one meeting.&lt;br&gt;Non-cooperation of children and their families until the end of the regular study period
    </Exclusion_Criteria>
    <Condition>Hemiplegia  cerebral palsy. &lt;br&gt;Spastic hemiplegic cerebral palsy;G80.2
    </Condition>
    <Intervention>Intervention 1: his group performed routine occupational therapy exercises for 45 minutes along with transcranial direct electrical stimulation technique, in which a low direct electric current with an intensity of 1.5-2 mV is injected into the primary motor area of the healthy hemisphere with a tDCS device. They receive for twenty minutes in each session and for twenty sessions in a period of one month. Intervention 2: Control group: This group receives routine occupational therapy exercises for forty-five minutes in each session and twenty sessions in a one-month period, and also to blind the participant, an electrical stimulation device is placed on the primary motor area of the healthy hemisphere for twenty minutes in each session. It can be done, but the stimulation does not take place.
    </Intervention>
    <Primary_outcome>Motor function of the upper limb. Timepoint: At the beginning of the intervention and after the end of the intervention. Method of measurement: Fugl-Meyer test.
    </Primary_outcome>
    <Secondary_outcome>Upper limb coordination. Timepoint: The beginning and end of the intervention. Method of measurement: Bruininks-Oseretsky test.;Upper limb Integration. Timepoint: The beginning and end of the intervention. Method of measurement: Bruininks-Oseretsky test.;Precision of fine movement. Timepoint: The beginning and end of the intervention. Method of measurement: Bruininks-Oseretsky test.;Upper extremity speed. Timepoint: The beginning and end of the intervention. Method of measurement: Box and block test.;Dexterity of Upper extremity. Timepoint: The beginning and end of the intervention. Method of measurement: Bruininks-Oseretsky test.
    </Secondary_outcome>
    <Source_Support>no
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>15/05/2022
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Ethics Committee of Shahid Beheshti University of Medical Sciences
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13433551
    </Internal_Number>
    <TrialID>JPRN-jRCTs042210161
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>transcranial direct current stimulation on neurological diseases
    </Public_title>
    <Scientific_title>Efficacy and safety of transcranial direct current stimulation on neurological diseases                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
    </Scientific_title>
    <Primary_sponsor>Nakatsuji Yuji
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220317
    </Date_registration3>
    <Date_registration>17/03/2022
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://jrct.niph.go.jp/latest-detail/jRCTs042210161
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>&gt;= 20age old
    </Inclusion_agemin>
    <Inclusion_agemax>Not applicable
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>27/05/2022
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>randomized controlled trial, double blind, placebo control, crossover assignment, treatment purpose
    </Study_design>
    <Phase>1-2
    </Phase>
    <Contact_Firstname>Ryoko
    </Contact_Firstname>
    <Contact_Lastname>Shibuya
    </Contact_Lastname>
    <Contact_Address>2630 Sugitani, Toyama City, Toyama
    </Contact_Address>
    <Contact_Email>ryosan@med.u-toyama.ac.jp
    </Contact_Email>
    <Contact_Tel>+81-76-434-7309
    </Contact_Tel>
    <Contact_Affiliation>Toyama University Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Neurological diseases
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Cases who have medical devices containing magnetic parts or electronic circuits in the bodies.
    </Exclusion_Criteria>
    <Condition>multiple screlosis and neuromyelitis optica, parkinson's disease (including parkinson syndrome)
    </Condition>
    <Intervention>Subjects are randomly divided into 2 groups: an intervention group (actual stimulation at the beginning) and sham group (sham stimulation at the beginning and stimulated by Transcranial direct current(1.0-2.0 mA) with the rehabilitation(ROM-ex, Muscle strength-ex etc).;tDCS, neurological disease
    </Intervention>
    <Primary_outcome>Expanded Disability Status Scale (EDSS), The MDS-sponsored Revision of the Unified Parkinson's Disease Rating Scale(MDS-UPDRS), Brief Repeatable Battery of Neuropsychological tests in multiple sclerosis(BRB-N), Visual analog scale(VAS), Numeric rating scale (NRS)
    </Primary_outcome>
    <Secondary_outcome>Biochemical Examination of blood, Magnetic Resonance Imaging(Brain)
    </Secondary_outcome>
    <Ethics_review_status>Approval
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>rinken@adm.u-toyama.ac.jp
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Clinical Research Review Board, University of Toyama
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+81-76-415-8857
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>rinken@adm.u-toyama.ac.jp
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>11986819
    </Internal_Number>
    <TrialID>NCT05264909
    </TrialID>
    <Last_Refreshed_on>7 March 2022
    </Last_Refreshed_on>
    <Public_title>Assessment of Transcranial Electrical Stimulation and Auditory Stimulation During Walking in Parkinson Patients
    </Public_title>
    <Scientific_title>Assessment of Transcranial Electrical Stimulation and Auditory Stimulation During Walking in Parkinson Patients
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Corporación de Rehabilitación Club de Leones Cruz del Sur
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20220222
    </Date_registration3>
    <Date_registration>22/02/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05264909
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 1, 2021
    </Date_enrollement>
    <Target_size>5
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Chile
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Patricio E Barría Aburto, MSc.;Patricio E Barria Aburto, MSc;Patricio E Barria Aburto, MSc. Eng
    </Contact_Lastname>
    <Contact_Email>;pbarria@rehabilitamos.org;pbarria@rehabilitamos.org
    </Contact_Email>
    <Contact_Tel>;+569684585709;+560612202200
    </Contact_Tel>
    <Contact_Affiliation>Corporación de Rehabilitacion Club de Leones Cruz del Sur;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parkinson Disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Both gender&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed consent accepted&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adults&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mental diseases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Injuries in the scalp skin&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inflammatory tegumentary diseases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Migraines&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Multi-channel Transcranial direct current stimulation
    </Intervention>
    <Primary_outcome>Gait Deviation Index Baseline;Gait Deviation Index Post-Intervention
    </Primary_outcome>
    <Secondary_outcome>EEG signals from primary motor cortex Baseline;EEG signals from primary motor cortex Baseline Post-Intervention
    </Secondary_outcome>
    <Secondary_ID>CorporacionRCLCS0006
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Colombian School of Engineering Julio Garavito;Universidad del Rosario
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>12652254
    </Internal_Number>
    <TrialID>NCT05243394
    </TrialID>
    <Last_Refreshed_on>14 November 2022
    </Last_Refreshed_on>
    <Public_title>Effects of a Treadmill Gait Training Protocol in a Gamified Virtual Reality Environment With tDCS in Parkinson's Disease
    </Public_title>
    <Scientific_title>Evaluating the Effects of a Treadmill Gait Training Protocol in a Gamified Virtual Reality Environment With tDCS in Parkinson's Disease: Randomized Controlled Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Universitat de Lleida
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20220120
    </Date_registration3>
    <Date_registration>20/01/2022
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05243394
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 2023
    </Date_enrollement>
    <Target_size>66
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Spain
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Helena Fernández-Lago;Helena Fernández-Lago;Helena Fernández-Lago
    </Contact_Lastname>
    <Contact_Email>;helena.fernandez@udl.cat;helena.fernandez@udl.cat
    </Contact_Email>
    <Contact_Tel>;973702282;973702282
    </Contact_Tel>
    <Contact_Affiliation>Universitat de Lleida;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic Parkinson's Disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Stage II - III in the Hoehn and Yahr Scale during ON state&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to walk for 10 minutes independently without stop&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Significant cognitive decline based on mini mental status examination (MMSE &lt;23)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe auditory or visual deficits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other neurological/psychiatric conditions&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any kind of cardiovascular complications that contraindicates physical activity&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical history of any brain surgery or deep brain stimulation device&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: Gamified virtual reality treadmill gait training with tDCS;Other: Gamified virtual reality treadmill gait training;Other: Treadmill gait training
    </Intervention>
    <Primary_outcome>Stride lenght;Speed;Step cadence;Stride Length during Dual Task;Speed during Dual Task;Step cadence during Dual Task;Stride Length Variation Coeficient;Stride Length Variation Coeficient during Dual Task;Step Cadence Variation Coeficient;Step Cadence Variation Coeficient during Dual Task
    </Primary_outcome>
    <Secondary_outcome>Total Cognitive Performance;Unified Parkinson's Disease Rating Scale (UPDRS);Hoehn &amp; Yahr;Parkinson's Disease Questionnaire 39;MiniBest Test;Montreal Cognitive Assessment
    </Secondary_outcome>
    <Secondary_ID>PI20/00403
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Turku;University of Maryland, Baltimore
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13646949
    </Internal_Number>
    <TrialID>DRKS00026640
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Multifocal tDCS in patients with Parkinson's Disease
    </Public_title>
    <Scientific_title>Multifocal tDCS in patients with Parkinson's Disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
    </Scientific_title>
    <Primary_sponsor>Charité Campus Charité Mitte
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210920
    </Date_registration3>
    <Date_registration>20/09/2021
    </Date_registration>
    <Source_Register>German Clinical Trials Register
    </Source_Register>
    <web_address>http://drks.de/search/en/trial/DRKS00026640
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>21/09/2021
    </Date_enrollement>
    <Target_size>21
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Allocation: Randomized controlled study; Masking: Blinded (masking used); Control: placebo; Assignment: crossover; Study design purpose: treatment 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Germany
    </Countries>
    <Contact_Firstname>Lukas
    </Contact_Firstname>
    <Contact_Lastname>Goede
    </Contact_Lastname>
    <Contact_Address>Charitéplatz 1
    </Contact_Address>
    <Contact_Email>lukas.goede@charite.de
    </Contact_Email>
    <Contact_Tel>+4930450660543
    </Contact_Tel>
    <Contact_Affiliation>Charité Campus Charité Mitte
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Patients with Parkinson's disease, age 40-70 years, informed consent
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Pronounced concomitant psychiatric symptoms (dementia symptoms, affective disorder), metal implants in the head, pacemaker, acute eczema of the scalp, known epilepsy, pregnancy, sensorineural hearing prosthesis, marked limitations of cognitive functions and verbal utterance
    </Exclusion_Criteria>
    <Condition> &lt;br&gt;G20;Parkinson disease
    </Condition>
    <Intervention>Group 1: 20 min network targeted multifocal tDCS&lt;br&gt;Group 2: 20 min sham stimulation
    </Intervention>
    <Primary_outcome>Changes in UPDRS-III as well as amplitude and velocity of diadochokinesis. Values will be compared to measurements on day of sham stimulation.
    </Primary_outcome>
    <Secondary_outcome>Subjective perception of the patients about the effect of the stimulation written in a scale (0-10)
    </Secondary_outcome>
    <Source_Support>Deutsche Forschungsgemeinschaft
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>22/10/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>ethikkommission@charite.de
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Ethikkommission der Charité – Universitätsmedizin Berlin
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>(+49)30-450517222
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>ethikkommission@charite.de
    </Ethics_review_contact_email>
    <results_date_completed>23/09/2022
    </results_date_completed>
    <results_url_link>http://drks.de/search/en/trial/DRKS00026640#studyResults
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13135909
    </Internal_Number>
    <TrialID>NCT05071586
    </TrialID>
    <Last_Refreshed_on>26 June 2023
    </Last_Refreshed_on>
    <Public_title>Pediatric Teleneuromodulation
    </Public_title>
    <Scientific_title>Remotely Monitored Transcranial Direct Current Stimulation in Children With Cerebral Palsy
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Wisconsin, Madison
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210913
    </Date_registration3>
    <Date_registration>13/09/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT05071586
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>8 Years
    </Inclusion_agemin>
    <Inclusion_agemax>21 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 21, 2022
    </Date_enrollement>
    <Target_size>10
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Bernadette Gillick, PhD, MSPT
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Wisconsin, Madison
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Aged between 8 years 0 days and 21 years 365 days&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children who have hemiparetic cerebral palsy with a history of perinatal brain&#x0D;&lt;br&gt;             bleed/stroke&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Receptive language function to follow two-step commands&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to give informed assent along with the informed consent of the legal guardian. If&#x0D;&lt;br&gt;             the participant is 18-21 (with the capacity to consent), they must be able to give&#x0D;&lt;br&gt;             informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Intentional about representing the sub-population of children with CP who experience&#x0D;&lt;br&gt;             intellectual disability (at least 2/10 participants with mild intellectual&#x0D;&lt;br&gt;             disabilities will be recruited)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  = 10 degrees of active motion at the metacarpophalangeal joint&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Children who have had surgeries, which may influence motor function e.g.- tendon&#x0D;&lt;br&gt;             transfer, will be included, yet surgical history will be documented and included in&#x0D;&lt;br&gt;             any publication within a participant characteristics table.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Inaccessibility to internet and a working computer/laptop/device.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Implants&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neoplasm&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Metabolic Disorders&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Seizure within two years preceding the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Acquired Traumatic Brain Injury&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Indwelling metal or incompatible medical devices&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of skin disease or skin abnormalities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Botulinum toxin or Phenol block within [six-months] preceding the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Disorder of Cellular Migration and Proliferation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        To be eligible for the optional 6-month/12-month follow-up:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  participants must have previously participated in the primary study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  have access to a reliable internet connection and a functioning computer, laptop, or&#x0D;&lt;br&gt;             mobile device.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  If participants become pregnant after participating in primary study, they may&#x0D;&lt;br&gt;             participate in the 6- and 12-month follow up sessions&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cerebral Palsy (CP)
    </Condition>
    <Intervention>Device: Soterix 1x1 tDCS LTE Stimulator Device Model 1401
    </Intervention>
    <Primary_outcome>Status/Safety Assessment;Status/Safety Assessment;Status/Safety Assessment;Change in tDCS headgear location;Change in responses to ease of set up survey;Change in responses to comfort survey;Medical Record Review at 6 months;Medical Record Review at 12 months;Change in tDCS Subject Report of Symptoms Questionnaire;Change in Qualitative tDCS Tolerance Survey;Change in Gross Motor Function Classification System
    </Primary_outcome>
    <Secondary_outcome>Change in time to complete montage setup;Change in contact quality (CQ);Change in Box and Blocks assessment score
    </Secondary_outcome>
    <Secondary_ID>Protocol ver 8 5/4/2023;Development Pediatrics;2021-0691
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>11987680
    </Internal_Number>
    <TrialID>ChiCTR2100047946
    </TrialID>
    <Last_Refreshed_on>7 March 2022
    </Last_Refreshed_on>
    <Public_title>Observation on the effect of hydrotherapy combined with transcranial direct current stimulation on children with cerebral palsy
    </Public_title>
    <Scientific_title>Observation on the effect of hydrotherapy combined with transcranial direct current stimulation on children with cerebral palsy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>the Second Affiliated Hospital of Qiqihar Medical University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210628
    </Date_registration3>
    <Date_registration>2021-06-28
    </Date_registration>
    <Source_Register>ChiCTR
    </Source_Register>
    <web_address>http://www.chictr.org.cn/showproj.aspx?proj=128232
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>4
    </Inclusion_agemin>
    <Inclusion_agemax>14
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2021-08-01
    </Date_enrollement>
    <Target_size>Experimental group:75;Control group:75;
    </Target_size>
    <Study_type>Interventional study
    </Study_type>
    <Study_design>Parallel
    </Study_design>
    <Phase>0
    </Phase>
    <Countries>China
    </Countries>
    <Contact_Firstname>Chen Xiaoliang
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>37 Zhonghua Road West, Longsha District, Qiqihar, Heilongjiang
    </Contact_Address>
    <Contact_Email>2010662788@qq.com
    </Contact_Email>
    <Contact_Tel>+86 13919088491
    </Contact_Tel>
    <Contact_Affiliation>the Second Affiliated Hospital of Qiqihar Medical University
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Patients with cerebral palsy aged 4-14;&#x0D;&lt;br&gt;2. Patients diagnosed with cerebral palsy according to the diagnostic criteria of the Chinese Medical Association Rehabilitation Specialist Group;&#x0D;&lt;br&gt;3. Voluntarily participate and sign the informed consent.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Visual, auditory and mental disorders affecting the evaluation results;&#x0D;&lt;br&gt;2. Children with epilepsy that cannot be controlled by drug treatment;&#x0D;&lt;br&gt;3. Skin problems such as open wounds or active infections;&#x0D;&lt;br&gt;4. Have received botulinum toxin injection or surgery within 6 months before the start of the project;&#x0D;&lt;br&gt;5. Participate in another clinical trial;&#x0D;&lt;br&gt;6. Patients with unclear consciousness, abnormal or uncontrollable behavior, and prone to medical malpractice during treatment.
    </Exclusion_Criteria>
    <Condition>cerebral palsy
    </Condition>
    <Intervention>Experimental group:hydrotherapy plus tDCS;Control group:treatment as usual;
    </Intervention>
    <Primary_outcome>Gross Motor Function Measure 88 (GMFM-88);Pediatric Balance Scale (PBS);
    </Primary_outcome>
    <Secondary_outcome>The Pediatric Evaluation Disability Inventory (PEDI);
    </Secondary_outcome>
    <Source_Support>self-funded
    </Source_Support>
    <Ethics_review_status>Not approved
    </Ethics_review_status>
    <Ethics_review_approval_date>26/08/2013
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>12361347
    </Internal_Number>
    <TrialID>NCT04811066
    </TrialID>
    <Last_Refreshed_on>20 June 2022
    </Last_Refreshed_on>
    <Public_title>Motor Learning and Multi-session tDCS in Parkinson's Disease
    </Public_title>
    <Scientific_title>The Effect of Multi-session Transcranial Direct Current Stimulation Applied Over the Primary Motor Cortex on Motor Sequence Learning in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>The Hong Kong Polytechnic University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210319
    </Date_registration3>
    <Date_registration>19/03/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04811066
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>April 19, 2021
    </Date_enrollement>
    <Target_size>48
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Hong Kong
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Margaret Mak, Dr
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>The Hong Kong Polytechnic University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Right-handed (Edinburgh Handedness Inventory; =50)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitively capable (Montreal Cognitive Assessment (MoCA); =23)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mild to moderate Parkinson's disease severity (Hoehn and Yar disease stage 2-3)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  On stable dopaminergic medication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of stroke&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Comorbidity&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cephalic implants&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Transcranial direct current stimulation
    </Intervention>
    <Primary_outcome>Change from baseline: sequential finger tapping performance;Change from baseline: shape-counting error
    </Primary_outcome>
    <Secondary_outcome>Change from baseline: oxygenated haemoglobin response;Change from baseline: Movement Disorders Society Unified Parkinson's Disease Rating Scale Motor Section (Part 3);Change from baseline: upper limb motor task performance;Change from baseline: Purdue pegboard task performance
    </Secondary_outcome>
    <Secondary_ID>HSEARS20200203002
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10819418
    </Internal_Number>
    <TrialID>NCT04819061
    </TrialID>
    <Last_Refreshed_on>12 April 2021
    </Last_Refreshed_on>
    <Public_title>Predicting Outcomes From tDCS Intervention in Parkinson' Disease Using Electroencephalographic Biomarkers and Machine Learning Approach: the PREDICT Study Protocol
    </Public_title>
    <Scientific_title>Predicting Outcomes From tDCS Intervention in Parkinson' Disease Using Electroencephalographic Biomarkers and Machine Learning Approach: the PREDICT Study Protocol
    </Scientific_title>
    <Acronym>PREDICT
    </Acronym>
    <Primary_sponsor>Federal University of Paraíba
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210306
    </Date_registration3>
    <Date_registration>06/03/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04819061
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 1, 2021
    </Date_enrollement>
    <Target_size>56
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: Triple (Participant, Care Provider, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Suellen Andrade
    </Contact_Lastname>
    <Contact_Email>suellenandrade@gmail.com
    </Contact_Email>
    <Contact_Tel>986046032
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of idiopathic Parkinson's disease by a neurologist based on Parkinson's&#x0D;&lt;br&gt;             Disease Society Brain Bank (PDSBB) criteria (Hughes et al.,1992)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Disease staging between 1.5 and 3, according to the modified Hoehn and Yahr scale&#x0D;&lt;br&gt;             (Hoehn and Yahr, 1967)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Regular pharmacological treatment with levodopa (equivalent dose &gt; 300mg) or taking&#x0D;&lt;br&gt;             antiparkinsonian medication such as anticholinergics, selegiline, dopamine agonists&#x0D;&lt;br&gt;             (amantadine) and COMT (catechol-O-methyl transferase) inhibitors&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Score of more than 24 points on the Mini-Mental State Examination (Folstein et al.,&#x0D;&lt;br&gt;             1975)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Associated neurological, musculoskeletal and/or cardiorespiratory diseases that could&#x0D;&lt;br&gt;             compromise gait;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  alcohol or substance abuse disorders;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Deep brain stimulation implant;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of brain trauma or neurological disease that would interfere with study&#x0D;&lt;br&gt;             procedures.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Electroencephalogram;Transcranial Direct Current Stimulation
    </Condition>
    <Intervention>Other: tDCS Active;Other: tDCS sham
    </Intervention>
    <Primary_outcome>Functional Mobility measured using the Timed Up and Go test (Podsiadlo D, Richardson S, 1991)
    </Primary_outcome>
    <Secondary_ID>EEGtDCS
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Universidade Federal do Rio Grande do Norte
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>11335817
    </Internal_Number>
    <TrialID>NCT04787406
    </TrialID>
    <Last_Refreshed_on>7 September 2021
    </Last_Refreshed_on>
    <Public_title>Motor Learning and tDCS in Parkinson's Disease
    </Public_title>
    <Scientific_title>The Effect of Single Session Transcranial Direct Current Stimulation on Sequential Motor Learning in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>The Hong Kong Polytechnic University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20210301
    </Date_registration3>
    <Date_registration>01/03/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04787406
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 7, 2019
    </Date_enrollement>
    <Target_size>33
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Hong Kong
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Magaret Mak, Dr
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>The Hong Kong Polytechnic University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Right-handed (Edinburgh Handedness Inventory; =50)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitively capable (Montreal Cognitive Assessment (MoCA); =23)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mild to moderate Parkinson's disease severity (Hoehn and Yar disease stage 2-3)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of stroke&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Comorbidity&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cephalic implants&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Transcranial direct current stimulation
    </Intervention>
    <Primary_outcome>Change from baseline sequential finger tapping performance;Change from baseline oxygenated haemoglobin response;Change from baseline shape-counting error
    </Primary_outcome>
    <Secondary_ID>HSEARS20181226002
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10590356
    </Internal_Number>
    <TrialID>NCT04725019
    </TrialID>
    <Last_Refreshed_on>1 February 2021
    </Last_Refreshed_on>
    <Public_title>Enhancing Motor Learning in Children With Cerebral Palsy Using Transcranial Direct-current Stimulation
    </Public_title>
    <Scientific_title>Enhancing Motor Learning in Children With Cerebral Palsy Using Transcranial Direct-current Stimulation
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Boston University Charles River Campus
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20210119
    </Date_registration3>
    <Date_registration>19/01/2021
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04725019
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Years
    </Inclusion_agemin>
    <Inclusion_agemax>17 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>August 1, 2021
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Claudio L Ferre, PhD
    </Contact_Lastname>
    <Contact_Email>clferre@bu.edu
    </Contact_Email>
    <Contact_Tel>(617) 353-7489
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Children between 6-17 years old who have been diagnosed with cerebral palsy, with the&#x0D;&lt;br&gt;        following joint mobility: wrist extension 20º, metacarpophalangeal and proximal&#x0D;&lt;br&gt;        interphalangeal joints 10º. Ability to cooperate and follow simple directions.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Seizure beyond age 2, use of anti-seizure medication, history or family history of&#x0D;&lt;br&gt;             epilepsy, cranial metal implants, structural brain lesion, devices that may be&#x0D;&lt;br&gt;             affected by tDCS or TMS (pacemaker, medication pump, cochlear implant, implanted brain&#x0D;&lt;br&gt;             stimulator)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  True positive response on the Transcranial Magnetic Stimulation and MRI Safety Screen&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current use of medications known to lower the seizure threshold&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous episode of unprovoked neurocardiogenic syncope&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Indwelling metal or incompatible medical devices&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Centrally-acting medications including anti-seizure medications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of scalp disease or skin abnormalities&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current medical illness unrelated to CP&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High motor ability in affected arm (i.e. no asymmetry in scores of hand function)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe spasticity&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Lack of asymmetry in hand function&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Orthopedic surgery in affected arm&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Botulinum toxin therapy in either upper extremity during last 6 months, or planned&#x0D;&lt;br&gt;             during study period&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently receiving intrathecal baclofen&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of broken arm (either arm) 1 year prior to study enrollment&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cerebral Palsy
    </Condition>
    <Intervention>Device: active transcranial direct current stimulation;Behavioral: Motor training
    </Intervention>
    <Primary_outcome>Changes in the Assisting Hand Assessment;Changes in the Box and Blocks test
    </Primary_outcome>
    <Secondary_outcome>Changes in Motor-evoked Potential assessment
    </Secondary_outcome>
    <Secondary_ID>5825
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13063393
    </Internal_Number>
    <TrialID>NCT04759898
    </TrialID>
    <Last_Refreshed_on>22 May 2023
    </Last_Refreshed_on>
    <Public_title>Direct Measurement of Motor Cortical Responses to tDCS
    </Public_title>
    <Scientific_title>Direct Measurement of Motor Cortical Responses to Transcranial Direct Current Stimulation
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Medical University of South Carolina
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201221
    </Date_registration3>
    <Date_registration>21/12/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04759898
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2021
    </Date_enrollement>
    <Target_size>80
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Nathan C Rowland, MD,PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Medical University of South Carolina
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 18 or older&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous consent to be contacted regarding potential participation in a research study&#x0D;&lt;br&gt;             at Medical University of South Carolina&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects unable to actively participate in the consent process physically and/or&#x0D;&lt;br&gt;             cognitively&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of scalp injury or disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prior history of seizures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Metal implants in head or neck&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prior intracranial surgery&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prior brain radiotherapy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Prior history of intracranial tumor, intracranial infection or cerebrovascular&#x0D;&lt;br&gt;             malformation&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Chronic Stroke
    </Condition>
    <Intervention>Device: transcranial direct current stimulation (noninvasive recording);Device: sham transcranial direct current stimulation (noninvasive recording);Device: transcranial direct current stimulation (invasive recording)
    </Intervention>
    <Primary_outcome>Change in primary motor cortical (PriMC) beta oscillations during cued arm reaching in relation to anodal tDCS activation;Change in primary motor cortical (PriMC) beta oscillations during arm flexion in relation to anodal tDCS activation
    </Primary_outcome>
    <Secondary_ID>00073545
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13217418
    </Internal_Number>
    <TrialID>NCT04655079
    </TrialID>
    <Last_Refreshed_on>21 August 2023
    </Last_Refreshed_on>
    <Public_title>Efficacy and Safety of Transcranial dIrect Current stiMulation (tDCS) in Progressive Supranuclear Palsy (PSP) (STIM-PSP)
    </Public_title>
    <Scientific_title>Efficacy and Safety of Transcranial dIrect Current stiMulation (tDCS) on Motor and Cognitive Symptoms in Progressive Supranuclear Palsy (PSP) (STIM-PSP)
    </Scientific_title>
    <Acronym>STIM-PSP
    </Acronym>
    <Primary_sponsor>University of Salerno
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201127
    </Date_registration3>
    <Date_registration>27/11/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04655079
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>89 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 1, 2021
    </Date_enrollement>
    <Target_size>24
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Italy
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of PSP according with Movement Disorder Society (MDS) criteria (Hoglinger et&#x0D;&lt;br&gt;             al., 2017);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &gt; 40 and &lt; 89 years;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of a caregiver supportive the patient for all study procedure;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to walk for at least 5 steps either independently or with a minimum support&#x0D;&lt;br&gt;             (another patients holding patient's arm or with a walker)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of electrical stimulators (for example, pacemaker, Deep Brain Stimulation,&#x0D;&lt;br&gt;             DBS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Difficult in understanding Italian language&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of severe sensory deficits (for example, visual or hearing impairments)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Education level &lt;5 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of drug abuse&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of severe psychiatric disorders&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of transient ischemic attacks&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cortical or sub-cortical vascular lesions&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Seizures or severe heart problems and previous neurosurgical operations&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Absence of subjective cognitive deficits&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MMSE (Mini-Mental State Examination) score &lt;20&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Left-handedness&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Progressive Supranuclear Palsy;Motor and Cognitive Symptoms
    </Condition>
    <Intervention>Device: Anodal transcranial direct current stimulation (a-tDCS);Device: Sham Condition
    </Intervention>
    <Primary_outcome>Change from baseline to 3-month follow up in verbal fluency task
    </Primary_outcome>
    <Secondary_outcome>Change from baseline to 3-month follow in motor symptoms as assessed with sensor recordings (OPAL system);Change from baseline to 3-month follow up in cognitive symptoms as assessed with Montreal Cognitive Assessment (MOCA);Change from baseline to 3-month follow up in caregiver distress as assessed with Neuropshychiatric Inventory (NPI);Change from baseline to 3-month follow up in executive function as assessed with Frontal Assessment Battery (FAB);Change from baseline to 3-month follow up in attention as assessed with Frontal Assessment Battery (FAB);Change from baseline to 3-month follow up in caregiver distress as assessed with Zarit Carer Burden Burden Interview (ZBI)
    </Secondary_outcome>
    <Secondary_ID>tDCS 01-2020
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>12790117
    </Internal_Number>
    <TrialID>NCT04651699
    </TrialID>
    <Last_Refreshed_on>6 February 2023
    </Last_Refreshed_on>
    <Public_title>Non-Invasive Brain Stimulation for the Treatment of Parkinson´s Disease-related Pain
    </Public_title>
    <Scientific_title>Non-Invasive Brain Stimulation Targeting Pain in Parkinson´s Disease Patients: A Randomized Controlled Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Universidad Francisco de Vitoria
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201119
    </Date_registration3>
    <Date_registration>19/11/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04651699
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 3, 2021
    </Date_enrollement>
    <Target_size>22
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Spain
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Juan Pablo Romero Muñoz, MD PhD;Josué Fernandez Carnero, PT PhD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>Universidad Francisco de Vitoria, Facultad de Ciencias Experimentales;Universidad Rey Juan Carlos
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neuroimaging study without previous pathologies.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Score &gt; 5 in transfers (bed to chair and back) item in Barthel Index.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Score = or &gt; 24 in Mini-Mental State Examination.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Tolerability for the application of electrotherapy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to provide informed consent to participate in the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neurologic disease different from PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pain non-related to PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dermatologic problems, wounds, or ulcers in the electrode's application area.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of implants or metal pieces in the head.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of cardiac pacemaker, vagal, brain or transcutaneous stimulators, medication&#x0D;&lt;br&gt;             pumps, ventriculoperitoneal shunts or aneurysm clips.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Significative difficulties in language.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of alcohol or drugs abuse.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Non-controlled medical problems.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnancy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Epilepsy.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Pain
    </Condition>
    <Intervention>Device: Active Transcranial Direct Current Stimulation;Device: Sham Transcranial Direct Current Stimulation
    </Intervention>
    <Primary_outcome>Change in King´s Parkinson´s Disease Pain Scale score;Change in King´s Parkinson´s Disease Pain Scale score;Change in Brief Pain Inventory score;Change in Brief Pain Inventory score;Change in Conditioned Pain Modulation;Change in Conditioned Pain Modulation;Change in Temporal Summation;Change in Temporal Summation;Changes in Pain Pressure Threshold;Changes in Pain Pressure Threshold
    </Primary_outcome>
    <Secondary_outcome>Beck Depression Inventory;Beck Depression Inventory;Beck Depression Inventory;State-Trait Anxiety Inventory;State-Trait Anxiety Inventory;State-Trait Anxiety Inventory;Tampa Scale of Kinesiophobia;Tampa Scale of Kinesiophobia;Tampa Scale of Kinesiophobia;Pain Catastrophizing Scale;Pain Catastrophizing Scale;Pain Catastrophizing Scale;Unified Parkinson´s Disease Rating Scale;Unified Parkinson´s Disease Rating Scale;Unified Parkinson´s Disease Rating Scale;Reaction Times;Reaction Times;Reaction Times;Transcranial Magnetic Stimulation;Transcranial Magnetic Stimulation;Transcranial Magnetic Stimulation
    </Secondary_outcome>
    <Secondary_ID>PainPD-tDCS
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Universidad Rey Juan Carlos;Hospital Beata María Ana
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13432929
    </Internal_Number>
    <TrialID>JPRN-jRCTs032200173
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Effect of tDCS on freezing of gait
    </Public_title>
    <Scientific_title>Effect of transcranial direct current stimulation on freezing of gait                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
    </Scientific_title>
    <Primary_sponsor>Umemura Atsushi
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201026
    </Date_registration3>
    <Date_registration>26/10/2020
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://jrct.niph.go.jp/latest-detail/jRCTs032200173
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>&gt;= 20age old
    </Inclusion_agemin>
    <Inclusion_agemax>Not applicable
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>20/02/2021
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>single arm study, open(masking not used), placebo control, single assignment, treatment purpose
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname>Atsushi
    </Contact_Firstname>
    <Contact_Lastname>Umemura
    </Contact_Lastname>
    <Contact_Address>3-1-3 Hongo, Bunkyo-ku, Tokyo, Japan
    </Contact_Address>
    <Contact_Email>aumemura@juntendo.ac.jp
    </Contact_Email>
    <Contact_Tel>+81-3-3813-3111
    </Contact_Tel>
    <Contact_Affiliation>Juntendo University
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1. Male and female patient aged 20 or older.&lt;br&gt;2. Patients diagnosed with Parkinson disease or Parkinson syndrome who are admitted to Department of Neurosurgery or Neurology, Juntendo Hospital, Juntendo University School of Medicine, for examination or treatment purpose.&lt;br&gt;3. Patients who suffer from freezing of gait.&lt;br&gt;4. Participants who have been given sufficient explanations to participate in this study and have given their full understanding and consent
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Patients who use implantable medical or electronic devices such as deep brain stimulation, pacemakers and defibrillators&lt;br&gt;2. Patients who are judged by the investigator to have a psychiatric problem, such as unrelated clinically significant depression&lt;br&gt;3. Patients who have injuries or defects in the stimulated part of the skull&lt;br&gt;4. Patients who have a history of epilepsy or seizures&lt;br&gt;5. Patients who have a metal coil in the skull&lt;br&gt;6. Patients who the investigator judged to be inappropriate as subjects
    </Exclusion_Criteria>
    <Condition>Parkinson disease, Parkinson syndrome &lt;br&gt;Parkinson disease, Parkinson syndrome;Parkinson disease, Parkinson syndrome
    </Condition>
    <Intervention>Transcranial direct current stimulation to supplementary motor cortex and primary motor cortex;Transcranial direct current stimulation
    </Intervention>
    <Primary_outcome>[PART1]&lt;br&gt;Comparison of changes in walking distance for 30 seconds from baseline to SMA and sham stimulation&lt;br&gt;[PART2]&lt;br&gt;Comparison of changes in walking distance for 30 seconds from baseline to M1 and sham stimulation
    </Primary_outcome>
    <Secondary_outcome>Walking time and number of steps in 10m walk&lt;br&gt;Timed Up and Go test&lt;br&gt;360 degree turn test
    </Secondary_outcome>
    <Ethics_review_status>Approval
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>crbjun@juntendo.ac.jp
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>Juntendo Hospital Certified Review Board
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+81-3-5802-1584
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>crbjun@juntendo.ac.jp
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>12261751
    </Internal_Number>
    <TrialID>NCT04606979
    </TrialID>
    <Last_Refreshed_on>9 May 2022
    </Last_Refreshed_on>
    <Public_title>tDCS of the Primary Motor Cortex to Improve Implicit Motor Sequence Learning in Parkinson's Disease
    </Public_title>
    <Scientific_title>The Potential of Transcranial Direct Current Stimulation of the Primary Motor Cortex to Promote Implicit Motor Sequence Learning in Individuals With Parkinson's Disease and Age-matched Healthy Controls
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Vrije Universiteit Brussel
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20201010
    </Date_registration3>
    <Date_registration>10/10/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04606979
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>55 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 11, 2020
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Belgium
    </Countries>
    <Contact_Firstname> ; ; ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Natacha Deroost, PhD;Kris Baetens, PhD;Chris Baeken, PhD, MD;Frank Van Overwalle, PhD;Eva Swinnen, PhD;Mahyar Firouzi, PhD
    </Contact_Lastname>
    <Contact_Email>;;;;;
    </Contact_Email>
    <Contact_Tel>;;;;;
    </Contact_Tel>
    <Contact_Affiliation>Vrije Universiteit Brussel - Brain Body and Cognition Research Group;Vrije Universiteit Brussel - Brain Body and Cognition Research Group;University Ghent;Vrije Universiteit Brussel - Brain Body and Cognition Research Group;Vrije Universiteit Brussel - Rehabilitation Research Group;Vrije Universiteit Brussel - Brain Body and Cognition Research Group
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosed with the idiopathic form of PD by a neurologist (PD subjects only)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dutch or French speaking&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  sufficient upper limb motor skills to perform the SRT-task (determined by means of a&#x0D;&lt;br&gt;             practice version of the SRT-task consisting of one block of 50 random trials)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  able to signal pain or discomfort&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  able to give informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  additional neurological disorders&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  any of the following tDCS contra-indications: deep brain stimulator; pacemaker; head&#x0D;&lt;br&gt;             wound; skin condition of the scalp; a history of epilepsy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Parkinson;Healthy
    </Condition>
    <Intervention>Device: 1x1 Low Intensity Transcranial Direct Current Stimulation (tDCS)
    </Intervention>
    <Primary_outcome>Serial Reaction Time task: Sequence-Specific Learning Effect (during and following active tDCS);Serial Reaction Time task: Sequence-Specific Learning Effect (during and following sham tDCS)
    </Primary_outcome>
    <Secondary_outcome>Serial Reaction Time task: General Learning Effect (during and following active tDCS);Serial Reaction Time task: General Learning Effect (during and following sham tDCS)
    </Secondary_outcome>
    <Secondary_ID>B1432020000012
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13658511
    </Internal_Number>
    <TrialID>TCTR20200909005
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Different transcranial direct current stimulation applications on dual task gait performance and cortical activity in Parkinson&amp;#039;s disease
    </Public_title>
    <Scientific_title>Different transcranial direct current stimulation applications on dual task gait performance and cortical activity in Parkinson&amp;#039;s disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>National Yang-Ming University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200909
    </Date_registration3>
    <Date_registration>09/09/2020
    </Date_registration>
    <Source_Register>TCTR
    </Source_Register>
    <web_address>https://www.thaiclinicaltrials.org/show/TCTR20200909005
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>09/10/2020
    </Date_enrollement>
    <Target_size>36
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Taiwan
    </Countries>
    <Contact_Firstname>Ray yau
    </Contact_Firstname>
    <Contact_Lastname>Wang
    </Contact_Lastname>
    <Contact_Address>No.155, Sec.2, Linong Street, Taipei, 112 Taiwan (ROC)
    </Contact_Address>
    <Contact_Email>rywang@ym.edu.tw
    </Contact_Email>
    <Contact_Tel>886 2 28267210
    </Contact_Tel>
    <Contact_Affiliation>Department of Physical therapy and Assistive Technology, National Yang Ming University
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1) idiopathic Parkinson&amp;#039;s disease&#x0D;&lt;br&gt;2) H&amp;amp;Y 1-3 stage &#x0D;&lt;br&gt;3) independently walk more than 10 meters without using assistive devices&#x0D;&lt;br&gt;4) normal visual and auditory senses&#x0D;&lt;br&gt;5) MMSE&amp;gt;24
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1.Unstable medical conditions&#x0D;&lt;br&gt;2.MMSE&amp;lt;24&#x0D;&lt;br&gt;3.implanted cardiac device&#x0D;&lt;br&gt;4.conditions known to interfere with participation in the study eg epilepsy&#x0D;&lt;br&gt;5.pregnant or breast-feeding women&#x0D;&lt;br&gt;6. metal implants in the brain or head&#x0D;&lt;br&gt;7.skin lesions
    </Exclusion_Criteria>
    <Condition>Parkinson&amp;#039;s disease &lt;br&gt;transcranial direct current stimulation &lt;br&gt;dual task gait performance &lt;br&gt;cortical activity ;transcranial direct current stimulation &lt;br&gt;dual task gait performance &lt;br&gt;cortical activity 
    </Condition>
    <Intervention>Patients will receive one session of anodal tDCS for 20 mins with the intensity of 2mA. The active electrode will be placed over the C3 or C4 (primary motor cortex according to EEG 10/20 system) of the dominant hemisphere. The reference electrode will be placed over the contralateral supraorbital region.,Patients will receive one session of anodal tDCS for 20 mins with the intensity of 2mA. The active electrode will be placed over the F3 or F4 (DLPFC according to EEG 10/20 system) of the dominant hemisphere. The reference electrode will be placed over the contralateral supraorbital region.,Patients will receive one session of anodal tDCS for 20 mins with the intensity of 2mA. The active electrode will be placed over the cerebellum of the dominant hemisphere. The reference electrode will be placed over the contralateral supraorbital region.,The electrodes will be positioned exactly as those of the M1 tDCS group, And the current will only be delivered for 60 s, with a gradual ramp up and ramp down for 30 s at the beginning and end of the 20 min respectively in order to mimic the sensation during the intensity increase and decrease.;Experimental Device,Experimental Device,Experimental Device,Placebo Comparator No treatment;M1 tDCS,DLPFC tDCS,cerebellum tDCS,sham tDCS
    </Intervention>
    <Primary_outcome>dual task gait performance pre&amp;#45;test and post&amp;#45;test GAITRite system for spatiotemporal parameters ,brain activity pre&amp;#45;test and post&amp;#45;test Magstim 200
    </Primary_outcome>
    <Secondary_outcome>functional mobility pre&amp;#45;test and post&amp;#45;test time up and go test
    </Secondary_outcome>
    <Secondary_ID>Nil Known
    </Secondary_ID>
    <Source_Support>Ministry of Science and Technology of Taiwan
    </Source_Support>
    <Ethics_review_status>Submitted, approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>irbopinion@vghtpe.gov.tw
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>The Institutional Review Board of Taipei Veterans General Hospital
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>+886&amp;#45;2&amp;#45;28757384  Ext. 
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>irbopinion@vghtpe.gov.tw
    </Ethics_review_contact_email>
    <results_date_completed>18/10/2021
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13565304
    </Internal_Number>
    <TrialID>NCT04504422
    </TrialID>
    <Last_Refreshed_on>4 December 2023
    </Last_Refreshed_on>
    <Public_title>tDCS for Dual-task Performance in Patients With PD
    </Public_title>
    <Scientific_title>Transcranial Direct Current Stimulation to Improve Dual-task Performance in Idiopathic Parkinson's Disease: A Prospective, Single-center, Double-blind, Explorative Clinical Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Seoul National University Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200805
    </Date_registration3>
    <Date_registration>05/08/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT04504422
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>19 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 5, 2020
    </Date_enrollement>
    <Target_size>24
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Korea, Republic of
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Han Gil Seo, MD, PhD;Han Gil Seo, MD, PhD;Han Gil Seo, MD
    </Contact_Lastname>
    <Contact_Email>;hgseo80@gmail.com;hgseo80@gmail.com
    </Contact_Email>
    <Contact_Tel>;82-2-2072-1659;82-2-2072-1659
    </Contact_Tel>
    <Contact_Affiliation>Seoul National University Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinically diagnosed as idiopathic Parkinson's disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  modified Hoehn &amp; Yahr stage 2, 2.5, or 3&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of seizure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Metallic implants, such as cardiac pacemaker or an artificial cochlea&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with inflammation, burns, or wounds in the stimulation area&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parkinson's disease dementia; cut-off is &lt; 7 of Korean-Montreal Cognitive Assessment&#x0D;&lt;br&gt;             for illiterate patients, &lt; 13 for those educated for 0.5-3 years, &lt; 16 for 4-6 years&#x0D;&lt;br&gt;             of education, &lt; 19 for 7-9 years of education, and &lt; 20 for 10 or more years of&#x0D;&lt;br&gt;             education.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe dyskinesia or severe on-off phenomenon&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Plan to adjust medication at the time of screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Sensory abnormalities of the lower extremities, other neurological or orthopedic&#x0D;&lt;br&gt;             disease affecting lower extremities, or severe cardiovascular diseases&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Vestibular disease or paroxysmal vertigo&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant or lactating patients&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other comorbidities that make it difficult to participate in this study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: transcranial Direct Current Stimulation (tDCS)
    </Intervention>
    <Primary_outcome>Cognitive dual-task interference (%) in Timed-up &amp; go test;Physical dual-task interference (%) in Timed-up &amp; go test
    </Primary_outcome>
    <Secondary_outcome>Timed-up &amp; go test (sec): single task;Timed-up &amp; go test (sec): cognitive dual-task;Timed-up &amp; go test (sec): physical dual-task;Stroop test;Trail making test;Digit span test
    </Secondary_outcome>
    <Secondary_ID>PD-tDCS-O
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10375484
    </Internal_Number>
    <TrialID>NCT04527809
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Transcranial Direct Current Stimulation (tDCS) and Virtual Reality Task in Parkinson Disease
    </Public_title>
    <Scientific_title>Effect of Transcranial Direct Current Stimulation (tDCS) on a Virtual Reality Task in Individuals With Parkinson's Disease - Cross-sectional Project
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Sao Paulo
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200802
    </Date_registration3>
    <Date_registration>02/08/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04527809
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 1, 2019
    </Date_enrollement>
    <Target_size>54
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Talita D Silva, Ph.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Sao Paulo
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parkinson's Disease with diagnosis previoulsy confirmed by a specialized doctor.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agreement to participate in the research by signing the informed consent form.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Wheelchair use&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unable to complete the procedures due to any reported fatigue.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unable to complete the procedures due having to leave previously.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Could not stand without any kind of help, such as a carrier or walking aids.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: tDCS-active;Device: tDCS-sham
    </Intervention>
    <Primary_outcome>Motor skills improvement
    </Primary_outcome>
    <Secondary_outcome>Heart Rate Variability
    </Secondary_outcome>
    <Secondary_ID>02908218.0.0000.5390
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>8981532
    </Internal_Number>
    <TrialID>ACTRN12620000330943
    </TrialID>
    <Last_Refreshed_on>23 March 2020
    </Last_Refreshed_on>
    <Public_title>Can adding brain stimulation to strength training improve outcomes in adults with cerebral palsy?
    </Public_title>
    <Scientific_title>Investigating the effects of strength training with and without transcranial direct current stimulation on strength and function in the upper limb of adults with spastic hemiplegic cerebral palsy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Victoria University
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20200310
    </Date_registration3>
    <Date_registration>10/03/2020
    </Date_registration>
    <Source_Register>ANZCTR
    </Source_Register>
    <web_address>https://anzctr.org.au/ACTRN12620000330943.aspx
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>35 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both males and females
    </Inclusion_gender>
    <Date_enrollement>01/04/2020
    </Date_enrollement>
    <Target_size>24
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy;
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Australia
    </Countries>
    <Inclusion_Criteria>Inclusion criteria: Diagnosis of spastic hemiplegic cerebral palsy.&#x0D;&lt;br&gt;Intellectual capacity to understand and cooperate during the proposed activities.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Surgical procedures or neurolytic block in the 12 months prior to testing; Orthopedic deformity of the upper limb with an indication for surgery; Epilepsy; Pregnancy; Contraindication for tDCS as per screening questionnaire, and / or any acute medical disorder that would make strength training contraindicated, including active malignancy, severe heart, lung, renal, and liver failure.
    </Exclusion_Criteria>
    <Condition>cerebral palsy; &lt;br&gt;cerebral palsy;Neurological - Other neurological disorders
    </Condition>
    <Intervention>Strength training + Transcranial Direct Current Stimulation.&lt;br&gt;Participants will perform a 12-week one-on-one strength training intervention with a focus on the upper limbs, under the supervision of an Accredited Exercise Physiologist, with the assistance of a PhD candidate. Participants will be trained at Victoria University Clinical Exercise and Rehabilitation (VUCER) clinic. This program will operate for three days per week; thirty minutes per day. The training program will consist of 1) 5 min aerobic exercise with an arm cycle ergometer; 2) 20 min strength exercise at 70% of 1RM   of the upper part of the body; and 3) 5 min of stretching.&lt;br&gt;Before each strength training session, 2 mA anodal tDCS over the primary motor cortex will be applied for 20 minutes. Anodal tDCS is a type of brain stimulation that involves placing electrodes over the head, which delivers low direct current through to the underlying brain. Anodal stimulation is positive, which means that the current will stimulate the part of the brain where the electrode is placed.&lt;br&gt;This study will be utilizing progressive resistance strength training, commonly used in people with CP. Participants will be asked to complete 2-3 sets of 12 repetitions maximum of each exercise (which correspond to an intensity of around 70% of 1RM), with at least 1 min between set. The weight will be increased by 5% at the successful completion of 2-3 set of 12 repetitions.
    </Intervention>
    <Primary_outcome>Change in strength, measured using an isokinetic dynamometer.[Baseline, 12 weeks after intervention commencement]
    </Primary_outcome>
    <Secondary_outcome>Change in cerebral hemodynamic response of the primary motor cortex, measured using functional Near Infrared Spectroscopy.[Baseline, 12 weeks after commencement of intervention];Change in upper limb function (box and block text, nine hole peg test, Disabilities of arm, shoulder and hand questionnaire).[Baseline, 12 weeks after commencement of intervention.]
    </Secondary_outcome>
    <Secondary_ID>Nil known
    </Secondary_ID>
    <Source_Support>Victoria University;Cerebral Palsy Alliance
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>03/03/2020
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Victoria University Human Research Ethics Committee
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10353227
    </Internal_Number>
    <TrialID>NCT04237948
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>tDCS Plus Physical Therapy for Progressive Supranuclear Palsy
    </Public_title>
    <Scientific_title>tDCS Plus Physical Therapy for Progressive Supranuclear Palsy: a Double Blind Randomized Sham-controlled Study With Wearing Sensors Technology
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Fondazione Europea di Ricerca Biomedica Ferb Onlus
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200118
    </Date_registration3>
    <Date_registration>18/01/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04237948
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>85 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2018
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Italy
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Andrea Pilotto, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>FERB onlus
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        probable PSP diagnosis ability to stand alone without support for at least 5 seconds&#x0D;&lt;br&gt;        ability to walk without aid for at least three meters&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        dementia or behavioral alterations contraindications of stimulation&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Progressive Supranuclear Palsy;Parkinsonism;Parkinsonian Disorders
    </Condition>
    <Intervention>Device: transcranial direct current stimulation (tDCS);Behavioral: Physical therapy
    </Intervention>
    <Primary_outcome>PSP rating scale (PSP-RS);Falls;Cognitive testing;Static Balance- area of sway
    </Primary_outcome>
    <Secondary_outcome>Tinetti Balance test (TBT);Static Balance: wearable sensor analyses - velocity;Gait speed;Turning speed;Activity of daily living
    </Secondary_outcome>
    <Secondary_ID>19/02
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Università degli Studi di Brescia;University of Kiel
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10352901
    </Internal_Number>
    <TrialID>NCT04233710
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Robotic Rehabilitation and Brain Stimulation for Children With Hemiparetic Cerebral Palsy
    </Public_title>
    <Scientific_title>Robotic Rehabilitation and Brain Stimulation for Children With Hemiparetic Cerebral Palsy
    </Scientific_title>
    <Acronym>RoboCP
    </Acronym>
    <Primary_sponsor>University of Calgary
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200115
    </Date_registration3>
    <Date_registration>15/01/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04233710
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Years
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 25, 2019
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Canada
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Sean P Dukelow, MD, PhD;Rachel L Hawe, DPT, PhD;Rachel L Hawe, DPT, PhD
    </Contact_Lastname>
    <Contact_Email>;rachel.hawe@ucalgary.ca;rachel.hawe@ucalgary.ca
    </Contact_Email>
    <Contact_Tel>;403-944-1094;403-944-1094
    </Contact_Tel>
    <Contact_Affiliation>University of Calgary;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  confirmed diagnosis of hemiparetic cerebral palsy due to unilateral perinatal stroke&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  age 6-18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Manual Ability Classification System (MACS) Level I-III&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Modified Ashworth Score in shoulder and elbow &lt;=3;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Visual acuity (corrected) better than 20/50 in both eyes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  able to follow instructions and comply with protocol;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  able to give consent/assent;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  able to commit to all assessment and intervention sessions.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  significant contractures in the upper extremity;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  other neurological conditions or active medical disease;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  unstable epilepsy;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  contraindications to tDCS;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  botulinum toxin A injections in the upper extremity in the past 6 months;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  upper extremity surgical intervention in past 6 months;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  involvement in another interventional study.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hemiplegic Cerebral Palsy;Perinatal Stroke
    </Condition>
    <Intervention>Combination Product: Robot Rehabilitation + tDCS;Behavioral: Robotic Rehabilitation + sham tDCS
    </Intervention>
    <Primary_outcome>Reaching Accuracy
    </Primary_outcome>
    <Secondary_outcome>Standardized robotic measures of motor and sensory performance;Assisting Hand Assessment;Box and Block Assessment;Purdue Pegboard
    </Secondary_outcome>
    <Secondary_ID>REB17-1008
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10351974
    </Internal_Number>
    <TrialID>NCT04221659
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Effects of Neuromodulation on Brain Electric Activity of Parkinson's Disease Patients
    </Public_title>
    <Scientific_title>Effects of Neuromodulation on Brain Electric Activity of Parkinson's Disease Patients: Randomized Controlled Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Federal University of Paraíba
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20200106
    </Date_registration3>
    <Date_registration>06/01/2020
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04221659
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 1, 2019
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Suellen Andrade;Suellen Andrade;Suellen Andrade
    </Contact_Lastname>
    <Contact_Email>;suellenandrade@gmail.com;suellenandrade@gmail.com
    </Contact_Email>
    <Contact_Tel>;+55 83 999371471;
    </Contact_Tel>
    <Contact_Affiliation>Federal University of Paraiba;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of idiopathic PD, issued by a neurologist specializing in movement&#x0D;&lt;br&gt;             disorders;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Disease staging between I and III, according to the modified Hoehn and Yahr scale;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Regular antiparkinsonian pharmacological treatment;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Score higher than 24 or 18 (for participants with low education) in the Mini -Mental&#x0D;&lt;br&gt;             State Examination&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Healthy Subjects inclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ages: 40 - 75 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Sex: All&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects who do not have self-report of neurodegenerative disorders&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of atypical parkinsonism;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neurological comorbidities;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of epilepsy, neurosurgery (including metal clip implantation) and pacemaker&#x0D;&lt;br&gt;             implantation;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  DBS implantation - deep brain stimulation;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients missing two consecutive protocol sessions.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Healthy Subjects exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of epilepsy;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Metallic implants in the head;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical evidence of brain injury.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Transcranial Direct Current Stimulation
    </Intervention>
    <Primary_outcome>Change in EEG microstates
    </Primary_outcome>
    <Secondary_outcome>Spectral analysis of EEG frequencies;Motor aspects of daily life;Stroop test;Dual Task;Verbal Fluency Test
    </Secondary_outcome>
    <Secondary_ID>EEGPark
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>11464389
    </Internal_Number>
    <TrialID>NCT04174573
    </TrialID>
    <Last_Refreshed_on>11 October 2021
    </Last_Refreshed_on>
    <Public_title>Group Therapy With Transcranial Direct Current Stimulation in Patients With Parkinson's Disease
    </Public_title>
    <Scientific_title>Efficacy of Group Therapy With Transcranial Direct Current Stimulation on Balance and Quality of Life in Patients With Parkinson's Disease: A Single Blind, Multi-centre, Randomized Clinical Study
    </Scientific_title>
    <Acronym>GTBQ-PD
    </Acronym>
    <Primary_sponsor>Maharishi Markendeswar University (Deemed to be University)
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20191120
    </Date_registration3>
    <Date_registration>20/11/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04174573
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 6, 2022
    </Date_enrollement>
    <Target_size>64
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Adarsh K Srivastav, MPT;Asir J Samuel, MPT, (Ph.D)
    </Contact_Lastname>
    <Contact_Email>;asirjohnsamuel@mmumullana.org
    </Contact_Email>
    <Contact_Tel>;8059930222
    </Contact_Tel>
    <Contact_Affiliation>Maharishi Markandeshwar Institute of Physiotherapy and Rehabilitation;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of mild neurocognitive disorders was based on the validated Montreal&#x0D;&lt;br&gt;             Cognitive Assessment (MoCA) cutoff scores (&lt;23.5)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Based on the Hoehn-Yahr Stage (HYS) staging, severity of PD was categorized as mild&#x0D;&lt;br&gt;             (HYS 1&amp;2), moderate (HYS 3) and severe (HYS 4&amp;5). Patient with PD with mild and&#x0D;&lt;br&gt;             moderate will be recruited&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient with PD with associated comorbidities such as stroke, uncontrolled diabetes,&#x0D;&lt;br&gt;             sensory impairments such as hearing, vision, etc.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patient with PD who is not willing to participate in the study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Other: GTO;Other: GT-tDCS
    </Intervention>
    <Primary_outcome>Movement Disorders Society Sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS).;Parkinson's Disease Questionnaire with 39 items
    </Primary_outcome>
    <Secondary_ID>U1111-1240-0949
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>12181834
    </Internal_Number>
    <TrialID>NCT04171804
    </TrialID>
    <Last_Refreshed_on>19 April 2022
    </Last_Refreshed_on>
    <Public_title>Efficacy of Transcranial Direct Current Stimulation In Parkinson's Disease MCI
    </Public_title>
    <Scientific_title>Efficacy of Prefrontal Transcranial Direct Current Stimulation On Cognitive Functions and Electrophysiological Measures In Parkinson's Disease Mild Cognitive Impairment
    </Scientific_title>
    <Acronym>PDMCIStim
    </Acronym>
    <Primary_sponsor>Istanbul University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20191103
    </Date_registration3>
    <Date_registration>03/11/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04171804
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 1, 2019
    </Date_enrollement>
    <Target_size>26
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Turkey
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Serkan Aksu
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Istanbul University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical diagnosis of PD with at least two of the four diagnostic criteria for PD&#x0D;&lt;br&gt;             (tremor, rigidity, bradykinesia, and postural instability) in accordance with the&#x0D;&lt;br&gt;             United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Criteria, issued by a&#x0D;&lt;br&gt;             neurologist specializing in movement disorders;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Disease staging between I and III, according to the modified Hoehn and Yahr scale;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical diagnosis of PD- MCI in accordance with Level 2 Movement Disorders Society-&#x0D;&lt;br&gt;             Task Force diagnostic criteria;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  An unchanged stable and optimal regimen of dopaminergic medication for at least one&#x0D;&lt;br&gt;             month before study entry and able to continue on a stable regimen for the duration of&#x0D;&lt;br&gt;             the study;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to provide written informed consent;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  5 or more years of education;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Right-hand dominancy;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Not taking any psychoactive medications before the previous month of the study and for&#x0D;&lt;br&gt;             the duration of the study;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Naïve to tDCS.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis or evidence of secondary or atypical parkinsonism;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with dementia;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Less than 5 years of education;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous history of surgical intervention for PD such as deep brain stimulation (DBS);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of active major depressive disorder, psychotic disorders, bipolar disorder,&#x0D;&lt;br&gt;             alcohol use disorder and substance use disorders;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any history of any clinically significant neurological disorder, including organic&#x0D;&lt;br&gt;             brain disease, epilepsy, stroke, brain lesions, multiple sclerosis, previous&#x0D;&lt;br&gt;             neurosurgery, or personal history of head trauma that resulted in loss of&#x0D;&lt;br&gt;             consciousness for &gt; 5 minutes and retrograde amnesia for &gt; 30 minutes;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Significant hearing loss or visual impairment;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of any serious or uncontrolled medical condition such as chronic obstructive&#x0D;&lt;br&gt;             pulmonary disease, congestive heart failure or renal failure;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Skin diseases that could potentially cause irritations under electrodes&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients missing two consecutive protocol sessions;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Illiteracy, deficient language or refusal to participate or being not able to follow&#x0D;&lt;br&gt;             instructions or complete study tasks;.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Transcranial direct current stimulation
    </Intervention>
    <Primary_outcome>Changes in response conflict in the Stroop Test during the study period;Change in the verbal fluency performance during the study period;Changes in Trail Making A Test performance during the study period;Changes in digit span during the study period;Changes in delayed recall performance during the study period;Changes in verbal memory processes performance during the study period;Changes in face recognition performance during the study period;Changes in judgment of line orientation performance during the study period;Changes in the naming performance during the study period;Changes in amplitudes (in microvolts) for parameters from the ERP tests during the study period for parameters from the ERP tests during the study period;Changes in detection sensitivity from the behavioral responses during the Two-tone auditory oddball and Continuous Performance Test ERP paradigms during the study period;Changes in reaction times from the behavioral responses during the Two-tone auditory oddball and Continuous Performance Test ERP paradigms during the study period
    </Primary_outcome>
    <Secondary_outcome>Correlation between changes in behavioral measures and changes in amplitudes of ERP components
    </Secondary_outcome>
    <Secondary_ID>2018-055
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13089080
    </Internal_Number>
    <TrialID>RBR-6bvnx6
    </TrialID>
    <Last_Refreshed_on>29 May 2023
    </Last_Refreshed_on>
    <Public_title>Physical therapy to improve walking in people with Parkinson's Disease.
    </Public_title>
    <Scientific_title>Effect of the transcranial direct current stimulation (tDCS) associated with Physical Therapy on freezing of gait and functionality after Parkinson’s disease.&#x0D;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Universidade Federal do Espírito Santo
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190923
    </Date_registration3>
    <Date_registration>23/09/2019
    </Date_registration>
    <Source_Register>REBEC
    </Source_Register>
    <web_address>http://ensaiosclinicos.gov.br/rg/RBR-6bvnx6
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40Y
    </Inclusion_agemin>
    <Inclusion_agemax>100Y
    </Inclusion_agemax>
    <Inclusion_gender>-
    </Inclusion_gender>
    <Date_enrollement>01/09/2019
    </Date_enrollement>
    <Target_size/>
    <Study_type>Intervention
    </Study_type>
    <Study_design>A two-arm paralell double-blind randomized controlled trial.
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname>Fernando
    </Contact_Firstname>
    <Contact_Lastname>Âreas
    </Contact_Lastname>
    <Contact_Address>Av Marechal Campos 1468 Maruípe 29043900 - Vitória, ES - Brasil
    </Contact_Address>
    <Contact_Email>fernandozanela@hotmail.com
    </Contact_Email>
    <Contact_Tel>+55-027-996087012
    </Contact_Tel>
    <Contact_Affiliation>Universidade Federal do Espírito Santo
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Participants will be individuals with Parkinson’s Disease, who will be eligible, if they: are over 40 years of age; are able to walk at least 14 meters, independently, with or without assistive devices; walk at speeds lower than 1.1 m/s; have experienced freezing episodes over the past month, according to the Part I of the New Freezing of Gait Questionnaire (Nieuwboer et al 2009); have adapted to their current anti-Parkinsonian medication for at least 2 weeks; provide written consent.&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: They will be excluded, if they: have cognitive deficits, which will be screened by the Mini-Mental State Examination. The cut-off scores are 26 for people with high levels of education, 18 for people with elementary and middle levels, and 13 for illiterate people (Bertolucci et al 1994);suffer from unstable cardiovascular disease or other uncontrolled chronic conditions that would interfere with the safety and conduct of the training and testing protocol or interpretation of the results; over 100 years of age.&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>Parkinson Disease.;C10.228.140.079.862.500
    </Condition>
    <Intervention>24 individuals will be recruited. The intervention is physical therapy including task-specific walking training associated with transcranial direct current stimulation (tDCS), 30 min per day, three days per week, over four weeks. &lt;br&gt;&lt;br&gt;A stimulator (DC-Stimulator Plus, NeuroConn, Ilmenau, Germany) will deliver a continuous direct current by a saline-soaked pair of surface sponge electrodes (size of electrodes 35cm2).  The anode will be placed at the Cz position on the scalp, corressponding to the location of the supplementary motor area, in accordance with the International EEG 10/20 system (Klem et al 1999, Yotnuengnit et al 2018). The cathode will be positioned over the supraorbital area. Participants will receive electrical stimulation of 2 mA, during the walking training. The 30-min sessions of task-specific walking training will include practicing part of the task (about 10 min), where the muscles are working in a manner similar to a full task performance and practicing the whole task (about 20 min).&lt;br&gt;&lt;br&gt;&lt;br&gt;The control group will undertake the task-specific walking training associated with a sham- tDCS. The control group will receive the same walking training, electrodes positioning and testing schedule as the experimental group. This will avoid bias related to type and amount of attention given to participants. If the addition of tDCS proves to be effective, the control group may receive the experimental training program after the experiment is complete.&lt;br&gt;&lt;br&gt;The intervention will be undertaken in Clinics of Physiotherapy at the Universidade Federal do Espírito Santo. To encourage the participants to comply with the protocol, both groups will be asked to sign a symbolic contract of commitment to the proposed protocol. &lt;br&gt;&lt;br&gt;12 partcipants will be randomi;Other;E02.779;E02.331.800;E01.370.600.250
    </Intervention>
    <Primary_outcome>The primary outcome is comfortable walking speed, measured by the 10-m Walk Test, and reported in m/s.
    </Primary_outcome>
    <Secondary_outcome>Walking step length and cadence will be measured using the 10-m Walk Test. Step length will be calculated by dividing the covered distance, i.e., 10m, by the number of steps to cover the distance, and reported in meters.  Walking cadence will be calculated by dividing the number of steps by the time to cover the distance, i.e., 10m, and reported in steps/min.;Walking confidence will be measured using the Brazilian version of the modified Gait Efficacy Scale, and reported as scores ranging from 10 to 100. ;Mobility will be measured by the Timed-up and Go Test (TUG) and reported as seconds. ;Freezing of gait will be measured using Parts II and III of the New Freezing of Gait Questionnaire, and reported as scores ranging from 0 to 28, where higher scores indicate worse episodes of freezing.;Fear of falling will be measured using the Brazilian version of the Falls Efficacy Scale – International (FES-I Brazil), and reported as scores ranging from 16 to 64, where higher scores indicate greater fear of falling. ;The number of falls will be recorded by the use of a “falls diary” , and the proportion of fallers in each group will also be compared. 
    </Secondary_outcome>
    <Source_Support>Fundação de Amparo à Pesquisa e Inovação do Espírito Santo 
    </Source_Support>
    <Secondary_Sponsor>Universidade Federal do Espírito Santo
    </Secondary_Sponsor>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10642175
    </Internal_Number>
    <TrialID>NCT04090385
    </TrialID>
    <Last_Refreshed_on>22 February 2021
    </Last_Refreshed_on>
    <Public_title>Multifocal Neuromodulation in Motor and Cognitive Function of People With Parkinson's Disease
    </Public_title>
    <Scientific_title>Multifocal Neuromodulation in Motor and Cognitive Function of People With Parkinson's Disease: Randomized Controlled Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Federal University of Paraíba
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190912
    </Date_registration3>
    <Date_registration>12/09/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04090385
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 30, 2020
    </Date_enrollement>
    <Target_size>45
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Suellen Andrade;Suellen Andrade;Suellen Andrade
    </Contact_Lastname>
    <Contact_Email>;suellenandrade@gmail.com;suellenandrade@gmail.com
    </Contact_Email>
    <Contact_Tel>;+55 83 999371471;
    </Contact_Tel>
    <Contact_Affiliation>Federal University of Paraiba;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of idiopathic PD, issued by a neurologist specializing in movement&#x0D;&lt;br&gt;             disorders;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Disease staging between I and III, according to the modified Hoehn and Yahr scale;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Be using antiparkinsonian medication regularly;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Score higher than 24 or 18 (for participants with low education), verified through the&#x0D;&lt;br&gt;             Mini Mental State Examination.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of atypical parkinsonism;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Neurological comorbidities;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of epilepsy, neurosurgery (including metal clip implantation) and pacemaker&#x0D;&lt;br&gt;             implantation;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous surgical intervention for PD (DBS implantation - deep brain stimulation);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of severe freezing episodes.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Transcranial Direct Current Stimulation
    </Intervention>
    <Primary_outcome>Changes in motor function assessed by the Unified Parkinson's Disease Rating Scale - Part III (UPDRS - III);Changes in cognitive function assessed by the Montreal Cognitive Assessment (MoCA)
    </Primary_outcome>
    <Secondary_outcome>Changes in attention and mental flexibility assessed by the Trail Making Test - A and B;Changes in executive functions and planning assessed by the London Tower Task;Changes in working memory assessed by the Digit Span Forward and Backward Test;Changes in balance assessed by the Mini-BESTest;Changes in gait speed assessed by 10 Meter Walk Test;Changes in quality of life for people with Parkinson's disease assessed by the Parkinson's Disease Questionnaire (PDQ-39)
    </Secondary_outcome>
    <Secondary_ID>NeuroPark
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10338484
    </Internal_Number>
    <TrialID>NCT04046055
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Cerebellar Transcranial Direct Current Stimulation in Parkinson's Disease
    </Public_title>
    <Scientific_title>Cerebellar Transcranial Direct Current Stimulation in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Craig D. Workman, PhD
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190802
    </Date_registration3>
    <Date_registration>02/08/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04046055
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 1, 2019
    </Date_enrollement>
    <Target_size>7
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Single (Participant). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Craig D Workman, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Iowa
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  1) Adult (50-90 yrs) with a positive diagnosis of Parkinson's disease from a movement&#x0D;&lt;br&gt;             disorder specialist&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  2) an unchanged regimen of dopaminergic medication for at least the last 3 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  3) able to independently walk for 6 min&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  4) without other chronic psychiatric or medical conditions&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  5) not taking any psychoactive medications&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  1) pregnant&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  2) known holes or fissures in the skull&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  3) metallic objects or implanted devices in the skull (e.g., metal plate, deep brain&#x0D;&lt;br&gt;             stimulator)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  4) current or previous injuries or surgeries that cause unusual gait&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  5) score less than 24 or 17 on the Montreal Cognitive Assessment or telephone-Montreal&#x0D;&lt;br&gt;             Cognitive Assessment, respectively&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  6) experience freezing of gait&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  7) a diagnosis of dementia or other neurodegenerative diseases&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Brain Stimulation;Cerebellum
    </Condition>
    <Intervention>Device: Transcranial direct current stimulation at 2 mA;Device: Transcranial direct current stimulation at 4 mA;Device: Sham transcranial direct current stimulation
    </Intervention>
    <Primary_outcome>Time to complete the fast 30 meter walk test;Distance walked in the 6 Minute Walk Test;Time to complete the Timed Up and Go test;Movement of the center of pressure (2D; forward-backward, left-right) while standing on a firm surface (force platform) for 1 minute;Movement of the center of pressure (2D; forward-backward, left-right) while standing on a foam surface (6 cm foam pad placed on top of force platform) for 1 minute;Movement of the center of pressure (1D; forward-backward) while standing on a firm surface for 1 minute;Movement of the center of pressure (1D; forward-backward) while standing on a foam surface for 1 minute;Movement of the center of pressure (1D; left-right) while standing on a firm surface for 1 minute;Movement of the center of pressure (1D; left-right) while standing on a foam surface for 1 minute
    </Primary_outcome>
    <Secondary_ID>201906759
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10338378
    </Internal_Number>
    <TrialID>NCT04044677
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Virtual Reality Therapy and Transcranial Direct Current Stimulation in Cerebral Palsy.
    </Public_title>
    <Scientific_title>Effect of Combined Virtual Reality Therapy and Transcranial Direct Current Stimulation on Children and Adolescents With Cerebral Palsy.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Sao Paulo
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190801
    </Date_registration3>
    <Date_registration>01/08/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT04044677
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 Years
    </Inclusion_agemin>
    <Inclusion_agemax>15 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 20, 2019
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Talita D Silva, PhD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Sao Paulo
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Agreement to participate in the research from their selves and their legal guardians&#x0D;&lt;br&gt;             (by signing assent form and consent form);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a clinical diagnosis of CP done by a neuropediatric clinician with non-&#x0D;&lt;br&gt;             progressive etiology;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  GMFCS levels I to IV;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  MACS I and IV.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Lack of understanding of the the tasks. The understanding of the task will be&#x0D;&lt;br&gt;             evaluated through five attempts of each task in VR, because even with low IQ a large&#x0D;&lt;br&gt;             part of the adolescents can understand virtual tasks and interact with improvement of&#x0D;&lt;br&gt;             performance;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Motor difficulties that impede the completing of the virtual tasks;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cardiac diseases (because of the HRV assessment).&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cerebral Palsy
    </Condition>
    <Intervention>Device: tDSC-active;Device: tDCS-sham
    </Intervention>
    <Primary_outcome>Motor skills improvement
    </Primary_outcome>
    <Secondary_outcome>Heart Rate Variability
    </Secondary_outcome>
    <Secondary_ID>99577318.0.0000.5390
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>8297153
    </Internal_Number>
    <TrialID>IRCT20190412043248N1
    </TrialID>
    <Last_Refreshed_on>26 August 2019
    </Last_Refreshed_on>
    <Public_title>Effect of brain stimulation on the improvement of swallowing disorder in Parkinson's patients
    </Public_title>
    <Scientific_title>The effectiveness of combined transcranial Direct Current Stimulation (tDCS) and conventional swallowing therapy on improvement of the swallowing disorder in persons with Parkinson’s disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
    </Scientific_title>
    <Primary_sponsor>Tehran University of Medical Sciences
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20190615
    </Date_registration3>
    <Date_registration>2019-06-15
    </Date_registration>
    <Source_Register>IRCT
    </Source_Register>
    <web_address>http://en.irct.ir/trial/38950
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 years
    </Inclusion_agemin>
    <Inclusion_agemax>no limit
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>2019-05-22
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>interventional
    </Study_type>
    <Study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random assignment by blocks: At this stage, 20 blocks were used. Therefore, each subject by random selection of one of these blocks is placed in one of two groups. So, randomly, there will be 10 subjects in each group, Blinding description: Unawareness of the participants and the evaluator of the outcomes about the groups.
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Iran (Islamic Republic of)
    </Countries>
    <Contact_Firstname>Aliakbar Dashtelei
    </Contact_Firstname>
    <Contact_Lastname/>
    <Contact_Address>Rehabilitation Faculty, Tehran University of Medical Sciences Pitch-e-Shemiran, Enghelab Ave., Tehran-IR
    </Contact_Address>
    <Contact_Email>ali_dashtelei@yahoo.com
    </Contact_Email>
    <Contact_Tel>+98 21 7762 8205
    </Contact_Tel>
    <Contact_Affiliation>Tehran University of Medical Sciences
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Parkinson's disease with swallowing disorder&lt;br&gt;Not having an implants&lt;br&gt;Being patient in the On phase&lt;br&gt;Age over 18 years&lt;br&gt;Not having a history of dysphagia&lt;br&gt;Non-pregnancy of subjects
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: The occurrence of any other neurological disorder (such as stroke, seizure, epilepsy, etc.) during the conduct of the research&lt;br&gt;After the study begins, the implant needs to be used&lt;br&gt;Do not cooperate&lt;br&gt;Getting pregnant
    </Exclusion_Criteria>
    <Condition>Parkinson. &lt;br&gt;Parkinson's disease
    </Condition>
    <Intervention>Intervention 1: Combined treatment group: Patients in this group receive anodal stimulation of tDCS with conventional treatment for 30 minutes. The anodal-tDCS with a 1 mA intensity is inserted bilaterally into the pharyngeal motor cortex in the left and right hemisphere. Conventional swallowing treatment is a protocol of rehabilitation and compensatory treatments. This protocol will be obtained according to the clinical evaluation results of swallowing. Rehabilitation treatment includes swallowing maneuvers (Mendelsohn maneuver, supraglottic swallowing maneuver, super-supraglottic swallowing maneuver, and effortful swallow ), oral-motor exercises, and Thermal-tactile stimulation. Compensatory methods will also include adjusting the volume, velocity, and speed of food delivery and postural techniques. Intervention 2: sham treatment group: In the sham-tDCS group, patients first receive tDCS stimulation for 30 seconds with an intensity of 1mA intensity, and after 30 seconds the stimulation stops and the device turns off without informing the patient. The conventional treatment is also provided to the patient simultaneously for 30 minutes.
    </Intervention>
    <Primary_outcome>Dysphagia score in aspiration-penetration scale. Timepoint: At the beginning of the sampling, after the last intervention session and one month after the last intervention session. Method of measurement: Fiberoptic endoscopic evaluation of swallowing (FEES) and aspiration-penetration scale.
    </Primary_outcome>
    <Secondary_outcome>Dysphagia handicap index and swallowing disturbance questionnaire. Timepoint: At the beginning of the sampling, after the last intervention session and one month after the last intervention session. Method of measurement: Swallowing Disturbance Questionnaire.;Dysphagia Handicap Index. Timepoint: At the beginning of the sampling, after the last intervention session and one month after the last intervention session. Method of measurement: Dysphagia Handicap Index.
    </Secondary_outcome>
    <Source_Support>Tehran University of Medical Sciences
    </Source_Support>
    <Ethics_review_status>Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>Ethics committee of Tehran University of Medical Sciences
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13604953
    </Internal_Number>
    <TrialID>NCT03981055
    </TrialID>
    <Last_Refreshed_on>8 January 2024
    </Last_Refreshed_on>
    <Public_title>Parkinson's Disease: Enhancing Physical Therapy With Brain Stimulation for Treating Postural Instability.
    </Public_title>
    <Scientific_title>Parkinson's Disease: Enhancing Physical Therapy With Brain Stimulation for Treating Postural Instability.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Spaulding Rehabilitation Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20190128
    </Date_registration3>
    <Date_registration>28/01/2019
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03981055
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 23, 2020
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: Triple (Participant, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Felipe Fregni, MD, PhD;Felipe Fregni, MD, PhD;Felipe Fregni, MD PhD MPH
    </Contact_Lastname>
    <Contact_Email>;Fregni.Felipe@mgh.harvard.edu;ffregni@partners.org
    </Contact_Email>
    <Contact_Tel>;6179526158;617-952-6156
    </Contact_Tel>
    <Contact_Affiliation>Spaulding Rehabilitation Hospital;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Diagnosis of "probable" or "possible" PD, as defined by the current clinical criteria&#x0D;&lt;br&gt;             (Gelb D, Oliver E, Gilman S. Diagnostic Criteria for Parkinson's Disease. Arch&#x0D;&lt;br&gt;             Neurol.1999;56:33-39) as confirmed by co-investigator neurologist, or confirmation via&#x0D;&lt;br&gt;             medical records or a letter from patient physician;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Complaints about balance impairment or postural instability due to PD (self-report);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Age from 40 to 90 years old;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Taking stable medications for PD for at least 30 days.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Features suggestive of other causes of parkinsonism/Parkinson's-plus syndromes;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. History of deep brain stimulation or brain ablation surgeries, malignant mass brain&#x0D;&lt;br&gt;             lesions;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. History of schizophrenia, bipolar illness; history of alcohol/drug abuse within the&#x0D;&lt;br&gt;             past 6 months;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Need for rapid clinical response due to conditions such as initiation, psychosis, or&#x0D;&lt;br&gt;             suicidality;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Contraindications to transcranial brain stimulation or TUS, i.e. metal in the head,&#x0D;&lt;br&gt;             implanted brain medical devices, etc.;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Unstable medical conditions (e.g., uncontrolled diabetes, uncompensated cardiac&#x0D;&lt;br&gt;             issues, heart failure, uncompensated pulmonary disease, or chronic obstructive&#x0D;&lt;br&gt;             pulmonary disease);&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Pregnancy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Epilepsy or disorders that significantly increase likelihood of seizures including:&#x0D;&lt;br&gt;             severe traumatic brain injury, congenital birth defects leading to seizures, brain&#x0D;&lt;br&gt;             tumor, metabolic disorders associated with seizures, intracranial or subarachnoid&#x0D;&lt;br&gt;             hemorrhage, and nonlacunar strokes.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Recent (&lt;= 2 months) or planned enrollment in an additional physician prescribed&#x0D;&lt;br&gt;             physical therapy program during their time in the trial.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Presence of another disorder that might have a significant impact on balance (as&#x0D;&lt;br&gt;             assessed by a co-investigator neurologist).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         11. Bed or wheelchair-bound&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Active Comparator: Active tDCS and Active TUS;Device: Sham Comparator: Sham TDCS and Sham TUS;Other: Physical Therapy
    </Intervention>
    <Primary_outcome>Change in postural sway
    </Primary_outcome>
    <Secondary_outcome>Unified Parkinson's Disease Rating Scale (UPDRS);Leg Agility;Arising from a chair;Balance;Gait;Toe tapping
    </Secondary_outcome>
    <Secondary_ID>2018P002733
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Highland Instruments, Inc.
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10316450
    </Internal_Number>
    <TrialID>NCT03759132
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Effects of Transcranial Direct Current Stimulation on Postural Control
    </Public_title>
    <Scientific_title>Effects of Transcranial Direct Current Stimulation on Postural Control: a Double-blind Randomized Controlled Trial.
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Universidade Federal do Piauí
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20181121
    </Date_registration3>
    <Date_registration>21/11/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03759132
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 1, 2018
    </Date_enrollement>
    <Target_size>18
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Brazil
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Medical diagnosis of idiopathic Parkinson's disease present for at least 12 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        In clinical follow-up and pharmacological treatment by a responsible physician&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Parkinson's classification of 1.5-3 according to the Hoehn and Yahr scale&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Signing of the free and informed consent form-&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Use any associated orthopedic device to aid gait or balance control&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Signs of severe dementia (evaluated by the Mini-Mental State Examination - MMSE)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Diagnosis of other neurological disorders (including those of central and peripheral&#x0D;&lt;br&gt;        nature)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Previous treatment with tDCS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Medical diagnosis of psychiatric illnesses with the use of centrally acting medications&#x0D;&lt;br&gt;        (depressants)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        The use of pacemakers or other implanted devices.-&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Procedure: Transcranial direct current stimulation
    </Intervention>
    <Primary_outcome>Change from COP - AP axis;Change from COP - ML axis;Change from COP - area
    </Primary_outcome>
    <Secondary_ID>tDCS in Parkinson's Disease
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13088417
    </Internal_Number>
    <TrialID>RBR-6zys9x
    </TrialID>
    <Last_Refreshed_on>29 May 2023
    </Last_Refreshed_on>
    <Public_title>Use of Transcranial Direct Current Eletrical Stimulation for treatment of involuntary movements on patients with Schizophrenia
    </Public_title>
    <Scientific_title>Use of Transcranial Direct Current Stimulation (tDCS) for treatment of Tardive Dyskinesia in schizophrenic patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Faculdade de Medicina da Universidade de Brasília - FM/UnB
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20181109
    </Date_registration3>
    <Date_registration>09/11/2018
    </Date_registration>
    <Source_Register>REBEC
    </Source_Register>
    <web_address>http://ensaiosclinicos.gov.br/rg/RBR-6zys9x
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18Y
    </Inclusion_agemin>
    <Inclusion_agemax>65Y
    </Inclusion_agemax>
    <Inclusion_gender>-
    </Inclusion_gender>
    <Date_enrollement>23/10/2018
    </Date_enrollement>
    <Target_size/>
    <Study_type>Intervention
    </Study_type>
    <Study_design>An open-label, crossover, single-arm clinical trial
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname>Thiago
    </Contact_Firstname>
    <Contact_Lastname>Correa
    </Contact_Lastname>
    <Contact_Address>Campus Darcy Ribeiro
    </Contact_Address>
    <Contact_Email>correatx@gmail.com
    </Contact_Email>
    <Contact_Tel>+55 61 98656-2606
    </Contact_Tel>
    <Contact_Affiliation>Faculdade de Medicina da Universidade de Brasília - FM/UnB
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Individuals diagnosed with schizophrenia (DSV-V) and clinical presentation of Tardive Dyskinesia (Schooler-Kane criteria), both genders, aged between 18 and 65 years, with no changes in drug treatment in the last 4 weeks.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Pregnant, presence of skin disease in the electrode region, patients with relevant psychiatric comorbidity (chemical dependence, suicide risk), neurological diseases (epilepsy, stroke, dementia) and clinical diseases (malignant tumors, infections, cardiac).
    </Exclusion_Criteria>
    <Condition>Tardive Dyskinesia; Schizophrenia.;C10.228.662.262.500.500;F03.700.750
    </Condition>
    <Intervention>60 individuals with schizophrenia and tardive dyskinesia are going to receive Anodic tDCS stimulation on cerebellum and bilateral primary motor cortex. 5 daily sessions of 20 min, a current of 2mA and electrodes of 35m2. Cathode positioned in the right supraorbital region. There will be no sham group or control.;Device;D065908
    </Intervention>
    <Primary_outcome>Reduction of Tardive Dyskinesia, verified by the Abnormal Involuntary Movement Scale (AIMS), based on a score reduction when compared to baseline evaluation (T0).
    </Primary_outcome>
    <Secondary_outcome>Reduction of symptoms in schizophrenia and global clinical improvement, verified by the The Positive and Negative Syndrome Scale (PANSS) and The Clinical Global Impression (CGI), based on a score reduction when compared to baseline evaluation (T0).
    </Secondary_outcome>
    <Source_Support>Faculdade de Medicina da Universidade de Brasília - FM/UnB
    </Source_Support>
    <Secondary_Sponsor>Faculdade de Medicina da Universidade de Brasília - FM/UnB
    </Secondary_Sponsor>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10307186
    </Internal_Number>
    <TrialID>NCT03638531
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Long- Term Transcranial Direct Current Stimulation in Parkinson's Disease
    </Public_title>
    <Scientific_title>Long-Term Transcranial Direct Current Stimulation in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Nevada, Las Vegas
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180816
    </Date_registration3>
    <Date_registration>16/08/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03638531
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>60 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>July 30, 2018
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Brach Poston, Ph.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Nevada, Las Vegas
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Able to provide informed consent.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. A clinical diagnosis of idiopathic PD.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. A stable and optimal medical regimen of anti-parkinsonian drug therapy for the&#x0D;&lt;br&gt;             duration of the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Modified Hoehn and Yahr stage between 1.0 and 3.0 in the OFF state.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Right-hand dominant and primarily right-side affected to prevent confounds due to&#x0D;&lt;br&gt;             handedness and affected side.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. An uncontrolled medical condition (i.e. hypertension, diabetes, etc).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Evidence of secondary or atypical parkinsonism as suggested by:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               1. History of CVA's, exposure to toxins, neuroleptics or encephalitis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;               2. Neurologic signs of upper motor neuron or cerebellar involvement, supranuclear&#x0D;&lt;br&gt;                  gaze palsy or significant orthostatic hypertension.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Metal in the skull or the eye, such as a cardiac pacemaker, brain stimulator,&#x0D;&lt;br&gt;             shrapnel, surgical metal, clips in the brain, cochlear implants, and metal fragments&#x0D;&lt;br&gt;             in the eye, as these may make TMS and tDCS unsafe.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. An uncertainty about the presence of metal objects in a subject's body exists.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Hearing loss, have had a brain tumor, a stroke, head trauma, epilepsy or a history of&#x0D;&lt;br&gt;             seizures, have another neurological disorder other than a movement disorder, or have a&#x0D;&lt;br&gt;             head injury where they passed out for more than a few seconds.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Pregnant or thought to be pregnant.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Irrepressible dyskinesia or tremor to prevent the confound of excessive EMG during TMS&#x0D;&lt;br&gt;             testing at rest.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Any other neurological disorders.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Meeting of any of the TMS exclusion criteria given in international guidelines.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Anodal tDCS;Device: SHAM tDCS
    </Intervention>
    <Primary_outcome>Force error in the precision grip task;Handwriting task performance
    </Primary_outcome>
    <Secondary_outcome>Transfer of motor learning;Transfer of motor learning;Transfer of motor learning
    </Secondary_outcome>
    <Secondary_ID>1002548
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10306974
    </Internal_Number>
    <TrialID>NCT03635775
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Single-session tDCS in Cerebral Palsy
    </Public_title>
    <Scientific_title>Effects of Single-session Transcranial Direct Current Stimulation in Children With Cerebral Palsy
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>University of Minnesota
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180712
    </Date_registration3>
    <Date_registration>12/07/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03635775
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>7 Years
    </Inclusion_agemin>
    <Inclusion_agemax>21 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 1, 2018
    </Date_enrollement>
    <Target_size>24
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria (for all participants):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ages 7-21&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to follow two-step commands.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of an MEP in the non-lesioned hemisphere&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria (for all participants):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Evidence of seizure within 2 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Other neurological or metabolic conditions&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Is pregnant (females only)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence of indwelling metal in the head (e.g. aneurysm clip) or medical device.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Inclusion Criteria (for participants with cerebral palsy):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical diagnosis of unilateral cerebral palsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Radiological evidence of stroke or periventricular leukomalacia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria(for participants with cerebral palsy):&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Treatment with injectable agents (e.g. Botox) for spasticity management within 2&#x0D;&lt;br&gt;             months&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cerebral Palsy;Perinatal Stroke;Periventricular Leukomalacia
    </Condition>
    <Intervention>Device: Active tDCS;Device: Sham tDCS
    </Intervention>
    <Primary_outcome>Change in MEP amplitude
    </Primary_outcome>
    <Secondary_outcome>Change in Movement accuracy
    </Secondary_outcome>
    <Secondary_ID>P2CHD086844;K01HD078484;STUDY00002820
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13467308
    </Internal_Number>
    <TrialID>JPRN-UMIN000033253
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Efficacy and safety of transsranial direct current stimulation in Parkinson&amp;#39;s disease
    </Public_title>
    <Scientific_title>Efficacy and safety of transsranial direct current stimulation in Parkinson&amp;#39;s disease - Whether tDCS can improve the symptoms of Parkinson&amp;#39;s disease?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
    </Scientific_title>
    <Primary_sponsor>Toyama University Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180703
    </Date_registration3>
    <Date_registration>03/07/2018
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037911
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20years-old
    </Inclusion_agemin>
    <Inclusion_agemax>90years-old
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2018/07/03
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel Randomized
    </Study_design>
    <Phase>Not applicable
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname>Koji Ishikuro
    </Contact_Lastname>
    <Contact_Address>2630 sugitani toyama city toyama prefecture
    </Contact_Address>
    <Contact_Email>ishikuro@med.u-toyama.ac.jp
    </Contact_Email>
    <Contact_Tel>076-434-7850
    </Contact_Tel>
    <Contact_Affiliation>Toyama University Hospital Departement of rehabilitation
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: The subject with the Metal in the body  pregnant
    </Exclusion_Criteria>
    <Condition>Parkinson&amp;#39;s disease
    </Condition>
    <Intervention>Transcranial direct current stimulation(Anodal )&lt;br&gt;Transcranial direct current stimulation(Sham)
    </Intervention>
    <Primary_outcome>UPDRS(unified parkinson&amp;#39;s disease rating scale)
    </Primary_outcome>
    <Secondary_outcome>STEF(simple test for evaluating hand function), FMA(fugl-meyer assessment), MMSE(mini mental state examination), TMT(trail maiking test)
    </Secondary_outcome>
    <Source_Support>Toyama University Hospital
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13088027
    </Internal_Number>
    <TrialID>RBR-94c26n
    </TrialID>
    <Last_Refreshed_on>29 May 2023
    </Last_Refreshed_on>
    <Public_title>Noninvasive brain stimulation to improve the gait of children with cerebral palsy
    </Public_title>
    <Scientific_title>Transcranial electrostimulation to facilitate gait rehabilitation of children with spastic cerebral palsy: cross-over randomized clinical trial, placebo-controlled, double-blinded                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Universidade de Sorocaba
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180629
    </Date_registration3>
    <Date_registration>29/06/2018
    </Date_registration>
    <Source_Register>REBEC
    </Source_Register>
    <web_address>http://ensaiosclinicos.gov.br/rg/RBR-94c26n
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5Y
    </Inclusion_agemin>
    <Inclusion_agemax>15Y
    </Inclusion_agemax>
    <Inclusion_gender>-
    </Inclusion_gender>
    <Date_enrollement>01/07/2018
    </Date_enrollement>
    <Target_size/>
    <Study_type>Intervention
    </Study_type>
    <Study_design>Randomized-controlled, double-blind, crossover, three-arm clinical trial
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname>Lucas
    </Contact_Firstname>
    <Contact_Lastname>Villalta Santos
    </Contact_Lastname>
    <Contact_Address>Rua Joao Krafecik, 9
    </Contact_Address>
    <Contact_Email>lucasvillalta.s@gmail.com
    </Contact_Email>
    <Contact_Tel>+55-015-998197899
    </Contact_Tel>
    <Contact_Affiliation>Faculdade de Ciências Médicas da Santa Casa de São Paulo
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: The children will be screened for participation in the study according to the following criteria:diagnosis of spastic CP confirmed by clinical examination; to obtain magnetic resonance imaging of the brain performed no more than two years before the beginning of the intervention; demonstrating lesion in the pyramidal system; without compromising the extrapyramidal system and cerebellum; age between five and 15 years; children levels I, II and III of GMFCS; children who have a muscular form degree equal to or greater than three in the flexor and extensor muscles of the trunk, hips and knees;  degree of spasticity of less than three in the Modified Ashworth Scale; agreement of those responsible by signing the Term of Free and Informed Consent.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Children will be excluded if are diagnosed with epilepsy or have had seizures at least 12 months before the beginning of the study, present neurological, neuromuscular or syndromic diseases associated with brain injury; have undergone orthopedic or neurological surgeries in the 12 months prior to the intervention; have undergone neurolithic blockade in the 12 months prior to intervention; present orthopedic deformities with surgical indication; have brain implants or have performed some neurosurgical procedure; have metallic implants in the regions of head, neck, thorax and / or upper limbs, have hearing aids; children with a degree of collaboration incompatible with the adequate performance in the activities proposed in this project.
    </Exclusion_Criteria>
    <Condition>children with spastic diplegic cerebral palsy;G80.1
    </Condition>
    <Intervention>Experimental group Cz: 10 children diagnosed with diplegic spastic cerebral palsy who will undergo treadmill training associated with anodic transcranial direct current stimulation (1mA, 20minutes) in the primary motor cortex relative to the lower limbs (Cz), according to the system 10-20 electroencephalogram;&lt;br&gt;Experimental group Cb: 10 children diagnosed with diplegic spastic cerebral palsy who will undergo treadmill training associated with anodic transcranial direct current stimulation (1mA, 20minutes) in the cerebellum (Cb);&lt;br&gt;Control group: 10 children diagnosed with diplegic spastic cerebral palsy who will undergo treadmill training associated with anodic transcranial direct current stimulation (0mA, 20minutes) in the region of the primary motor cortex for the lower limbs (Cz).;Behavioural;E02.331;E01.370.600.250
    </Intervention>
    <Primary_outcome>Improvement in walking speed, evaluation by the G-WALK inertial sensor 1 week before the intervention, 1 week after an intervention, 1 month after the intervention and 3 months after the intervention.&lt;br&gt;Effect considered for sample calculation:&lt;br&gt;• Gait speed: experimental group: 0.9 ± 0.1m / s and control group: 0.6 ± 0.1m / s;;The improvement in functional mobility, evaluated by the 6-minute walk test and the Timed Up and Go test 1 week before the intervention, before and after each intervention, 1 week after the intervention, 1 month after the intervention and 3 months after the intervention .&lt;br&gt;Effect considered for sample calculation:&lt;br&gt;• Functional mobility assessed by the six-minute walk test: experimental group: 448.2 ± 100.5m and control group: 367.2 ± 97.6m;
    </Primary_outcome>
    <Secondary_outcome>Improvement in functional performance, assessed by the Pediatric Disability Inventory (PEDI) 1 week before the intervention, 1 week after the intervention, 1 month after the intervention and 3 months after the intervention.&#x0D;&lt;br&gt;;The improvement in gross motor function, through the Gross Motor Function Measure (GMFM-66) 1 week before the intervention, 1 week after the intervention, 1 month after the intervention and 3 months after the intervention.&#x0D;&lt;br&gt;Effect considered for sample calculation:&#x0D;&lt;br&gt;• Gross motor function assessed by the Gross Motor Function Measurement: experimental group: 75.4 ± 11.6 and control group: 70.0 ± 9.2;;The improvement of the functional balance, evaluated by the Pediatric Balance Scale 1 week before the intervention, 1 week after the intervention, 1 month after the intervention and 3 months after the intervention.&#x0D;&lt;br&gt;Effect considered for sample calculation:&#x0D;&lt;br&gt;• Functional balance assessed by the Pediatric Balance Scale: experimental group: 45.3 ± 7.9 and control group: 39.7 ± 9.8;;The improvement in treadmill exercise test, evaluated by the modified Bruce protocol 1 week before the intervention, 1 week after the intervention, 1 month after the intervention and 3 months after the intervention.&#x0D;&lt;br&gt;;The report of potential adverse effects of transcranial electrostimulation by direct current, evaluated at each session through a questionnaire applied with the child.
    </Secondary_outcome>
    <Source_Support>Universidade de Sorocaba;Faculdade de Ciências Médicas da Santa Casa de São Paulo;Centro de Neuroestimulação Pediátrica;Vento Leste - Habilitação Infantil Especializada
    </Source_Support>
    <Secondary_Sponsor>Faculdade de Ciências Médicas da Santa Casa de São Paulo;Centro de Neuroestimulação Pediátrica;Vento Leste - Habilitação Infantil Especializada
    </Secondary_Sponsor>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10921387
    </Internal_Number>
    <TrialID>NCT03473522
    </TrialID>
    <Last_Refreshed_on>10 May 2021
    </Last_Refreshed_on>
    <Public_title>Effects of tDCS Combined With Therapeutic Exercises in Patients With Parkinson's Disease.
    </Public_title>
    <Scientific_title>Effects of Transcranial Direct Current Stimulation Combined With Therapeutic Exercises in Patients With Parkinson's Disease: Randomized Clinical Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Alessandra Tanuri Magalhães
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20180207
    </Date_registration3>
    <Date_registration>07/02/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03473522
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 1, 2018
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Brazil
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  medical diagnosis of idiopathic Parkinson's disease present for at least 12 months,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  spontaneous demand for treatment,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  in clinical follow-up and pharmacological treatment by a responsible physician,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parkinson's classification of 1.5-3 according to the Hoehn and Yahr scale,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  absence of cardiovascular diseases and musculoskeletal,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  signing of the free and informed consent form.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Use any associated orthopedic device to aid gait or balance control,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  signs of severe dementia (evaluated by the Mini-Mental State Examination - MMSE),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of other neurological disorders (including those of central and peripheral&#x0D;&lt;br&gt;             nature)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  previous treatment with tDCS,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  medical diagnosis of psychiatric illnesses with the use of centrally acting&#x0D;&lt;br&gt;             medications (depressants)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  the use of pacemakers or other implanted devices.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: tDCS;Behavioral: Exercise Therapy
    </Intervention>
    <Primary_outcome>Change From balance
    </Primary_outcome>
    <Secondary_outcome>Change From balance;Change From Unified Parkinson´s Disease Rating Scale;Change From Parkinson Disease Quality of Life;Change in the perception scale of the overall effect;Maximal Isometric Voluntary Contraction;Tampa Scale for Kinesiophobia (TSK)
    </Secondary_outcome>
    <Secondary_ID>2.085.438
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Foundation for Research Support of the State of Piauí
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13177732
    </Internal_Number>
    <TrialID>NCT03402854
    </TrialID>
    <Last_Refreshed_on>25 July 2023
    </Last_Refreshed_on>
    <Public_title>tDCS and Bimanual Therapy for Children With Hemiplegic Cerebral Palsy
    </Public_title>
    <Scientific_title>tDCS and Bimanual Therapy for Children With Hemiplegic Cerebral Palsy
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Burke Medical Research Institute
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180110
    </Date_registration3>
    <Date_registration>10/01/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03402854
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Years
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 1, 2019
    </Date_enrollement>
    <Target_size>80
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Kathleen M Friel, PhD;Kathleen M Friel, PhD;Kathleen M Friel, PhD
    </Contact_Lastname>
    <Contact_Email>;kaf3001@med.cornell.edu;kaf3001@med.cornell.edu
    </Contact_Email>
    <Contact_Tel>;914-368-3116;914-368-3116
    </Contact_Tel>
    <Contact_Affiliation>Burke Medical Research Institute;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of congenital hemiplegic cerebral palsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to lift and grasp light objects with affected hand&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to extend wrist of affected hand 15 degrees&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to follow instructions and provide informed assent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parent(s) able to provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Seizures after age 2 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Spasticity medication within 6 months before study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Selective dorsal rhizotomy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Surgery in affected upper extremity within year before study&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cerebral Palsy;Hemiplegic Cerebral Palsy;Spastic Hemiplegic Cerebral Palsy;Spastic Hemiparesis;Spastic Hemiplegia
    </Condition>
    <Intervention>Device: active transcranial direct current stimulation;Behavioral: bimanual training
    </Intervention>
    <Primary_outcome>Change in Assisting Hand Assessment
    </Primary_outcome>
    <Secondary_outcome>Jebsen-Taylor Test of Hand Function;Box and Blocks test
    </Secondary_outcome>
    <Secondary_ID>tDCS_bimanual
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Minnesota;Teachers College, Columbia University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10289039
    </Internal_Number>
    <TrialID>NCT03401996
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>tDCS in Tourette (TIC-TDCS)
    </Public_title>
    <Scientific_title>tDCS Over the Supplemental Motor Area for the Treatment of Tourette Syndrome
    </Scientific_title>
    <Acronym>TIC-TDCS
    </Acronym>
    <Primary_sponsor>University of Calgary
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20180102
    </Date_registration3>
    <Date_registration>02/01/2018
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03401996
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>16 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 1, 2018
    </Date_enrollement>
    <Target_size>30
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Canada
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Davide Martino, MD, PhD;Yamile Jasaui, MSc;Yamile Jasaui, MSc
    </Contact_Lastname>
    <Contact_Email>;yjasauic@ucalgary.ca;yjasauic@ucalgary.ca
    </Contact_Email>
    <Contact_Tel>;001-403-220-4992;001-403-220-4992
    </Contact_Tel>
    <Contact_Affiliation>Department of Clinical Neurosciences, University of Calgary;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants who meet Diagnostic and Statistical Manual of Mental Disorders criteria&#x0D;&lt;br&gt;             for TS (APA, DSM V).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  16 years of age or older.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A "moderately ill" or worse score on the Clinical Global Impression Severity scale&#x0D;&lt;br&gt;             (CGI-S).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  A total motor tic or vocal tic severity score greater or equal to 15/25 on the Yale&#x0D;&lt;br&gt;             Global Tic Severity Scale (YGTSS) or a combined score greater than 22/50.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants should be either un-medicated or on stable medication treatment for tics&#x0D;&lt;br&gt;             for the previous 3 months. If receiving botulinum toxin treatment, their enrolment&#x0D;&lt;br&gt;             should be at least 16 weeks after the last treatment session.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Psychiatric comorbidities should be clinically stable; treatment has not changed in&#x0D;&lt;br&gt;             the last 3 months.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Participants will be excluded from the study if they meet any of the following criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a metal object/implant in their brain, skull, scalp, or neck.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have an implantable device (e.g., cardiac pacemaker).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a diagnosis of epilepsy or cardiac disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a history of traumatic brain injury, learning disability or dyslexia.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Have a severe impediment in vision or hearing.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Tourette Syndrome
    </Condition>
    <Intervention>Device: 1 mA tDCS over bilateral SMA
    </Intervention>
    <Primary_outcome>Tic severity total subscore on the Yale Global Tic Severity Scale (YGTSS);Tic severity total subscore on the Yale Global Tic Severity Scale (YGTSS)
    </Primary_outcome>
    <Secondary_outcome>Tic inhibition potential on the Modified Video-Based Tic Rating Scale (MVBTRS);Adverse effects;Tourette Syndrome Clinical Global Impression (TS-CGI);Individualized-Premonitory Urge for Tics Scale (iPUTS);Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
    </Secondary_outcome>
    <Secondary_ID>REB17-1615
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10283069
    </Internal_Number>
    <TrialID>NCT03302871
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Integrated Management Enhances Functional Gains in Children With Cerebral Palsy Treated by BoNT-A
    </Public_title>
    <Scientific_title>Integrated Management With Brain Stimulation and Hybrid Training Enhances Functional Gains in Children With Cerebral Palsy Treated by Botulinum Toxin A
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Kocaeli University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20171002
    </Date_registration3>
    <Date_registration>02/10/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03302871
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>5 Years
    </Inclusion_agemin>
    <Inclusion_agemax>16 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 18, 2016
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Investigator). 
    </Study_design>
    <Phase>Phase 3
    </Phase>
    <Countries>Turkey
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Nigar Dursun, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Kocaeli University
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosis of unilateral cerebral palsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  able to activate wrist and finger extensors&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  being scheduled for BoNT-A treatment for upper limb&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  significant loss of wrist and or fingers&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  history of orthopedic surgery to plegic upper limb&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cerebral Palsy
    </Condition>
    <Intervention>Drug: Botulinum toxin type A;Device: transcranial direct current stimulation;Other: hybrid training model of CIMT and BIT;Other: usual care
    </Intervention>
    <Primary_outcome>Assisting Hand Assesment
    </Primary_outcome>
    <Secondary_outcome>Jebsen Taylor Hand Function Test
    </Secondary_outcome>
    <Secondary_ID>KOUKAEK 2016/20
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13462084
    </Internal_Number>
    <TrialID>JPRN-UMIN000027977
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Transcranial direct current stimulation (tDCS) therapy for movement disorder and cognitive impairment in neurological patients
    </Public_title>
    <Scientific_title>Transcranial direct current stimulation (tDCS) therapy for movement disorder and cognitive impairment in neurological patients - tDCS study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    </Scientific_title>
    <Primary_sponsor>Shimane University Faculty of Medicine
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170801
    </Date_registration3>
    <Date_registration>01/08/2017
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032044
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20years-old
    </Inclusion_agemin>
    <Inclusion_agemax>90years-old
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2017/08/01
    </Date_enrollement>
    <Target_size>90
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Parallel Randomized
    </Study_design>
    <Phase>Not selected
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname>Hiroaki Oguro
    </Contact_Lastname>
    <Contact_Address>89-1 Enya cho Izumo city Shimane
    </Contact_Address>
    <Contact_Email>oguro@med.shimane-u.ac.jp
    </Contact_Email>
    <Contact_Tel>0853202199
    </Contact_Tel>
    <Contact_Affiliation>Shimane University Faculty of Medicine Department of Neurology
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Psychiatric disorder(major depression,schizophrenia),drug abuse,epilepsy,post head injury
    </Exclusion_Criteria>
    <Condition>post stroke, parkinson&amp;#39;s disease, multiple system atrophy
    </Condition>
    <Intervention>The tDCS stimulation menus are 2mA intensity with 20 minutes a day for 5 days.&lt;br&gt;The sham stimulation is setted in tDCS program.
    </Intervention>
    <Primary_outcome>Motor function are Unified Parkinoson&amp;#39;s Disease Rating Scale(UPDRS) and International Cooperative Ataxia Rating Scale (ICARS).  Memory function are MMSE and HDSR. Frontal function is Frontal Assessment Battery,FAB.Mood scale are Apathy scale  and Self depression scale, SDS.
    </Primary_outcome>
    <Source_Support>Shimane University Faculty of Medicine
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_date_completed>30/04/2018
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10278198
    </Internal_Number>
    <TrialID>NCT03216837
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Stimulation for Perinatal Stroke Optimizing Recovery Trajectories
    </Public_title>
    <Scientific_title>Stimulation for Perinatal Stroke Optimizing Recovery Trajectories
    </Scientific_title>
    <Acronym>SPORT
    </Acronym>
    <Primary_sponsor>University of Calgary
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170609
    </Date_registration3>
    <Date_registration>09/06/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03216837
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>8 Years
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 1, 2017
    </Date_enrollement>
    <Target_size>80
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>Phase 2/Phase 3
    </Phase>
    <Countries>Canada
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Adam Kirton, MD;Jacquie Hodge, MSc;Adam Kirton, MD
    </Contact_Lastname>
    <Contact_Email>;jacquie.hodge@ahs.ca;adam.kirton@ahs.ca
    </Contact_Email>
    <Contact_Tel>;403-955-7733;
    </Contact_Tel>
    <Contact_Affiliation>University of Calgary;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Clinical and MRI confirmed perinatal ischemic stroke (NAIS, APPIS, PVI)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Symptomatic hemiparetic CP including parent/child perceived limitations in function&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Able to briefly lift light object off a surface (estimated House class 3-6).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Term birth (&gt; 36 weeks)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Other neurological disorder not related to perinatal stroke&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Multifocal stroke&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Sever hemiparesis (no voluntary contraction, MACS V)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Sever spasticity (Modified Ashworth Scale &gt;3)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Severe delay or inability to comply with protocol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Unstable epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. TMS or MRI contraindication&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Botox, orthopedic surgery, constraint, brain stimulation or other modulatory therapy&#x0D;&lt;br&gt;             in past 6 months prior to camp day 1&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Perinatal Stroke;Hemiplegic Cerebral Palsy
    </Condition>
    <Intervention>Device: Cathodal transcranial direct current stimulation;Device: Sham transcranial direct current stimulation
    </Intervention>
    <Primary_outcome>Change from baseline in Assisting Hand Assessment (AHA) at 1 week, 2 month and 6 month post intervention.;Change from baseline in Canadian Occupational Performance Measure (COPM) at 1 week, 2 month and 6 month post intervention.
    </Primary_outcome>
    <Secondary_outcome>Change from baseline in Children's Hand-use Experience Questionnaire (CHEQ) at 1 week, 2 month, and 6 month post intervention.;Change from baseline in Mirror Movements at 1 week, 2 month and 6 month post intervention.;Change from baseline in Jebsen Taylor Test of Hand Function (JTTHF) at 1 week, 2 month and 6 month post intervention.;Change from baseline using the Box and blocks at 1 week, 2 month and 6 month post intervention.;Change from baseline in the Quality of Life (QoL) assessment at 1 week, 2 month and 6 month post intervention.;Change in CNS Vitals battery at 1 week, 2 month and 6 month post intervention;Change from baseline in mean movements during regular daily activities measured by MotionWatch at 1 week, 2 month and 6 month post intervention.
    </Secondary_outcome>
    <Secondary_ID>REB16-2535
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Alberta;Holland Bloorview Kids Rehabilitation Hospital;The Hospital for Sick Children
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10276681
    </Internal_Number>
    <TrialID>NCT03189472
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Remotely-supervised Transcranial Direct Current Stimulation (tDCS) for At-home Treatment of Fatigue and Cognitive Slowing in Parkinson's Disease
    </Public_title>
    <Scientific_title>Remotely-supervised Transcranial Direct Current Stimulation (tDCS) for At-home Treatment of Fatigue and Cognitive Slowing in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>NYU Langone Health
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170605
    </Date_registration3>
    <Date_registration>05/06/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03189472
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>35 Years
    </Inclusion_agemin>
    <Inclusion_agemax>89 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>November 1, 2017
    </Date_enrollement>
    <Target_size>31
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Patrick Drummond, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>NYU Langone Health
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of PD confirmed by neurologist;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Parkinson fatigue scale binary coding scoring a score of &gt; 7;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Able to understand the informed consent process and provide consent to participate in&#x0D;&lt;br&gt;             the study&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Has stable and continuous access to internet service at home compatible with the study&#x0D;&lt;br&gt;             laptop (Wi-Fi or ethernet cable)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Adequate internet capacity for remote monitoring, as tested by&#x0D;&lt;br&gt;             http://www.speedtest.net/)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Subjects who are stable in their PD medication for 2 or more weeks prior to&#x0D;&lt;br&gt;             enrollment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Visual, auditory and motor deficits that would prevent full ability to understand&#x0D;&lt;br&gt;             study instructions or operate the tDCS device or study laptop, as judged by treating&#x0D;&lt;br&gt;             neurologist or study staff&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current chronic headaches or migraines. In addition, if a subject has had a change in&#x0D;&lt;br&gt;             the rate or severity of head pressure, headache, or migraine in the past two weeks,&#x0D;&lt;br&gt;             they are excluded.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of significant head trauma (e.g., brain injury, brain surgery) or medical&#x0D;&lt;br&gt;             device implanted in the head (such as Deep Brain Stimulator) or in the neck (such as a&#x0D;&lt;br&gt;             Vagus Nerve Stimulator)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any skin disorder/sensitive skin (e.g., eczema, severe rashes, blisters, open wounds,&#x0D;&lt;br&gt;             burn including sunburns, cuts or irritation, or other skin defects) which compromise&#x0D;&lt;br&gt;             the integrity of the skin at or near stimulation locations where electrodes are placed&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Serious uncontrolled medical condition (e.g., cancer or acute myocardial infarction)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Alcohol or other substance use disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Hoehn and Yahr score &gt;3&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant or breastfeeding&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of dementia or Montreal Cognitive Assessment (MoCA) score &lt;20&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Not capable of passing the neuropsychology /computer and tDCS aptitude test&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unable to tolerate discomfort from the tDCS tolerability stimulation test&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Active tDCS;Device: Sham tDCS
    </Intervention>
    <Primary_outcome>Number of participants having completed 80% sessions
    </Primary_outcome>
    <Secondary_ID>17-00486
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>11830769
    </Internal_Number>
    <TrialID>NCT03145532
    </TrialID>
    <Last_Refreshed_on>17 January 2022
    </Last_Refreshed_on>
    <Public_title>Transcranial Direct-Current Stimulation (tCDS) and Robotics for Children With Hemiplegia
    </Public_title>
    <Scientific_title>Transcranial Direct-Current Stimulation (tCDS) and Robotics for Children With Hemiplegia
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Blythedale Children's Hospital
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170504
    </Date_registration3>
    <Date_registration>04/05/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03145532
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Years
    </Inclusion_agemin>
    <Inclusion_agemax>17 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 12, 2017
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 6-17&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant and caregiver willing and able to provide informed consen/assent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of hemiplegia&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Joint mobility: wrist extension, 20º, metacarpophalangeal and proximal interphalangeal&#x0D;&lt;br&gt;             joints 10º&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive deficits that impede understanding of study protocol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current medical illness unrelated to CP&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Visual problems (uncorrected by glasses/contact lenses)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High motor ability in affected arm Pre-intervention screening measures; Motor activity&#x0D;&lt;br&gt;             log, score &gt; 2.5 ( &gt; slight-to-moderate)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe spasticity Pre-intervention screening measures; Modified Ashworth test, score &gt;&#x0D;&lt;br&gt;             3 ( &gt; moderate)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Lack of asymmetry in hand function&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Orthopedic surgery in affected arm within 2 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dorsal root rhizotomy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Botulinum toxin therapy in either upper extremity during last 2 months, or planned&#x0D;&lt;br&gt;             during study period&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently receiving intrathecal baclofen&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Seizure beyond age 2, use of anti-seizure medication, history of epilepsy (in self or&#x0D;&lt;br&gt;             first degree relatives), brain surgery, cranial metal implants, structural brain&#x0D;&lt;br&gt;             lesion, devices that may be affected by TMS (pacemaker, medication pump, cochlear&#x0D;&lt;br&gt;             implant, implanted brain stimulator)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  True positive response on the Transcranial Magnetic Stimulation Safety Screen&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current use of medications known to lower the seizure threshold&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous episode of neurocardiogenic syncopy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cerebral Palsy;Hemiplegia
    </Condition>
    <Intervention>Other: tDCS plus robotic training
    </Intervention>
    <Primary_outcome>Change in Assisting Hand Assessment after intervention;Change in Jebsen-Taylor Test of Hand Function after intervention;Change in Box and blocks test after intervention
    </Primary_outcome>
    <Secondary_ID>16-1003KF
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13603829
    </Internal_Number>
    <TrialID>NCT03191916
    </TrialID>
    <Last_Refreshed_on>8 January 2024
    </Last_Refreshed_on>
    <Public_title>Transcranial Direct Current Stimulation for Cognitive Improvement in Parkinson's Patients (tDCS)
    </Public_title>
    <Scientific_title>Transcranial Direct Current Stimulation (tDCS) to Improve Cognitive Function and Cognitive Fatigue in Parkinson's Patients
    </Scientific_title>
    <Acronym>tDCS
    </Acronym>
    <Primary_sponsor>Sanford Health
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170428
    </Date_registration3>
    <Date_registration>28/04/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03191916
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>N/A
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>October 19, 2015
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Jau-Shin Lou, MD;Jessica Keller, B.S.;Jessica Keller, B.S.
    </Contact_Lastname>
    <Contact_Email>;parkinsonsresearch@sanfordhealth.org;parkinsonsresearch@sanfordhealth.org
    </Contact_Email>
    <Contact_Tel>;701-417-5781;701-417-5781
    </Contact_Tel>
    <Contact_Affiliation>Sanford Health;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Clinical diagnosis of PD with at least two of the four diagnostic criteria for PD&#x0D;&lt;br&gt;             (tremor, rigidity, bradykinesia, and postural instability)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Meets criteria for MCI (21 = MOCA scores = 26)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Must be able to consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with dementia (MOCA &lt; 21)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  PD treatment using deep brain stimulation (DBS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of psychosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of multiple sclerosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of stroke&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of chronic obstructive pulmonary disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of congestive heart failure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of renal failure&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participants not fluent in English&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: transcranial direct current stimulation;Device: Sham (for transcranial direct current stimulation)
    </Intervention>
    <Primary_outcome>Change in Reaction Time (RT) on contextual cueing computer task
    </Primary_outcome>
    <Secondary_outcome>Change in Error Rate on contextual cueing computer task;Multidimensional Fatigue Inventory (MFI);Center for Epidemiological Studies Depression Scale (CES-D);McGill Quality of Life (QOL) Scale;Neuropsychological battery (Stroop and Digit Span);Montreal Cognitive Assessment (MOCA)
    </Secondary_outcome>
    <Secondary_ID>SH tDCS Parkinsons
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10273911
    </Internal_Number>
    <TrialID>NCT03137940
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>A Study on Safety of tDCS One-shot in UCP
    </Public_title>
    <Scientific_title>A Study on Safety and Feasibility of a Session of Transcranial Electrical Stimulation (tDCS "One-shot") in Children and Young Adults With Unilateral Cerebral Palsy (UCP)
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>IRCCS Fondazione Stella Maris
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170418
    </Date_registration3>
    <Date_registration>18/04/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03137940
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>10 Years
    </Inclusion_agemin>
    <Inclusion_agemax>28 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 20, 2017
    </Date_enrollement>
    <Target_size>8
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Other. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Italy
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Giovanni Cioni, MD
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>IRCCS Fondazione Stella Maris, Università di Pisa
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Symptomatic Unilateral Cerebral Palsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any contraindication for tDCS&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Hemiplegic Cerebral Palsy
    </Condition>
    <Intervention>Device: real tDCS;Device: sham tDCS
    </Intervention>
    <Primary_outcome>Incidence of Treatment Emergent Adverse Events [Safety and Tolerability]
    </Primary_outcome>
    <Secondary_outcome>Changes in heart rate [heartbeats per minute];Changes in blood pressure [mmHg];Changes in Box and Block Test (BBT);Changes in Hand Grip
    </Secondary_outcome>
    <Secondary_ID>Safety_tDCS1.0
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>12572560
    </Internal_Number>
    <TrialID>NCT03038269
    </TrialID>
    <Last_Refreshed_on>10 October 2022
    </Last_Refreshed_on>
    <Public_title>tDCS and Robotic Training in Adults With Cerebral Palsy
    </Public_title>
    <Scientific_title>Transcranial Direct Current Stimulation and Robotic Training in Adults With Cerebral Palsy
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Burke Medical Research Institute
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20170130
    </Date_registration3>
    <Date_registration>30/01/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03038269
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>15 Years
    </Inclusion_agemin>
    <Inclusion_agemax>70 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>December 2013
    </Date_enrollement>
    <Target_size>22
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Double (Participant, Investigator). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Participant willing and able to provide informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of hemiplegic Cerebral Palsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Joint mobility: wrist extention (20 degrees), metacarophalangeal and proximal&#x0D;&lt;br&gt;             interphalangeal joints (10 degrees)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Cognitive deficits that impede understanding of study protocol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current medical illness unrelated to CP&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Visual problems (uncorrected by glasses/contact lenses)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High motor ability in affected arm&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Severe spasticity&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Lack of asymmetry in hand function&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Orthopedic surgery in affected arm within 2 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dorsal root rhizotomy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Botulinum toxin therapy in either upper extremity during last 2 months, or planned&#x0D;&lt;br&gt;             during study period&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Currently receiving intrathecal baclofen&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Seizure beyond age 2, use of anti-seizure medication, history of epilepsy (in self or&#x0D;&lt;br&gt;             first degree relatives), brain surgery, cranial metal implants, structural brain&#x0D;&lt;br&gt;             lesion, deices that may be affected by TMS (pacemaker, medication pump, cochlear&#x0D;&lt;br&gt;             implant, implanted brain stimulator)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  True positive response on the Transcranial Magnetic Stimulation Safety Screen&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current use of medications known to lower the seizure threshold&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous episode of neurocardiogenic snycopy&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cerebral Palsy;Hemiplegia
    </Condition>
    <Intervention>Behavioral: Upper Extremity Robotics, tDCS
    </Intervention>
    <Primary_outcome>Fugl-Meyer Assessment of Motor Recovery
    </Primary_outcome>
    <Secondary_outcome>Wolf Motor Function Test;Box and Blocks Test
    </Secondary_outcome>
    <Secondary_ID>BRC 467
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13572436
    </Internal_Number>
    <TrialID>NCT03025334
    </TrialID>
    <Last_Refreshed_on>11 December 2023
    </Last_Refreshed_on>
    <Public_title>tDCS on Parkinson's Disease Cognition
    </Public_title>
    <Scientific_title>Transcranial Direct Current Stimulation Treatment of Cognitive Dysfunction in Parkinson's Disease
    </Scientific_title>
    <Acronym>tDCS-PD-fMRI
    </Acronym>
    <Primary_sponsor>University of Manitoba
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20170116
    </Date_registration3>
    <Date_registration>16/01/2017
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/ct2/show/NCT03025334
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>March 22, 2017
    </Date_enrollement>
    <Target_size>36
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Canada
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Ji Hyun Ko, PhD;Ji Hyun Ko, PhD
    </Contact_Lastname>
    <Contact_Email>ji.ko@umanitoba.ca;ji.ko@umanitoba.ca
    </Contact_Email>
    <Contact_Tel>204-318-2566;204-318-2566
    </Contact_Tel>
    <Contact_Affiliation/>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients must meet diagnostic criteria for idiopathic Parkinson's disease, defined as&#x0D;&lt;br&gt;             the presence of two or more of the cardinal clinical features of PD in the absence of&#x0D;&lt;br&gt;             known causes of parkinsonism such as encephalitis or neuroleptic treatment&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to provide written informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  defined by the Diagnostic and Statistical Manual of Mental Disorders; DSM-5)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age &gt; 40&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  fluent in English.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients' cognitive statuses will be evaluated by the participating neuropsychiatrist&#x0D;&lt;br&gt;             or a trained psychiatry or neurology resident.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with dementia (defined as a Montreal Cognitive Assessment score &lt; 18)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Atypical parkinsonian features including myoclonus, apraxia, oculomotor abnormalities,&#x0D;&lt;br&gt;             ataxia, sensory loss, or pyramidal signs.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Abnormal MRI&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  metal implants or a cardiac pacemaker&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pregnant or breastfeeding women (female subjects of child bearing potential will be&#x0D;&lt;br&gt;             screened for pregnancy before MRI imaging).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe dyskinesia that may interfere with the quality of the scan (e.g., dyskinesia&#x0D;&lt;br&gt;             involving head movement).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  severe hypertension.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  cardiovascular disease.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients with a history of seizure, stroke, moderate to severe head injury, high&#x0D;&lt;br&gt;             intracranial pressure, severe headaches, or presence of other neurologic disease that&#x0D;&lt;br&gt;             may be associated with an altered seizure threshold; or concurrent medication use,&#x0D;&lt;br&gt;             such as tricyclic antidepressants, neuroleptic medications, or other drugs that are&#x0D;&lt;br&gt;             known to lower seizure threshold&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  secondary conditions that may significantly alter electrolyte balance or lower seizure&#x0D;&lt;br&gt;             threshold.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Family history of epilepsy.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Mild Cognitive Impairment
    </Condition>
    <Intervention>Device: High-definition transcranial direct current stimulation
    </Intervention>
    <Primary_outcome>cognitive performance in neuropsychological tests
    </Primary_outcome>
    <Secondary_ID>B2016:052
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Parkinson Society Canada
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>5876701
    </Internal_Number>
    <TrialID>NCT02960464
    </TrialID>
    <Last_Refreshed_on>21 November 2016
    </Last_Refreshed_on>
    <Public_title>tDCS for Treatment of Depression in Parkinson's Disease
    </Public_title>
    <Scientific_title>Transcranial Direct Current Stimulation for Treatment of Depression in Parkinson's Disease, a Randomized Placebo-controlled Clinical Trial
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Hospital Santa Marcelina
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20161108
    </Date_registration3>
    <Date_registration>08/11/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02960464
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>35 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>October 2016
    </Date_enrollement>
    <Target_size>50
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Maria Sheila Rocha, MD, PhD;Jamana Barbosa;Pedro Gordon, MD
    </Contact_Lastname>
    <Contact_Email>;jamana.bp@ig.com.br;dr.pedrogordon@gmail.com
    </Contact_Email>
    <Contact_Tel>;2070-6000;
    </Contact_Tel>
    <Contact_Affiliation>Hospital Santa Marcelina;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Idiopathic Parkinson's Disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Geriatric Depression Scale - 15 higher that 5&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Major Depression Disorder&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  CNS disease other than Parkinson's Disease (i.e. epilepsy, stroke)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Mental disorder other than depression on anxiety disorder (i.e. bipolar disorder,&#x0D;&lt;br&gt;             schizophrenia)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Previous neurosurgical intervention (i.e. DBS)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current use of antidepressant drug&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  High suicidality risk&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Limited capacity of understanding written and spoken Portuguese&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Idiopathic Parkinson Disease;Depression
    </Condition>
    <Intervention>Device: Transcranial direct current stimulation;Device: Sham Transcranial direct current stimulation
    </Intervention>
    <Primary_outcome>Hamilton Rating Scale for Depression
    </Primary_outcome>
    <Secondary_outcome>Montgomery-Åsberg Depression Rating Scale;Mini-Mental State Examination;Hamilton Anxiety Rating Scale;Geriatric Depression Scale -15;Parkinson's Disease Questionnaire - 39;Lille apathy rating scale;Quantitative EEG
    </Secondary_outcome>
    <Secondary_ID>HSMarcelina
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>6663367
    </Internal_Number>
    <TrialID>NCT02850159
    </TrialID>
    <Last_Refreshed_on>16 December 2017
    </Last_Refreshed_on>
    <Public_title>Effect of Simultaneous Dual Stimulation on Freezing of Gait in Parkinson's Disease
    </Public_title>
    <Scientific_title>Effect of Simultaneous Dual Stimulation on Freezing of Gait in Parkinson's Disease
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Samsung Medical Center
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20160722
    </Date_registration3>
    <Date_registration>22/07/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02850159
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20 Years
    </Inclusion_agemin>
    <Inclusion_agemax>N/A
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 2013
    </Date_enrollement>
    <Target_size>32
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosed as Parkinson's disease (PD) with freezing of gait&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  walk independently without walking devices&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pre-existing and active major neurological diseases other than PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  a previous history of seizures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  implanted metallic objects that would contraindicate rTMS&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosed as Parkinson's disease (PD) with freezing of gait&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  walk independently without walking devices&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pre-existing and active major neurological diseases other than PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  a previous history of seizures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  implanted metallic objects that would contraindicate rTMS&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosed as Parkinson's disease (PD) with freezing of gait&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  walk independently without walking devices&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pre-existing and active major neurological diseases other than PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  a previous history of seizures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  implanted metallic objects that would contraindicate rTMS&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  diagnosed as Parkinson's disease (PD) with freezing of gait&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  walk independently without walking devices&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pre-existing and active major neurological diseases other than PD&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  a previous history of seizures&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  implanted metallic objects that would contraindicate rTMS&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Parkinson Disease;Parkinson Disease;Parkinson Disease
    </Condition>
    <Intervention>Device: rTMS and tDCS;Device: rTMS;Device: rTMS and tDCS;Device: rTMS;Device: rTMS and tDCS;Device: rTMS;Device: rTMS and tDCS;Device: rTMS
    </Intervention>
    <Primary_outcome>Change of Freezing of Gait Questionnaire (FOG-Q);Change of Freezing of Gait Questionnaire (FOG-Q);Change of Freezing of Gait Questionnaire (FOG-Q)
    </Primary_outcome>
    <Secondary_ID>2013-09-122
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>02/07/2017
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT02850159
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>5785284
    </Internal_Number>
    <TrialID>NCT02917122
    </TrialID>
    <Last_Refreshed_on>10 October 2016
    </Last_Refreshed_on>
    <Public_title>The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's Disease
    </Public_title>
    <Scientific_title>The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's Disease
    </Scientific_title>
    <Acronym>Parkinson's
    </Acronym>
    <Primary_sponsor>National Cheng-Kung University Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20160630
    </Date_registration3>
    <Date_registration>30/06/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02917122
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>75 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>August 2015
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 1/Phase 2
    </Phase>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Kao Chin Chen, PhD;Kao Chin Chen, PhD
    </Contact_Lastname>
    <Contact_Email>;
    </Contact_Email>
    <Contact_Tel>;
    </Contact_Tel>
    <Contact_Affiliation>National Cheng-Kung University Hospital;National Cheng-Kung University Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. In the opinion of the investigator, the participant is capable of understanding and&#x0D;&lt;br&gt;             complying with protocol requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. The participant or, when applicable, the participant's legally acceptable&#x0D;&lt;br&gt;             representative signs and dates a written, informed consent form and any required&#x0D;&lt;br&gt;             privacy authorization prior to the initiation of any study procedures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Suffers from Parkinson's disease fulfill the Parkinson's Disease Society Brain Bank&#x0D;&lt;br&gt;             clinical criteria with insidious 2 or more PD symptoms (bradykinesia, tremor, or&#x0D;&lt;br&gt;             rigidity).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Suffers from "DSM-IV major depressive disorder, single episode" or "DSM-IV major&#x0D;&lt;br&gt;             depressive disorder, recurrent" according to Diagnostic &amp; Statistical Manual of&#x0D;&lt;br&gt;             Mental Disorders, 4th Edition - Text Revision (DSM-IV-TR) criteria.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Reported duration of the current episode is =4 weeks and has not been treated with&#x0D;&lt;br&gt;             antidepressants.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Has a Montgomery-Åsberg Depression Rating Scale (MADRS) total score =20 at the&#x0D;&lt;br&gt;             screening (baseline) visit.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Is a man or woman aged 18 to 75 years, inclusive.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subjects known to have allergies to sertraline and pimozide.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subjects showed any signs of substantial risk of suicide during the trial.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Subjects ever received electroconvulsive treatment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Subjects co-morbid with other major mental disorders or with substance/alcohol&#x0D;&lt;br&gt;             dependence or abuse in the past 6 months per DSM-IV criteria.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Nursing women, pregnant women or patients suspected pregnant.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. History or presence of clinically significant hepatic, cardiovascular or renal&#x0D;&lt;br&gt;             disease, or other serious medical disease that might compromise the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. History of seizure disorder or need to taking medications that increase the risk of&#x0D;&lt;br&gt;             seizure.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. History or presence of dementia and any previous history of brain tumor, brain&#x0D;&lt;br&gt;             arteriovenous malformation, encephalitis or meningitis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Subjects ever received or plan to receive brain surgery during the trial.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Subjects with pacemaker or are contraindicated for MRI.&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. In the opinion of the investigator, the participant is capable of understanding and&#x0D;&lt;br&gt;             complying with protocol requirements.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. The participant or, when applicable, the participant's legally acceptable&#x0D;&lt;br&gt;             representative signs and dates a written, informed consent form and any required&#x0D;&lt;br&gt;             privacy authorization prior to the initiation of any study procedures.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Suffers from Parkinson's disease fulfill the Parkinson's Disease Society Brain Bank&#x0D;&lt;br&gt;             clinical criteria with insidious 2 or more PD symptoms (bradykinesia, tremor, or&#x0D;&lt;br&gt;             rigidity).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Suffers from "DSM-IV major depressive disorder, single episode" or "DSM-IV major&#x0D;&lt;br&gt;             depressive disorder, recurrent" according to Diagnostic &amp; Statistical Manual of&#x0D;&lt;br&gt;             Mental Disorders, 4th Edition - Text Revision (DSM-IV-TR) criteria.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Reported duration of the current episode is =4 weeks and has not been treated with&#x0D;&lt;br&gt;             antidepressants.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Has a Montgomery-Åsberg Depression Rating Scale (MADRS) total score =20 at the&#x0D;&lt;br&gt;             screening (baseline) visit.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Is a man or woman aged 18 to 75 years, inclusive.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Subjects known to have allergies to sertraline and pimozide.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Subjects showed any signs of substantial risk of suicide during the trial.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Subjects ever received electroconvulsive treatment.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Subjects co-morbid with other major mental disorders or with substance/alcohol&#x0D;&lt;br&gt;             dependence or abuse in the past 6 months per DSM-IV criteria.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Nursing women, pregnant women or patients suspected pregnant.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. History or presence of clinically significant hepatic, cardiovascular or renal&#x0D;&lt;br&gt;             disease, or other serious medical disease that might compromise the study.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. History of seizure disorder or need to taking medications that increase the risk of&#x0D;&lt;br&gt;             seizure.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. History or presence of dementia and any previous history of brain tumor, brain&#x0D;&lt;br&gt;             arteriovenous malformation, encephalitis or meningitis.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Subjects ever received or plan to receive brain surgery during the trial.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;         10. Subjects with pacemaker or are contraindicated for MRI.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Depression;Parkinson Disease;Depression
    </Condition>
    <Intervention>Device: active tDCS;Drug: Sertraline;Device: sham tDCS;Device: active tDCS;Drug: Sertraline;Device: sham tDCS
    </Intervention>
    <Primary_outcome>Change of Unified Parkinson's Disease Rating Scale among different weeks;Change of Hoehn and Yahr scale among different weeks;Change of Hamilton Rating Scale for Depression among different weeks;Change of Taiwanese Depression Questionnaire among different weeks;Change of Global Assessment of Functioning among different weeks;Change of clinical global impression among different weeks;Change of Unified Parkinson's Disease Rating Scale among different weeks;Change of Hoehn and Yahr scale among different weeks;Change of Hamilton Rating Scale for Depression among different weeks;Change of Taiwanese Depression Questionnaire among different weeks;Change of Global Assessment of Functioning among different weeks;Change of clinical global impression among different weeks
    </Primary_outcome>
    <Secondary_outcome>Change of finger tapping test among different weeks;Change of continuous performance task among different weeks;Change of Wisconsin Card Sorting Test among different weeks;Change of Wechsler Memory Scale - Revised among different weeks;Change of finger tapping test among different weeks;Change of continuous performance task among different weeks;Change of Wisconsin Card Sorting Test among different weeks;Change of Wechsler Memory Scale - Revised among different weeks
    </Secondary_outcome>
    <Secondary_ID>A-BR-103-079;A-BR-103-079
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors;Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13662279
    </Internal_Number>
    <TrialID>TCTR20160330002
    </TrialID>
    <Last_Refreshed_on>22 January 2024
    </Last_Refreshed_on>
    <Public_title>Effects of transcranial direct current stimulation (tDCS)  plus physical therapy on gait in Parkinson
    </Public_title>
    <Scientific_title>Effects of transcranial direct current stimulation (tDCS) &#x0D;
plus physical therapy on gait in Parkinson&#x0D;
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
    </Scientific_title>
    <Primary_sponsor>Ratchadapiseksompotch Fund
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20160330
    </Date_registration3>
    <Date_registration>30/03/2016
    </Date_registration>
    <Source_Register>TCTR
    </Source_Register>
    <web_address>https://www.thaiclinicaltrials.org/show/TCTR20160330002
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>08/05/2011
    </Date_enrollement>
    <Target_size/>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Randomized
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Thailand
    </Countries>
    <Contact_Firstname>Krisna
    </Contact_Firstname>
    <Contact_Lastname>Piravej
    </Contact_Lastname>
    <Contact_Address>1873 Rama 4 rd&amp;#44; Patumwan
    </Contact_Address>
    <Contact_Email>kppmrchula@gmail.com
    </Contact_Email>
    <Contact_Tel>022564433
    </Contact_Tel>
    <Contact_Affiliation>Faculty of Medicine
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 1.	Age between 40 to 80 year&amp;#45;old&#x0D;&lt;br&gt;2.	Patients who were diagnosed with Parkinson disease under the diagnosis criterion of United Kingdom Parkinsonâ€™s Disease Society Brain Bank Diagnostic Criteria for Parkinsonâ€™s Disease.&#x0D;&lt;br&gt;3.	Patients who are at stage 2 &amp; 3 of Parkinsonâ€™s disease&amp;#44; which certified by modified Hoehn &amp; Yahr Staging criterion.&#x0D;&lt;br&gt;4.	Patients who has been treated with medication regularly with no changes in medication during the study period.&#x0D;&lt;br&gt;5.	Patients who have slower walking speed than normal elderly were enrolled (average walking speed was set at 0.4 to 0.9 meters per second)&#x0D;&lt;br&gt;6.	Patients who agreed to participated throughout the whole period settled&#x0D;&lt;br&gt;
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1.	Patients who were unable to walk (on a flat surface) by themselves or needed to use gait aid&#x0D;&lt;br&gt;2.	Patients who previously had epilepsy or had done a surgery in around the skull area (might be dangerous or risky to do tDCS).&#x0D;&lt;br&gt;3.	Patients who have been taking sodium channel blocker or calcium channel blocker medicine.&#x0D;&lt;br&gt;4.	Patients who have other abnormalities that affect the motor system and communication skills such as dementia&amp;#44; stroke&amp;#44; patients with bone disease or eye diseases that affect their visual ability.&#x0D;&lt;br&gt;
    </Exclusion_Criteria>
    <Condition>&amp;#45; Parkinson patients age 40&amp;#45;80 year &#x0D;
&amp;#45; Modified Hoehn &amp; Yahr stage 2 &amp; 3 &#x0D;
&amp;#45; Walking speed slower than normal elderly &lt;br&gt;Transcranial direct current stimulation&amp;#44; Parkinson&amp;#44; gait;Transcranial direct current stimulation&amp;#44; Parkinson&amp;#44; gait
    </Condition>
    <Intervention>The 1st group was treated with anodal tDCS &lt;br&gt;2 mA stimulated on lower extremity motor cortex for 30 minutes.,The 2nd group was treated with the same anodal tDCS protocol and underwent physical therapy for 30 minutes.,the 3rd group was given sham tDCS and underwent physical therapy for 30 minutes;Active Comparator Procedure/Surgery,Experimental Procedure/Surgery,Sham Comparator Procedure/Surgery;First group,Second group,Third group
    </Intervention>
    <Primary_outcome>gait parameters  2&amp;#44; 4&amp;#44; 8 week post treatment gait and motion analysis
    </Primary_outcome>
    <Secondary_outcome>none none none
    </Secondary_outcome>
    <Source_Support>Ratchadapiseksompotch Fund 
    </Source_Support>
    <Secondary_Sponsor>Ratchadapiseksompotch Fund 
    </Secondary_Sponsor>
    <Ethics_review_status>Submitted, approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address>IRB
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>022564455 Ext. 
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email/>
    <results_date_completed>11/01/2013
    </results_date_completed>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>12956773
    </Internal_Number>
    <TrialID>NCT03074812
    </TrialID>
    <Last_Refreshed_on>10 April 2023
    </Last_Refreshed_on>
    <Public_title>Exploring Mechanisms for Neuropsychiatric Symptoms of Parkinson Disease Using Transcranial Direct Current Stimulation
    </Public_title>
    <Scientific_title>Exploring Mechanisms for Neuropsychiatric Symptoms of Parkinson Disease Using Transcranial Direct Current Stimulation
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Johns Hopkins University
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20160302
    </Date_registration3>
    <Date_registration>02/03/2016
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT03074812
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>95 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>February 2016
    </Date_enrollement>
    <Target_size>80
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname> ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Kelly Mills, M.D.;Yousef Salimpour, Ph.D.;Yousef Salimpour, Ph.D.
    </Contact_Lastname>
    <Contact_Email>;ysalimp1@jhmi.edu;ysalimp1@jhmi.edu
    </Contact_Email>
    <Contact_Tel>;410-502-2666;410-502-2666
    </Contact_Tel>
    <Contact_Affiliation>Johns Hopkins University;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Abel to provide written informed consent is obtained in the English language&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age 18 to 95 years old&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Movement Disorder Society Clinical Diagnostic Criteria for probable idiopathic&#x0D;&lt;br&gt;             Parkinson disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Report disabling depressive or neuropsychiatric symptoms prior to study entry&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Capacity to understand the nature of the study;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Known structural brain disease such as a neoplasm, abscess etc.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Pre-existing skull / scalp defects that would impede standardized electrode placement&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current electronic or metal implants&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of Bipolar Disorder, Post-Traumatic Stress Disorder, a Psychotic Disorder or&#x0D;&lt;br&gt;             any other non-unipolar depressive disorder as a principal diagnosis in the 6 months&#x0D;&lt;br&gt;             prior to screening;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Concurrent treatment with medication which may affect tDCS (benzodiazepines,&#x0D;&lt;br&gt;             anticonvulsants, dextromethorphan and pseudoephedrine)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Endorse active suicidal ideation at enrollment or during any study visit, or have&#x0D;&lt;br&gt;             attempted suicide in the six months prior to screening;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of substance abuse or dependence in the 2 months prior to screening;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Considered to be at significant risk of committing homicide;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Unstable medical condition;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Score less than 22 on the Montreal Cognitive Assessment (MoCA)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Women of childbearing potential who are pregnant or are considering becoming pregnant&#x0D;&lt;br&gt;             during the length of the study;&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  There has been a change in their depression or psychotherapy treatment regimen in the&#x0D;&lt;br&gt;             2 weeks preceding screening;&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Idiopathic Parkinson's Disease;Parkinson Disease;Depression
    </Condition>
    <Intervention>Device: Transcranial Direct Current Stimulation
    </Intervention>
    <Primary_outcome>Number of Participants Demonstrating improvements on Objective Rating Scales of Depression via structured interview
    </Primary_outcome>
    <Secondary_outcome>Apathy Scores as measure by a self-report scale (the Apathy Scale);Subjective Depression Severity rated via self-report on depression inventory;Subjective reactive to pleasure (i.e. improvement of anhedonia) as rated via self-report;Subjective improvement of Anxiety Symptoms via Rating Scale;Performance on abbreviated cognitive battery;Improvement of Parkinsonian Motor Symptoms
    </Secondary_outcome>
    <Secondary_ID>IRB00087957
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13086641
    </Internal_Number>
    <TrialID>RBR-95xwc7
    </TrialID>
    <Last_Refreshed_on>29 May 2023
    </Last_Refreshed_on>
    <Public_title>Evaluation of effects of differents montages of non invasive brain eletrical stimulation in funcionality of children with cerebral palsy of type spastic hemiparesis
    </Public_title>
    <Scientific_title>Effects of differents montages of tDCS in functionality of children with Cerebral Palsy of type Spastic Hemiparesis: clinical trial randomized, placebo-controlled and double blind                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
    </Scientific_title>
    <Primary_sponsor>Universidade Nove de Julho
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150727
    </Date_registration3>
    <Date_registration>27/07/2015
    </Date_registration>
    <Source_Register>REBEC
    </Source_Register>
    <web_address>http://ensaiosclinicos.gov.br/rg/RBR-95xwc7
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6Y
    </Inclusion_agemin>
    <Inclusion_agemax>10Y
    </Inclusion_agemax>
    <Inclusion_gender>-
    </Inclusion_gender>
    <Date_enrollement>10/11/2015
    </Date_enrollement>
    <Target_size/>
    <Study_type>Intervention
    </Study_type>
    <Study_design>Clinical trial randomized, placebo-controlled and double blind with three arms.
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname>Natália
    </Contact_Firstname>
    <Contact_Lastname>Duarte
    </Contact_Lastname>
    <Contact_Address>Avenida francisco Matarazzo
    </Contact_Address>
    <Contact_Email>natycarvalho_fisio@hotmail.com
    </Contact_Email>
    <Contact_Tel>55(35)36659335
    </Contact_Tel>
    <Contact_Affiliation>Universidade Nove de Julho
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Inclusion criteria will be thirty children who: a) have the diagnosis of CP spastic hemiparesis; functionally classified as levels I and II by GMFCS (Palisano et al, 1997;. Hiratuka et al, 2010).; have independent walking at least 12 months; the age group of six and ten years of life; have degrees of understanding and consistent collaboration with the completion of the proposed activities; The parents agree with their participation in the study by signing the Informed Consent
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Children who will be excluded have undergone surgical procedures or neurolytic blocks in the last 12 months before the start of the training sessions; presenting structured orthopedic deformities with surgical indications; have epilepsy; having metal implant in the brain or hearing aids.
    </Exclusion_Criteria>
    <Condition>Cerebral Palsy. Hemiparesis.;C10.228.140.140.254;C10.597.636
    </Condition>
    <Intervention>Group 1: anodal tDCS on motor cortex primary and cathode in the contralateral supraorbital region associated to gait training on a treadmill; Group 2: placebo tDCS anode  on the primary motor cortex and cathode in the contralateral supraorbital region associated to gait training on a treadmill; Group3: anodal tDCS on the primary motor cortex of the injured hemisphere and cathodic stimulation in the contralateral primary motor cortex associated with gait training on a treadmill. Participants will be assessed at three points in time (before, immediately after and one month after the proposed training).&lt;br&gt;&lt;br&gt;The tdcs will be perform in 30 children, with 10 children per group. This stimulation will be perform during 2 weeks consecutively, 10 sessions during 20 minutes, using 1mA of current stimulation.;Behavioural;E02.342
    </Intervention>
    <Primary_outcome>We believe that the group with de bilateral montage has better results when compared with unilateral montage.&lt;br&gt;Perform a comparative analysis between the effects of different montages of transcranial direct current stimulation associated with gait training on the treadmill on functional mobility, gait pattern (spatiotemporal, kinematic and kinetic gait parameters), static equilibrium and functional performance in children with spastic hemiparetic cerebral palsy, after 10 sessions of treadmill training simultaneously the use of tDCS (2 weeks consecutively - 5 sessions per week). The evaluations will be performed before de intervention, after and one month after the end of the sessions of intervention&lt;br&gt;&lt;br&gt;The sample size calculation was performed using the statistical software STATA 11, based on the research Grecco et al. (2013) "A comparison of treadmill training and overground walking in ambulant children with cerebral palsy: randomized controlled clinical trial." For Calculated based gait speed. Gait velocity was considered to represent an important clinical outcome and directly related to the intervention. The study Grecco et al. was selected by engaging a similar population to which this project aims to engage (children with CP levels I - III of the GMFCS). Based on the average of the experimental group of 1.0 m / s, with standard deviation of 0,22m / s of 0,71m / s control group, with standard deviation of 0.12 M / s, for a bidirectional alpha 0.05 and a power of 80% will be required 8 children per group. The sample is increased by 20% in order to avoid the effects of possible losses ending with a number of 10 children in each group, a total of 30 participants.
    </Primary_outcome>
    <Secondary_outcome>Verify proper montage of tDCS performed during gait training on a treadmill, to optimize the function of gait, static balance and functional performance of children with cerebral palsy spastic hemiparesis, after 10 sessions of treadmill training simultaneously the use of tDCS (2 weeks consecutively - 5 sessions per week). The evaluations will be performed before de intervention, after and one month after the end of the sessions of intervention
    </Secondary_outcome>
    <Source_Support>Universidade Nove de Julho
    </Source_Support>
    <Secondary_Sponsor>Universidade Nove de Julho
    </Secondary_Sponsor>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>5019833
    </Internal_Number>
    <TrialID>NCT02503930
    </TrialID>
    <Last_Refreshed_on>3 August 2015
    </Last_Refreshed_on>
    <Public_title>The Effect of tDCS on a Motor-cognitive Dual-task Performance of Parkinson's Patients
    </Public_title>
    <Scientific_title>The Effect of Transcranial Direct Cortical Stimulation (tDCS) on a Motor-cognitive Dual-task Performance of Parkinson's Patients
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Tel-Aviv Sourasky Medical Center
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20150709
    </Date_registration3>
    <Date_registration>09/07/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02503930
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>20 Years
    </Inclusion_agemin>
    <Inclusion_agemax>90 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>July 2015
    </Date_enrollement>
    <Target_size>60
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
    </Study_design>
    <Phase>N/A
    </Phase>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>Nir Giladi, M.D;Anat Mirelman, PhD
    </Contact_Lastname>
    <Contact_Email>;anatmi@tlvmc.gov.il
    </Contact_Email>
    <Contact_Tel>;972-3-6974958
    </Contact_Tel>
    <Contact_Affiliation>Tel Aviv Sourasky medical Center, Tel Aviv, Israel. Phone: 972-3-6974790;
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Diagnosis of idiopathic PD (defined by the UK Brain Bank criteria)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Hoehn and Yahr score between 1.5-3&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Taking anti-parkinsonian medications.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Mini Mental State Exam (MMSE) score =&lt; 24&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Brain surgery in the past including implanted DBS&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Major depression (DSM-IV Criteria)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Cerebral Infarction with Residual Deficits Diagnosis&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Neurological diseases (except from PD)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Orthopaedic or cardiovascular diseases that may affect walking and cognitive&#x0D;&lt;br&gt;             abilities.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Active tDCS;Device: Sham tDCS
    </Intervention>
    <Primary_outcome>Changes in frequency and severity of the freezing of gait phenomenon
    </Primary_outcome>
    <Secondary_outcome>fMRI scans - changes in gray matter (GM) volume;fNIRS related frontal lobe activation - changes in  tissue oxygenation;Changes in cognitive performance;Immediate change in gait speed;Immediate change in gait variability
    </Secondary_outcome>
    <Secondary_ID>TASMC-15-NG-261-CTIL
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Tel Aviv University
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>8762894
    </Internal_Number>
    <TrialID>ACTRN12615000592549
    </TrialID>
    <Last_Refreshed_on>13 January 2020
    </Last_Refreshed_on>
    <Public_title>Pilot study of transcranial Direct Current Stimulation (tDCS) as a therapeutic intervention for Tourette Syndrome
    </Public_title>
    <Scientific_title>Does transcranial Direct Current Stimulation (tDCS) result in a reduction in the severity and frequency of tics in individuals with Tourette Syndrome?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
    </Scientific_title>
    <Primary_sponsor>University of New South Wales
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150605
    </Date_registration3>
    <Date_registration>05/06/2015
    </Date_registration>
    <Source_Register>ANZCTR
    </Source_Register>
    <web_address>https://anzctr.org.au/ACTRN12615000592549.aspx
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>12 Years
    </Inclusion_agemin>
    <Inclusion_agemax>No limit
    </Inclusion_agemax>
    <Inclusion_gender>Both males and females
    </Inclusion_gender>
    <Date_enrollement>10/07/2016
    </Date_enrollement>
    <Target_size>8
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Crossover;Type of endpoint: Safety/efficacy;
    </Study_design>
    <Phase>Not Applicable
    </Phase>
    <Countries>Australia
    </Countries>
    <Inclusion_Criteria>Inclusion criteria: 1. Participant aged over 12 years.&#x0D;&lt;br&gt;2. Participant meets criteria for a primary diagnosis of DSM-5 Tourette’s Disorder: presence of multiple motor and one or more vocal tics which have persisted for more than one year with onset before 18 years of age (American Psychiatric Association, 2013).&#x0D;&lt;br&gt;3. Participants taking psychotropic medications to manage tics will be included as long as the dose had been stable for at least six weeks prior to participation, with no planned changes during the course of the study.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: 1. Unacceptable risk factors for unsafe administration or side effects of tDCS (implanted cranial devices; previous head or brain injury; skin lesions on scalp at proposed electrode sites; epilepsy or history of seizures; drug abuse).&#x0D;&lt;br&gt;2. Participants who are not fluent in English will be excluded from the trial for safety reasons. It is usually not possible to have an interpreter readily available every weekday for up to four weeks and it is not safe to administer tDCS to a participant who cannot immediately inform us of any side effects (e.g., development of skin irritation during stimulation).&#x0D;&lt;br&gt;3. Participant has a primary psychiatric or medical diagnosis apart from Tourette's Disorder. While participants with comorbidities commonly associated with a primary diagnosis of Tourette's Disorder (such as Obsessive-Compulsive Disorder and Attention Deficit Hyperactivity Disorder) will not be excluded, those with any major psychiatric conditions such as psychosis, bipolar disorder etc will be excluded.&#x0D;&lt;br&gt;4. Pregnancy.
    </Exclusion_Criteria>
    <Condition>Tourette Syndrome; &lt;br&gt;Tourette Syndrome;Neurological - Other neurological disorders;Human Genetics and Inherited Disorders - Other human genetics and inherited disorders
    </Condition>
    <Intervention>Transcranial Direct Current Stimulation (tDCS) will be administered via sponge electrodes (stimulating electrode 25cm2) soaked in saline and held in place by a neoprene cap, with the cathode positioned over the preSMA (4cm in front of the vertex/Cz) and the return electrode positioned over the right deltoid. The current intensity will be given at between 1.0mA to 2.0mA (milliamps) for a duration of up to 30 minutes per session, dependent on participant-reported tolerability. Participants will receive a course of tDCS three times per week for six weeks (a total of 18 tDCS sessions). To allow for contingencies (e.g., non-attendance due to unforeseen circumstances), participants will be required to complete a minimum of two and maximum of three sessions in any one week, and complete the total 18 sessions, meaning that treatment duration could be for up to nine weeks. Participants will complete the first two treatment sessions face-to-face in order to have the procedure explained and to ascertain the tolerability and any potential side-effects of the treatment. Participants will be able to complete subsequent treatment sessions at their home using a portable unit. Settings on the unit will be programmed by a study investigator, and these are unable to be changed by the participant. Sessions conducted at participants' homes will be supervised remotely by a study investigator.
    </Intervention>
    <Primary_outcome>The Premonitory Urge for Tics Scale (PUTS; Woods, Piacentini, Himle, &amp; Chang, 2005)[For all participants, the PUTS will be administered at baseline, week 3, week 6, week 9, and then three months and six months post-treatment.];The Parent/Self Tic Questionnaire (PTQ; Chang, Himle, Tucker, Woods, &amp; Piacentini, 2009)[For all participants, the PTQ will be administered at baseline, week 3, week 6, week 9, and then three months and six months post-treatment.];The National Hospital Interview Schedule for the assessment of Gilles de la Tourette syndrome (NHIS) which includes the Yale Global Tic Severity Rating Scale (Robertson &amp; Eapen, 1996)[For all participants, the NHIS, including the YGTSS, will be administered at baseline. The YGTSS will be administered at week 3, week 6, week 9, and then three months and six months post-treatment.]
    </Primary_outcome>
    <Secondary_outcome>Laboratory-based assessment of inhibitory function will be assessed by a task based on the foreperiod go/no-go task introduced by Los (2013).[For all participants, inhibitory function will be assessed at baseline, week 3, week 6, week 9, and six months post-treatment.]
    </Secondary_outcome>
    <Secondary_ID>Nil
    </Secondary_ID>
    <Secondary_Sponsor>Macquarie University
    </Secondary_Sponsor>
    <Ethics_review_status>Approved;Approved
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900;01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name>;
    </Ethics_review_contact_name>
    <Ethics_review_contact_address>University of New South Wales Human Research Ethics Committee;Macquarie University HREC
    </Ethics_review_contact_address>
    <Ethics_review_contact_phone>;
    </Ethics_review_contact_phone>
    <Ethics_review_contact_email>;
    </Ethics_review_contact_email>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10242451
    </Internal_Number>
    <TrialID>NCT02453763
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>In Vivo Imaging of Therapeutic Electric Current Flow
    </Public_title>
    <Scientific_title>In Vivo Imaging of Therapeutic Electric Current Flow
    </Scientific_title>
    <Acronym>tDCS
    </Acronym>
    <Primary_sponsor>University of Florida
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20150521
    </Date_registration3>
    <Date_registration>21/05/2015
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02453763
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>30 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>June 2015
    </Date_enrollement>
    <Target_size>17
    </Target_size>
    <Study_type>Observational
    </Study_type>
    <Study_design/>
    <Phase/>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Thomas H Mareci, Ph.D.
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Florida
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  right handed (as determined by the Edinburgh battery),&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  English as native language.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  appreciable deficits in hearing,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  appreciable problems with articulation,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  appreciable accent schizophrenia, bipolar disorder, or major depression,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  any neurological disorder associated with cognitive impairment or neuroanatomic&#x0D;&lt;br&gt;             abnormality,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  language-based learning disorder,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  any implanted metal device (precludes use of tDCS), any implanted cardiac pacemaker,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  dementia or mini-mental state exam,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  &lt;24 estimated verbal intelligence,&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  &lt;70 active or prior history of seizure disorder, family history of seizure disorder,&#x0D;&lt;br&gt;             prescribed seizure inducing medication.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Epilepsy;Alzheimer's Disease;Stroke;Autism;Depression;Schizophrenia
    </Condition>
    <Intervention>Device: Transcranial direct current stimulation;Procedure: MRI
    </Intervention>
    <Primary_outcome>Magnetic Resonance Imaging (MRI) of therapeutic current flow
    </Primary_outcome>
    <Secondary_ID>1R21NS081646-01A1;506-2012-N
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Arizona State University;National Institute of Neurological Disorders and Stroke (NINDS)
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13086522
    </Internal_Number>
    <TrialID>RBR-4hvfzj
    </TrialID>
    <Last_Refreshed_on>29 May 2023
    </Last_Refreshed_on>
    <Public_title>Physiotherapy techniques in Parkinson's Disease
    </Public_title>
    <Scientific_title>Physiotherapy approaches in Parkinson's Disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    </Scientific_title>
    <Primary_sponsor>Sociedade Unificada de Ensino Augusto Motta - UNISUAM
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20150407
    </Date_registration3>
    <Date_registration>07/04/2015
    </Date_registration>
    <Source_Register>REBEC
    </Source_Register>
    <web_address>http://ensaiosclinicos.gov.br/rg/RBR-4hvfzj
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>50Y
    </Inclusion_agemin>
    <Inclusion_agemax>80Y
    </Inclusion_agemax>
    <Inclusion_gender>-
    </Inclusion_gender>
    <Date_enrollement>02/06/2014
    </Date_enrollement>
    <Target_size/>
    <Study_type>Intervention
    </Study_type>
    <Study_design>Clinical trial randomized controlled, parallel, double-blind, three-arm.
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname>Laura Alice
    </Contact_Firstname>
    <Contact_Lastname>de Oliveira
    </Contact_Lastname>
    <Contact_Address>Rua Professor Henrique Costa 324, apt 409. Pechincha
    </Contact_Address>
    <Contact_Email>lauraoliveira.ft@gmail.com
    </Contact_Email>
    <Contact_Tel>+55 (21) 3327-8995
    </Contact_Tel>
    <Contact_Affiliation>Sociedade Unificada de Ensino Augusto Motta - UNISUAM
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Signed the Free and Informed Consent Statement; age of 50 to 80 years; both sexes; diagnosis of idiopathic Parkinson's disease (PD) according to the UK Parkinson's Disease Brain Bank; stage 1-3 on the Hoehn and Yahr disability scale; ability to ambulate alone for 10 meters; be using regular medication for PD; target sample of 60 participants.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Cognitive impairment (Mini-Mental less than or equal to 18); other neurological disorders; hypertension or uncontrolled arrhythmia; severe visual impairment uncorrected; vertigo; presence of metal implant brand or pacemaker; constant headache and without diagnosis; history of convulsion; use of medication that alters cortical excitability; younger than 50 years; older than 80 years.
    </Exclusion_Criteria>
    <Condition>Parkinson's disease, Enfermedad de Parkinson;C10.228.140.079.862.500
    </Condition>
    <Intervention>This project will lead to three. Initially all patients with Parkinson's disease (PD) (60 individuals) of both sexes in treatment in the physiotherapy clinic of Deolindo Couto Institute of Neurology will be evaluated for the cross-sectional study on the epidemiological, functional (global function, balance, mobility), activity and participation profile through an interview and the following methods: Functional Independence Measure (FIM), Unified Parkinson's Disease Rating Scale (UPDRS), Berg Balance Scale, Stabilometry,Balance Evaluation Systems Test (Bestest), Kinematics, 10 meters Walk Test, Timed up and go (TUG), Dynamic Gait Index (DGI), Freezing of Gait Questionnaire (FOG-Q), Independence Index of Daily Life Activities Katz (Katz Index), Lawton and Brody Scale, Parkinson's Disease Questionnaire 39 (PDQ-39 ), Parkinson's Disease Quality of Life Questionnaire (PDQL) and Parkinson Activity Scale (PAS) (study 1).&lt;br&gt;For the physiotherapy protocol group (study 2), 20 of this PD participants will be randomly assigned and they will be treated with exercises in groups of 6 to 8 participants, including 6 categories of exercises (tai chi, kayaking, agility training, boxing, lunges and Pilates ) about 10 minutes each, three times a week for 4 weeks for 60 minutes, a total of 12 sessions.&lt;br&gt;For the application of transcranial direct current stimulation (tDCS) (study 3), the other patients with PD will be allocated randomly, by lottery, in 2 groups. Experimental group: 20 participants will receive active tDCS (transcranial direct current stimulation, which stimulates brain region on which the electrode is positioned) and physiotherapy exercise program. Control group: 20 participants will receive sham tDCS and physiotherapy exercise program. For the application of tDCS, par;Other;E02.779.483;E05.723.402;L01.453.245.945.450;G11.427.690;C23.888.550;E01.370.600.250
    </Intervention>
    <Primary_outcome>Improved mobility, verified by the Timed up and go test, from the observation of decrease of at least 5% at execution time (seconds) in the pre and post intervention.  
    </Primary_outcome>
    <Secondary_outcome>Improving the ability to modify the gait in response to changes in demand, checked through the Dynamic Gait Index, from the increasing the score at least 5% in pre and post intervention measurements. Increased walking speed (meters/second) and cadence (steps/minute), verified through the 10-meter walk test, based on the statement of a variation of at least 5% in pre and post intervention measurements. Improvement in the level of activity (mobility, freezing, dual task), checked by Parkinson Activity Scale, from the observation of an increase in the score of at least 5% in pre and post intervention measurements. Improvement in gait parameters, such as increased stride length (cm) and speed (m/s), checked by means of kinematics, from the observation of an increase of at least 5% in pre and post intervention measurements. Improvement in disability and disability caused by Parkinson's disease, verified by the Unified Parkinson's Disease Rating Scale from the decrease of the finding in the score of at least 5% in pre and post intervention measurements. Decrease in the stage of Parkinson's disease, verified by Hoehn and Yahr Modified Scale, based on the statement of decrease of at least 5% in pre and post intervention measurements. Improves the individual's ability perform daily activities, verified by the percentage of Schwab and England Activities of Daily Living Scale, from the realization of the increase of at least 5% in pre and post intervention measurements. Improved balance and decrease the risk of falling, verified by the score of the Berg Balance Scale, based on the statement of increase of at least 5% in pre and post intervention measurements. Improvement of static balance, with decreased postural sway, verified by Stabilometry, from the variation of finding at least 5% in pre and post intervention measurements. Improvement in gait and decreased episodes of freezing of gait disorders, verified by the score Freezing of Gait Questionnaire, based on the statement of decrease of at least 5% in pre and post intervention. Improved self-reported quality of life, verified by the score of Parkinson's Disease Questionnaire 39 from the decrease of finding at least 5% in pre and post intervention.
    </Secondary_outcome>
    <Source_Support>Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro - FAPERJ
    </Source_Support>
    <Secondary_Sponsor>Instituto de Neurologia Deolindo Couto (INDC) - Universidade Federal do Rio de Janeiro (UFRJ)
    </Secondary_Sponsor>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13086472
    </Internal_Number>
    <TrialID>RBR-6v4y3k
    </TrialID>
    <Last_Refreshed_on>29 May 2023
    </Last_Refreshed_on>
    <Public_title>Transcranial current stimulation for childrens with cerebral palsy
    </Public_title>
    <Scientific_title>Transcranial direct current stimulation associated with upper limb functional training for childrens with spastic hemiparetic cerebral palsy:a randomized controlled double-blind clinical trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Associação Educacional Nove de Julho
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20150211
    </Date_registration3>
    <Date_registration>11/02/2015
    </Date_registration>
    <Source_Register>REBEC
    </Source_Register>
    <web_address>http://ensaiosclinicos.gov.br/rg/RBR-6v4y3k
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6Y
    </Inclusion_agemin>
    <Inclusion_agemax>16Y
    </Inclusion_agemax>
    <Inclusion_gender>-
    </Inclusion_gender>
    <Date_enrollement>10/07/2014
    </Date_enrollement>
    <Target_size/>
    <Study_type>Intervention
    </Study_type>
    <Study_design>Therapeutic clinical trial, parallel, two-arm, double-blind, randomized study.&lt;br&gt;&lt;br&gt;
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname>Claudia;Renata
    </Contact_Firstname>
    <Contact_Lastname>Oliveira;Franco de Moura
    </Contact_Lastname>
    <Contact_Address>Rua:Itapicuru 380 apto111;Rua Mussumés 210 apto 21
    </Contact_Address>
    <Contact_Email>csantos@uninove.br;franco.renata@terra.com.br
    </Contact_Email>
    <Contact_Tel>+55(11)38681681;+55(11)26312581
    </Contact_Tel>
    <Contact_Affiliation>Associação Educacional nove de Julho ( UNINOVE);Associação Educacional nove de Julho ( UNINOVE)
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: The criteria for inclusion will be children with  spastic hemiparetic cerebral palsy  come from school of physiotherapy clinics of UNINOVE which have, diagnosis of spastic hemiparetic cerebral palsy;functional classification of upper limbs as levels I, II or III for MACS; have age between 6 and 16 years old;have degrees of understanding and cooperation that are compatible with the achievement of the proposed activities;the legal guardians for the children, agree with your participation in the study through the signing of the informed consent already approved by the COEP UNINOVE
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Will be excluded childrens who:have  performed surgery or neurolíticos locks procedures in the upper limb paretic, in the last 12 months before the beginning of the training sessions;have structured deformities with Orthopedic Surgical indications;have epilepsy;have metal implant in the brain or hearing aids.
    </Exclusion_Criteria>
    <Condition>Spastic hemiparesis cerebral palsy .;C10.228.140.140.254;G80.2
    </Condition>
    <Intervention>Intervention Group (IG) - 17 childrens will receive active stimulation transcranial direct current, associated with functional training of upper limb.&lt;br&gt;Control Group (CG) - 17 childrens will&lt;br&gt;receive placebo transcranial stimulation, associated with functional training of upper limb.&lt;br&gt;The training for both groups, will consist of functional activities for paretic upper limb,using educational toys,performed over a period of 20 minutes / day, 5 times a week for 2 consecutives weeks.&lt;br&gt;Transcranial stimulation will be held in the primary motor cortex during training sessions, with an intensity of 1 mA.&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;;Other;E02.342
    </Intervention>
    <Primary_outcome>Functional improvement of manual dexterity, as measured by the quality test of the skills of upper limbs (QUEST) after 10 sessions of transcranial direct current stimulation in the primary motor cortex of children with spastic hemiparetic cerebral palsy.
    </Primary_outcome>
    <Secondary_outcome>Secondary outcomes are not expected
    </Secondary_outcome>
    <Source_Support>FAPESP -Fundação de Amparo à pesquisa do estado de São Paulo
    </Source_Support>
    <Secondary_Sponsor>Associação Educacional Nove de Julho
    </Secondary_Sponsor>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10234188
    </Internal_Number>
    <TrialID>NCT02216474
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Brain Stimulation in Movement Disorders
    </Public_title>
    <Scientific_title>Brain Stimulation in Movement Disorders
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Birmingham and Solihull Mental Health NHS Foundation Trust
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140812
    </Date_registration3>
    <Date_registration>12/08/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02216474
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>18 Years
    </Inclusion_agemin>
    <Inclusion_agemax>65 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>September 2014
    </Date_enrollement>
    <Target_size>20
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Other. Masking: Double (Participant, Outcomes Assessor). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United Kingdom
    </Countries>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Patients will have either Tourette syndrome (TS) diagnosed according to Diagnostic and&#x0D;&lt;br&gt;             Statistical Manual of Mental Disorders criteria or Huntington's disease (HD) diagnosed&#x0D;&lt;br&gt;             genetically&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Controls will be generally healthy individuals not taking any psychoactive medications&#x0D;&lt;br&gt;             and without diagnosed psychiatric or serious medical conditions (e.g. history of&#x0D;&lt;br&gt;             seizures, heart disease, head injury)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  18-65 years of age for TS; 40-65 years of age for HD; 18-65 for controls&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  English as a first language&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No current significant co-morbid psychiatric disorder (e.g. learning disability,&#x0D;&lt;br&gt;             schizophrenia) or medical condition which may contraindicate brain stimulation or&#x0D;&lt;br&gt;             magnetic resonance imaging (e.g. epilepsy, chronic heart disease, scalp skin&#x0D;&lt;br&gt;             conditions, metal skull implants). Mild symptoms of obsessive compulsive disorder,&#x0D;&lt;br&gt;             attention deficit hyperactivity disorder and/or mood disorders will be accepted as&#x0D;&lt;br&gt;             these are very common&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No contraindications to MRI scanning (if they will be scanned) such as metal in the&#x0D;&lt;br&gt;             body, claustrophobia or seizure history&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  No complex medication regimes (e.g. combinations of multiple dopaminergic drugs plus&#x0D;&lt;br&gt;             selective serotonin reuptake inhibitors&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Huntington's Disease;Tourette Syndrome
    </Condition>
    <Intervention>Other: Transcranial direct current stimulation
    </Intervention>
    <Primary_outcome>Change in cognitive function (working memory, response inhibition)
    </Primary_outcome>
    <Secondary_outcome>Change in motor symptom severity (tics/chorea);Mood change (anxiety and depression questionnaire scores)
    </Secondary_outcome>
    <Secondary_ID>14/WM/0119-NRR1301
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>University of Birmingham
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>5014670
    </Internal_Number>
    <TrialID>NCT02205216
    </TrialID>
    <Last_Refreshed_on>3 August 2015
    </Last_Refreshed_on>
    <Public_title>Can tDCS Enhance Efficacy of Rehabilitative Intervention for Freezing of Gait in Parkinson's Disease?
    </Public_title>
    <Scientific_title>Can Transcranial Direct Stimulation Enhance the Efficacy of a Rehabilitative Intervention for the Treatment of Freezing of Gait in Parkinson's Disease? A Double Blind Randomized Controlled Study
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Centre Hospitalier Universitaire Vaudois
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20140730
    </Date_registration3>
    <Date_registration>30/07/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT02205216
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>30 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>September 2014
    </Date_enrollement>
    <Target_size>40
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor)
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Switzerland
    </Countries>
    <Contact_Firstname> ; 
    </Contact_Firstname>
    <Contact_Lastname>David Benninger, MD;David Benninger, MD
    </Contact_Lastname>
    <Contact_Email>;david.benninger@chuv.ch
    </Contact_Email>
    <Contact_Tel>;+41 21 314 95 83
    </Contact_Tel>
    <Contact_Affiliation>Centre Hospitalier Universitaire Vaudois
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  men and women aged 30 to 80 years with DOPA-responsive PD Hoehn and Yahr (HY) grade&#x0D;&lt;br&gt;             of 2 to 4 while "off"&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  must be on a regimen including levodopa&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  total dose of levodopa and dopamine agonists (using dopamine equivalents) has to be&#x0D;&lt;br&gt;             equal to or more than 300 milligrams per day&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Gait difficulties with Freezing of Gait as defined by MDS-UPDRS I score = 2 in FOG&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Optimal conventional PD medication for &gt; 1 month prior to screening&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  scheduled for rehabilitative intervention for the treatment of freezing of gait&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  significant concurrent medical or psychiatric disease&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  history of seizures and epilepsy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Dementia or other neurodegenerative disease (besides PD)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pallidotomy, implanted electrodes and generator for deep brain stimulation&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  pregnancy&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  surgically or traumatically implanted foreign bodies such as an implanted medical&#x0D;&lt;br&gt;             pump, implanted hearing aids, metal plate in the skull, or metal implant in the skull&#x0D;&lt;br&gt;             or eyes (other than dental appliances or fillings) that may pose a physical hazard&#x0D;&lt;br&gt;             during tDCS.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Study would cause undue risk or stress for reasons such as tendency to fall,&#x0D;&lt;br&gt;             excessive fatigue, general frailty, or excessive apprehensiveness.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  significant postural instability with daily falls, inability to walk the parcours or&#x0D;&lt;br&gt;             inability to walk 10 meters.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  presence of significant cognitive dysfunction as determined by Montreal Cognitive&#x0D;&lt;br&gt;             Assessment (MOCA) &lt;20 or mentally impaired patients having no capacity to provide&#x0D;&lt;br&gt;             their own consent (the physician establishing the diagnosis and applying UPDRS will&#x0D;&lt;br&gt;             evaluate patient's mental capacity using conventional clinical interview).&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  presence of other co-morbid conditions that can contribute to gait dysfunction&#x0D;&lt;br&gt;             (orthopedic, rheumatologic, cardiac, other)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  presence of clinically significant hallucinations&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  participation in any rehabilitation therapy for FOG within the last six months prior&#x0D;&lt;br&gt;             to screening&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease
    </Condition>
    <Intervention>Device: Active tDCS;Device: Sham tDCS;Behavioral: Rehabilitation Therapy
    </Intervention>
    <Primary_outcome>Walking parcours
    </Primary_outcome>
    <Secondary_outcome>New Freezing of Gait Questionnaire (N-FOGQ);Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS);39-Item Parkinson's Disease Questionnaire (PDQ-39);Beck Depression Inventory (BDI);10 Meter Walk Test (10MWT);Timed Up &amp; GO (TUG)
    </Secondary_outcome>
    <Secondary_ID>VD226/14
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>4951859
    </Internal_Number>
    <TrialID>NCT02170285
    </TrialID>
    <Last_Refreshed_on>8 June 2015
    </Last_Refreshed_on>
    <Public_title>Enhancing Motor Plasticity After Perinatal Stroke Using tDCS
    </Public_title>
    <Scientific_title>Enhancing Developmental Motor Plasticity After Perinatal Stroke With Transcranial Direct Current Stimulation
    </Scientific_title>
    <Acronym>tDCS
    </Acronym>
    <Primary_sponsor>University of Calgary
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20140616
    </Date_registration3>
    <Date_registration>16/06/2014
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>http://clinicaltrials.gov/show/NCT02170285
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6 Years
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>Both
    </Inclusion_gender>
    <Date_enrollement>May 2014
    </Date_enrollement>
    <Target_size>23
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment
    </Study_design>
    <Phase>Phase 2
    </Phase>
    <Countries>Canada
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Adam Kirton, MD, MSc
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>University of Calgary
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Symptomatic hemiparetic CP (Pediatric Stroke Outcome Measure (PSOM) &gt;0.5) AND Manual&#x0D;&lt;br&gt;             Abilities Classification System (MACS) grade I-IV AND child/parent perceived&#x0D;&lt;br&gt;             limitations&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Clinical and MRI-confirmed perinatal stroke syndrome (NAIS, APPIS, PVI)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Active wrist extension &gt;20 degrees, finger extension &gt;10 degrees&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Can lift the affected arm 15 cm above a table surface and grasp light objects&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Term birth (&gt;36 weeks) and current age 6 - 18 years&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Informed consent&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          1. Other neurological disorder not related to perinatal stroke&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          2. Multifocal perinatal stroke&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          3. Severe hemiparesis (no voluntary contraction in paretic hand, MACS level V)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          4. Severe spasticity in the affected limb (Modified Ashworth Scale &gt;3)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          5. Severe developmental delay or other inability to comply with study protocol&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          6. Unstable epilepsy (&gt;1 seizure/month or &gt;2 medication changes last 6 months)&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          7. Any TMS or MRI contraindication including implanted electronic devices&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          8. Botox, orthopedic surgery, or other invasive therapy in past 12 months&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          9. Constraint, brain stimulation or other modulatory therapy in past 6 months&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Perinatal Stroke;Cerebral Palsy
    </Condition>
    <Intervention>Device: Interventional TDCS;Device: Sham TDCS
    </Intervention>
    <Primary_outcome>Change from baseline in the Assisting Hand Assessment (AHA) at 8 weeks
    </Primary_outcome>
    <Secondary_outcome>tDCS Safety and Tolerability evaluation (TST);Change from baseline in the Canadian Occupational Performance Measure (COPM) at 1 week;Change from baseline in the Canadian Occupational Performance Measure (COPM) at 8 weeks
    </Secondary_outcome>
    <Secondary_ID>E24720
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>6505921
    </Internal_Number>
    <TrialID>NCT01877148
    </TrialID>
    <Last_Refreshed_on>19 October 2017
    </Last_Refreshed_on>
    <Public_title>Effects Of tDCS With Physical Therapy On Rehabilitation In Parkinson's Disease
    </Public_title>
    <Scientific_title>Effects of Transcranial Direct Current Stimulation Associated With Physical Therapy on Motor Rehabilitation in Parkinson´s Disease Patients
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Universidade Federal de Pernambuco
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20130611
    </Date_registration3>
    <Date_registration>11/06/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01877148
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>40 Years
    </Inclusion_agemin>
    <Inclusion_agemax>80 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>January 2010
    </Date_enrollement>
    <Target_size>12
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design/>
    <Phase>Phase 2
    </Phase>
    <Countries>Brazil;Brazil;Brazil;Brazil
    </Countries>
    <Contact_Firstname> ; ; ; 
    </Contact_Firstname>
    <Contact_Lastname>Kátia K Monte-Silva, PhD;Kátia K Monte-Silva, PhD;Kátia K Monte-Silva, PhD;Kátia K Monte-Silva, PhD
    </Contact_Lastname>
    <Contact_Email>;;;
    </Contact_Email>
    <Contact_Tel>;;;
    </Contact_Tel>
    <Contact_Affiliation>Universidade Federal de Pernambuco;Universidade Federal de Pernambuco;Universidade Federal de Pernambuco;Universidade Federal de Pernambuco
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Parkinson disease comproved by a neurologist Regular treatment with dopamine or other drugs&#x0D;&lt;br&gt;        against parkinson -&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        pregnant history of convulsion metal implant in the region of skull or face change in&#x0D;&lt;br&gt;        medication during the study realize other physical therapy in the same time of the study&#x0D;&lt;br&gt;        previous surgery for parkinson disease&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Parkinson disease comproved by a neurologist Regular treatment with dopamine or other drugs&#x0D;&lt;br&gt;        against parkinson -&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        pregnant history of convulsion metal implant in the region of skull or face change in&#x0D;&lt;br&gt;        medication during the study realize other physical therapy in the same time of the study&#x0D;&lt;br&gt;        previous surgery for parkinson disease&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Parkinson disease comproved by a neurologist Regular treatment with dopamine or other drugs&#x0D;&lt;br&gt;        against parkinson -&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        pregnant history of convulsion metal implant in the region of skull or face change in&#x0D;&lt;br&gt;        medication during the study realize other physical therapy in the same time of the study&#x0D;&lt;br&gt;        previous surgery for parkinson disease&#x0D;&lt;br&gt;      ;&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Parkinson disease comproved by a neurologist Regular treatment with dopamine or other drugs&#x0D;&lt;br&gt;        against parkinson -&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        pregnant history of convulsion metal implant in the region of skull or face change in&#x0D;&lt;br&gt;        medication during the study realize other physical therapy in the same time of the study&#x0D;&lt;br&gt;        previous surgery for parkinson disease&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Parkinson Disease;Parkinson Disease;Parkinson Disease;Parkinson Disease
    </Condition>
    <Intervention>Device: tDCS;Behavioral: Physiotherapy;Device: tDCS;Behavioral: Physiotherapy;Device: tDCS;Behavioral: Physiotherapy;Device: tDCS;Behavioral: Physiotherapy
    </Intervention>
    <Primary_outcome>Change From Unified Parkinson´s Disease Rating Scale - UPDRS;Change From Unified Parkinson´s Disease Rating Scale - UPDRS
    </Primary_outcome>
    <Secondary_outcome>Change From Cortical Excitability Via Single Transcranial Magnetic Stimulation
    </Secondary_outcome>
    <Secondary_ID>Parkinson_tDCS_rehabilitation
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <results_yes_no>Yes
    </results_yes_no>
    <results_date_posted>15/05/2015
    </results_date_posted>
    <results_url_link>https://clinicaltrials.gov/ct2/show/results/NCT01877148
    </results_url_link>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>10224072
    </Internal_Number>
    <TrialID>NCT01852474
    </TrialID>
    <Last_Refreshed_on>12 December 2020
    </Last_Refreshed_on>
    <Public_title>Effects of Transcranial Direct Current Stimulation (tDCS) and Motor Learning in Children With Cerebral Palsy (CP)
    </Public_title>
    <Scientific_title>Effects of tDCS in Cortical Plasticity and Motor Learning in Children With Cerebral Palsy
    </Scientific_title>
    <Acronym/>
    <Primary_sponsor>Spaulding Rehabilitation Hospital
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20130508
    </Date_registration3>
    <Date_registration>08/05/2013
    </Date_registration>
    <Source_Register>ClinicalTrials.gov
    </Source_Register>
    <web_address>https://clinicaltrials.gov/show/NCT01852474
    </web_address>
    <Recruitment_Status>Not recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>8 Years
    </Inclusion_agemin>
    <Inclusion_agemax>18 Years
    </Inclusion_agemax>
    <Inclusion_gender>All
    </Inclusion_gender>
    <Date_enrollement>May 2013
    </Date_enrollement>
    <Target_size>5
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label). 
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>United States
    </Countries>
    <Contact_Firstname>&#x20;
    </Contact_Firstname>
    <Contact_Lastname>Felipe Fregni, MD PhD MPH
    </Contact_Lastname>
    <Contact_Email/>
    <Contact_Tel/>
    <Contact_Affiliation>Spaulding Rehabilitation Hospital
    </Contact_Affiliation>
    <Inclusion_Criteria>&#x0D;&lt;br&gt;        Inclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Age of participants must be between 8 and 18 years old.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Diagnosis of spastic or mixed CP with distribution of diplegia and/or hemiplegia form.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Gross Motor Function Classification System for Cerebral Palsy (GMFCS) level II and&#x0D;&lt;br&gt;             III.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Manual Ability Classification System for Children with CP (MACS) level II up to IV.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Ability to cooperate and follow directions.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;        Exclusion Criteria:&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Muscle tone reduction therapy in the past 3 months prior to study onset.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Upper limb orthopedic surgery in the past 3 months prior to study onset.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Any other form of therapy or procedure involving motor neuron junction inhibition;&#x0D;&lt;br&gt;             either by biochemical and/or mechanical denervation, in the past 3 months prior to&#x0D;&lt;br&gt;             study onset.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  History of convulsive disorder in the past 2 years prior to study onset.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Current use of carbamazepine as anticonvulsive therapy.&#x0D;&lt;br&gt;&#x0D;&lt;br&gt;          -  Presence ventriculoperitoneal shunt.&#x0D;&lt;br&gt;      
    </Inclusion_Criteria>
    <Condition>Cerebral Palsy
    </Condition>
    <Intervention>Device: Transcranial Direct Current Stimulation (tDCS)
    </Intervention>
    <Primary_outcome>Changes in motor assessments
    </Primary_outcome>
    <Secondary_outcome>Changes in TMS measurements
    </Secondary_outcome>
    <Secondary_ID>2012-p-000629
    </Secondary_ID>
    <Source_Support>Please refer to primary and secondary sponsors
    </Source_Support>
    <Secondary_Sponsor>Pedal with Pete
    </Secondary_Sponsor>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13086264
    </Internal_Number>
    <TrialID>RBR-9b5dh7
    </TrialID>
    <Last_Refreshed_on>29 May 2023
    </Last_Refreshed_on>
    <Public_title>Effects of Stimulation Transcranial Direct Current by Associated Gait Training and Mobility Functionality About Children with Cerebral Palsy
    </Public_title>
    <Scientific_title>Effects of Stimulation Transcranial Direct Current by Associated Gait Training and Mobility Functionality About Children with Cerebral Palsy: Clinical Trial Randomized Controlled, Double Blind                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
    </Scientific_title>
    <Primary_sponsor>Universidade Node de Julho
    </Primary_sponsor>
    <Retrospective_flag>No
    </Retrospective_flag>
    <Date_registration3>20130418
    </Date_registration3>
    <Date_registration>18/04/2013
    </Date_registration>
    <Source_Register>REBEC
    </Source_Register>
    <web_address>http://ensaiosclinicos.gov.br/rg/RBR-9b5dh7
    </web_address>
    <Recruitment_Status>Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>4Y
    </Inclusion_agemin>
    <Inclusion_agemax>12Y
    </Inclusion_agemax>
    <Inclusion_gender>-
    </Inclusion_gender>
    <Date_enrollement>01/11/2012
    </Date_enrollement>
    <Target_size/>
    <Study_type>Intervention
    </Study_type>
    <Study_design>Therapeutic, parallel, four arms, double blind, randomized clinical trial.
    </Study_design>
    <Phase>N/A
    </Phase>
    <Countries>Brazil
    </Countries>
    <Contact_Firstname>Luanda 
    </Contact_Firstname>
    <Contact_Lastname>Grecco
    </Contact_Lastname>
    <Contact_Address>Avenida Eulina, 217 - Jardim Primavera
    </Contact_Address>
    <Contact_Email>luandacollange@hotmail.com
    </Contact_Email>
    <Contact_Tel>+55(11)3936-3756
    </Contact_Tel>
    <Contact_Affiliation>Universidade Nove de Julho
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: Children with cerebral palsy. Age between 4 and 12 years. Absence of cognitive or visual impairment that could compromise the performance of the tasks. Levels I, II and III of the Gross Motor Functional. Classification System (GMFCS). Functional ambulation for at least 12 months.
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Orthopedic surgical procedures or neuromuscular block in the 12 months prior to the training sessions. Presence of orthopedic deformities with surgical indications.
    </Exclusion_Criteria>
    <Condition>Cerebral palsy, child, physicotherapy, cerebral cortex, eletrical stimulation.;C10.228.140.140.254;C10.597.404
    </Condition>
    <Intervention>Ten children in group 1 will be submitted to treadmill gait training with transcranial direct current stimulation placebo. Ten children in group 2 will be submitted to treadmill gait training with transcranial direct current stimulation activates the motor cortex. The treadmill gait training performed in group 1 and group 2 will consist of ten weekly sessions, lasting 30 minutes per session. For the training will be used 60-80% of the maximum speed reached during exercise testing. Ten children from Group 3 are subjected to training mobility using virtual reality with transcranial direct current stimulation placebo. Ten children in group 4 will be submitted to mobility training using virtual reality with transcranial direct current stimulation activates the motor cortex. Training mobility with virtual reality will be conducted through the games of Wii Fit PlusTM and consist of ten weekly sessions, lasting 30 minutes per session. The transcranial stimulation will be performed in primary motor cortex during training sessions, with an intensity of 1 mA.;Other;H02.010.625;E01.370.600.250;I01.880.552.673
    </Intervention>
    <Primary_outcome>Improvement in functional mobility and fitness evaluated by testing six-minute walk.
    </Primary_outcome>
    <Secondary_outcome>Improved functional balance assessed by Berg balance scale.;Improvement in static balance measured by stabilometry.;Improvement in functional performance measured by thePediatric Evaluation of Disability Inventory.;Improvement in gross motor function assessed by Gross Motor Fucntion Measure.;Improved gait pattern assessed by evaluating three-dimensional gait.
    </Secondary_outcome>
    <Source_Support>Conselho Nacional de Desenvolvimento Científico e Tecnológico
    </Source_Support>
    <Secondary_Sponsor>Centro de Neurocirurgia Pediátrica
    </Secondary_Sponsor>
    <results_url_link/>
    
  </Trial>

    
  <Trial><Export_date>02/03/2024 14:34:55</Export_date>
    <Internal_Number>13442956
    </Internal_Number>
    <TrialID>JPRN-UMIN000008796
    </TrialID>
    <Last_Refreshed_on>17 October 2023
    </Last_Refreshed_on>
    <Public_title>Effect of transcranial direct current stimulation on involuntary movement ofs Cerebral Palsy
    </Public_title>
    <Scientific_title>Effect of transcranial direct current stimulation on involuntary movement ofs Cerebral Palsy - tDCS on CP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
    </Scientific_title>
    <Primary_sponsor>Tohoku University Graduate School of Medicine
    </Primary_sponsor>
    <Retrospective_flag>Yes
    </Retrospective_flag>
    <Date_registration3>20120901
    </Date_registration3>
    <Date_registration>01/09/2012
    </Date_registration>
    <Source_Register>JPRN
    </Source_Register>
    <web_address>https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010336
    </web_address>
    <Recruitment_Status>Not Recruiting
    </Recruitment_Status>
    <other_records>No
    </other_records>
    <Inclusion_agemin>6years-old
    </Inclusion_agemin>
    <Inclusion_agemax>18years-old
    </Inclusion_agemax>
    <Inclusion_gender>Male and Female
    </Inclusion_gender>
    <Date_enrollement>2012/09/01
    </Date_enrollement>
    <Target_size>5
    </Target_size>
    <Study_type>Interventional
    </Study_type>
    <Study_design>Single arm Non-randomized
    </Study_design>
    <Phase>Not selected
    </Phase>
    <Countries>Japan
    </Countries>
    <Contact_Firstname/>
    <Contact_Lastname>Mayumi Nagai
    </Contact_Lastname>
    <Contact_Address>2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi
    </Contact_Address>
    <Contact_Email>nagai062@gmail.com
    </Contact_Email>
    <Contact_Tel>022-717-7338
    </Contact_Tel>
    <Contact_Affiliation>Tohoku University Graduate school of Medicine Department of Physical Medicine and Rehabilitation
    </Contact_Affiliation>
    <Inclusion_Criteria>Inclusion criteria: 
    </Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: Patients:  1) had previous neurosurgery with implants of metal.  2) had a history head trauma and neurosurgery.  3) had stent placement within the heart.  4) had high pressure heart.  5) are baby.  6) had heart disease.  7) implanted pacemaker.  8) take orally tricyclic antidepressant.  9) had a history of febrile seizures and epilepsy.  10) are a family history of epilepsy.  11) had disease requiring medical care.  12) had sever cognitive impairment.  13) had aphasia.  14) are not suited to this study jugged by PI.
    </Exclusion_Criteria>
    <Condition>Cerebral Palsy
    </Condition>
    <Intervention>Transcranial direct current stimulation
    </Intervention>
    <Primary_outcome>Movement for arm, neck and mouth.
    </Primary_outcome>
    <Source_Support>None
    </Source_Support>
    <Ethics_review_status>YES
    </Ethics_review_status>
    <Ethics_review_approval_date>01/01/1900
    </Ethics_review_approval_date>
    <Ethics_review_contact_name/>
    <Ethics_review_contact_address/>
    <Ethics_review_contact_phone/>
    <Ethics_review_contact_email/>
    <results_url_link/>
    
  </Trial>
</Trials_downloaded_from_ICTRP>